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ABSTRACT 
 This thesis focuses on the design, statistical operating characteristics and 
interpretation of early phase oncology clinical trials. Anti-cancer drugs are generally 
highly toxic and it is imperative to deliver a dose to the patient that is low enough to 
be safe but high enough to produce a clinically meaningful response. Thus, a study of 
dose limiting toxicities (DLTs) and a determination of the maximum tolerated dose 
(MTD) of a drug that can be used in later phase trials is the focus of most Phase I 
oncology trials. We first comprehensively compare the statistical operating 
characteristics of various early phase oncology designs, finding that all the designs 
examined select the MTD more accurately when there is a clear separation between 
the true DLT rate at the MTD and the rates at the dose levels immediately above and 
below. Among the rule-based designs studied, we found that the 3+3 design under-
doses a large percentage of patients and is not accurate in selecting the MTD for all 
the cases considered. The 5+5 a design picks the MTD as accurately as the model 
based designs for the true DLT rates generated using the chosen log-logistic and 
linear dose-toxicity curves, but requires enrolling a larger number of patients. The 
model based designs examined, mTPI, TEQR, BOIN, CRM and EWOC designs, perform 
well on the whole, assign the maximum percentage of patients to the MTD, and pick 
  xv 
the MTD fairly accurately. However, the limited sample size of these Phase I oncology 
trials makes it difficult to accurately predict the MTD. Hence, we next study the effect 
of sample size and cohort size on the accuracy of dose selection in early phase 
oncology designs, finding that an adequate sample size is crucial. We then propose 
some integrated Phase 1/2 oncology designs, namely the 20+20 accelerated titration 
design and extensions of the mTPI and TEQR designs, that consider both toxicity and 
efficacy in dose selection, utilizing a larger sample size. We demonstrate that these 
designs provide an improvement over the existing early phase designs. 
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CHAPTER ONE 
Introduction 
 
This statistical thesis focuses on the design, statistical operating characteristics and 
interpretation of early phase oncology clinical trials. To put our work in perspective, we 
begin by explaining the genetic and cytoskeletal changes that take place in cancer cells and 
that result in their hallmarks, including the key one of limitless cell division. We then 
describe the process of cell division. Cell division is a very precise and controlled process, 
and the changes in its control mechanisms, such as in specific genes and proteins, that lead 
to abnormal cell division in cancer cells can be utilized in the development of anti-cancer 
drugs. Subsequently, we discuss anti-cancer drugs as well as their rigorous process of 
testing i.e. oncology clinical trials. Finally, we discuss the aims and scope of this thesis. In 
brief, the aims of this thesis include gaining a comprehensive understanding of the 
statistical operating characteristics of several existing early phase oncology designs, 
systematically studying the effect of cohort and sample size on the accuracy of dose 
selection in some existing designs, and then proposing new integrated Phase 1/2 oncology 
designs that are improvements over the existing designs in various ways. This thesis is 
unique in its comprehensive survey of existing early phase oncology designs and in its 
proposal of new designs that are based on a thorough statistical understanding of the 
existing designs. 
 
  
2 
Cancer1  
Cancer has long been a dreaded disease and has long been synonymous with a death 
sentence. However, a tremendous amount of progress has been made in the past 50 
years and today at the beginning of the 21st century, this is no longer always the case. 
Today, there are many patients diagnosed with cancer who proceed to live their full 
functional life spans. For example, the drug Gleevec has turned chronic myeloid 
leukemia (CML) into a chronic, manageable disease for many CML patients [1]. The 
prognosis of the cancer diagnosis usually depends on the stage2 at which the cancer 
is detected. In many cases, early detection followed by immediate treatment results 
in the best outcome [5, 6, 7, 8, 9]. Early detection tools such as a mammogram for 
breast cancer, Pap test for cervical cancer, PSA test for prostate cancer, flexible 
sigmoidoscopy and colonoscopy for colorectal cancer aim to help improve the 
outcome from these cancers [10]. The typical treatment regimen for cancer consists 
of anti-cancer drugs, such as chemotherapy, hormonal therapy, targeted therapy, and 
or radiation and or surgery. There are also other new innovative therapies currently 
being investigated, which we discuss later. Known risk factors for cancer include 
cigarette smoking and tobacco use, exposure to radiation, inhalation of asbestos 
fibers, infections and genetics for e.g. the presence of mutations in the BCRA1 and 
                                                        
1 This section and the following sections until the section”Aims and Scope of this Thesis” are based 
on my two review articles on oncology trials [23] and [50].  
2 For most solid tumors, the TNM (tumor, node, metastasis) staging is used, which depends on the 
tumor size, how many lymph nodes are affected and if the tumor has metastasized [2]. The results 
from the TNM staging are combined to determine the final staging result of Stage IA, IB, IIA etc. 
and this conversion differs for different solid tumor types. For liquid tumors, the staging criteria 
and their definitions are different for different leukemias [3] and lymphoma [4]. 
  
3 
BCRA2 genes significantly increases the risk of breast cancer [11]. Other risk factors 
for cancer can include diet, drinking, obesity, exercise and environmental factors.   
 
So, what is cancer? Firstly, cancer is not a single disease but a complex family of 
diseases that are primarily characterized by uncontrolled cell division. The molecular 
underpinnings and mysteries of cancer are still being unraveled. However, all the 
research done so far generally points to cancer being a disease of genetic alterations 
such as chromosomal abnormalities (e.g. genetic mutations) [12]. These mutations 
lead to abnormal cell growth and division and to nearby tissue invasion by these cells. 
Some of these cells may break away from the original tumor and travel to far off sites, 
which is called metastasis. The number and type of mutations can vary greatly even 
between two patients diagnosed with the same cancer e.g. lung cancer. In addition, 
the same patient may have different mutations at different time points after the initial 
diagnosis, as the mutations can evolve over time. This is why patients often develop 
resistance to the targeted therapy that they are being treated with — the specific 
mutation that the drug was initially targeting has likely changed over time and the 
patient needs to then be treated with another drug that targets the new mutation. 
Thus, the key to treating cancer seems to lie in identifying the unique genetic 
signature of each patient’s cancer at the given time point and in personalizing the 
treatment plan accordingly. 
  
4 
Hallmarks of Cancer and Genetic and Cytoskeletal Changes in Cancer Cells  
The main hallmarks of cancer cells are thought to include self-sufficiency in growth 
signals, insensitivity to anti-growth signals, tissue invasion and metastasis, limitless 
replicative potential, sustained angiogenesis (formation of new blood vessels) and 
evasion of apoptosis (cell death)  [13]. These hallmarks have been revised in a more 
recent paper [14] by the same authors as those of the original paper to include 
abnormal metabolic pathways and evading the body’s immune system (Figures 1 and 
2 show the original hallmarks and the emerging hallmarks respectively, taken from 
[14]).  
 
Figure 1   Original Hallmarks of Cancer (taken from Hanahan 2011 [14]) 
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Figure 2 Emerging Hallmarks of Cancer (taken from Hanahan 2011 [14]) 
 
Cancer cells exhibit these hallmarks due to the genetic and cytoskeletal changes that 
take place in them compared to their normal counterparts. Most of the cell’s genetic 
material is contained in the genes that make up the chromosomes. The chromosomes 
are found in the cell’s nucleus, a dense body in the cell interior. The main genetic 
changes in cells that contribute to the development of cancer relate to oncogenes, 
tumor suppressor genes, DNA repair genes and apoptosis genes, which are genes that 
control cell death [15, 16]. Proto-oncogenes and tumor suppressor genes are critical 
in regulating cell division, and mutations in these genes can render them unable to 
function normally. In general, when proto-oncogenes are activated due to gain of 
function mutations, they become oncogenes, while when tumor suppressor genes are 
inactivated due to loss of function mutations, they can lead to cancer. The functions 
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of various proto-oncogenes include regulating cell growth and apoptosis, and 
controlling the timing and frequency of cell division via signals sent to the nucleus; 
when a proto-oncogene becomes an oncogene, it causes the signaling mechanism that 
instructs the cell when to divide to function abnormally, resulting in excessive cell 
division. The presence of a single oncogene in a cell is not likely to make it cancerous 
but promotes cell division, which may aid one or more daughter cells down the line 
in acquiring additional mutations and becoming cancerous. In general, tumor 
suppressor genes function to stop cell division when it is no longer necessary. Hence, 
when a tumor suppressor gene is mutated and does not function normally, it can lead 
to abnormal cell division. Thus, a cancer cell with oncogenes and mutated tumor 
suppressor genes is often compared to a car whose accelerator pedal is permanently 
pushed down and whose brakes do not function. Examples of oncogenes include the 
BCR-ABL oncogene, which promotes cell growth and division through tyrosine kinase 
activity and is associated with CML, and the HER2 oncogene, which promotes cell 
growth and division by over expression of signaling kinase due to gene amplification 
and is usually associated with breast, cervical, endometrial and ovarian cancer. 
Examples of tumor suppressor genes include the BRCA1, BRCA2 genes, whose 
mutations are associated with breast and ovarian cancer, and the p53 gene, whose 
mutations are associated with several cancers such as breast, colorectal, liver, lung 
and ovarian cancers. Genes that are involved in DNA replication and repair are also 
vital; when these genes are mutated, their ability to automatically correct mutations 
that may cause cancer is lost. Apoptosis genes are also very important with regard to 
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cancer because some cancer cells are able to divide forever. Two main genes whose 
mutations can lead to the loss of apoptosis are p53 and BCL-2. Some cancer cells are 
able to divide indefinitely by activating the enzyme telomerase, which controls the 
length of the telomeres – telomeres act like caps at the ends of chromosomes [17]. 
When telomerase is activated, it prevents the shortening of the telomeres and enables 
these cancer cells to keep on dividing; in normal cells, when the telomeres shorten to 
or beyond a certain threshold, further cell division does not take place. 
 
Cytoskeletal changes also occur in cancer cells [18]. The cytoskeleton is a dynamic, 
composite polymeric network spanning the interior of eukaryotic cells, which are 
cells that have a nucleus. This polymeric network acts as a skeleton to provide the cell 
structure and shape. The biopolymers actin, microtubules and intermediate filaments 
comprise the cytoskeletal network [18]. These cytoskeletal polymers function 
synergistically to carry out several key cellular activities such as motility, division and 
intracellular transport [18]. The actin cortex, a shell-like dynamically crosslinked 
polymer network situated just below the cell membrane, is made out of semiflexible 
actin filaments. Actin filaments can also form stiff bundle like structures known as 
stress fibers. The actin cytoskeleton, comprising the actin cortex and stress fibers, is 
very important in cell elasticity and shape, cell motility and muscle contraction [19]. 
Microtubules are rigid rod like structures that start at the centrosome, located near 
the nucleus, and extend to the cell membrane in a radial array-like configuration. 
They are key in cell division, by enabling the movement and separation of sister 
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chromatids to opposite sides of the cell by attachment proteins called kinetochores. 
They also act as a set of tracks for organelles and vesicles to move on, and hence are 
vital in intracellular transport. The flexible intermediate filaments (IFs), which are 
intermediate in size (diameter) between actin filaments and microtubules, comprise 
a class of filaments such as vimentin, neurofilaments, nestin, keratin and desmin; 
different cells can have different IFs. IFs provide mechanical support to the cell 
membrane when it comes into contact with other cells. IFs have high tensile strength 
and long-range elasticity and are crucial when the cell undergoes large deformations. 
Frequently, the actin cytoskeleton is remodeled in many cancer cells, with the actin 
cortex beneath the cell membrane usually being less extensive in the cancer cells than 
in their normal counterparts. This results in the altered elastic/viscoelastic and other 
properties of these cancer cells, and consequently in their altered functioning [20, 21, 
22, 23]. Since the actin network and its dynamics are crucial in cell shape and 
movement, these altered properties affect cell shape, movement and growth. The 
smaller shear modulus and the more liquid-like viscoelastic properties rather than 
solid-like elastic properties of these cancer cells compared to their normal 
counterparts allow them to squeeze through gaps much more easily and move more 
quickly than their normal counterparts [24]. Some cancer cell types also divide more 
quickly than their normal counterparts. In addition, changes in microtubule stability 
and disruption of processes that microtubules are involved in have been observed in 
many cancers [25, 26]. Further, the roles for IFs in cancer include the following: 
vimentin plays a role in lung cancer, keratin plays a role in apoptosis and nestin plays 
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a role in cancer cell migration [27, 28, 29, 30].  
In summary, the genetic and cytoskeletal changes that occur in cancer cells result in 
their altered functioning, including cell division. 
Cell Division 
Cell division is usually initiated when growth factors attach to specific receptors on 
the cell surface and send signals to the cell’s nucleus, leading to a series of events that 
culminate in the creation of two cells with identical genetic material [31]. In 
eukaryotic cells, the cell cycle, the process by which one cell divides into two, can be 
divided into various stages [32]. The cell first prepares for division in interphase. The 
stages of interphase are G1 (Gap 1 stage, where there is growth and preparation of 
chromosomes for replication), S (“Synthesis”, where DNA replication occurs) and G2 
(Gap 2 stage, where the cell prepares for mitosis). The next stage is the M stage or 
“Mitosis” stage, where the nuclear chromosomes separate. Mitosis is split into four 
main stages: prophase, metaphase, anaphase and telophase. Over the course of these 
four stages, the centrosomes are first separated and migrate to opposite ends of the 
nucleus, the chromosomes are then aligned at the cell center and finally the sister 
chromatids are separated and pulled to opposite sides of the cell by kinetochores. The 
end result of mitosis, where microtubule dynamics play an essential role, is that 
duplicate copies of chromosomes are split equally. During the next stage called 
cytokinesis, the cell’s cytoplasm gets divided; this finally results in the creation of two 
genetically identical daughter cells. In some cells, there can also be a post-mitotic G0 
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phase where the cell has left the cell cycle and is resting and not dividing. The cell 
cycle is a very complex and regulated process, whose precise orchestration involves 
numerous checkpoint proteins such as cyclins, cyclin dependent kinases as well as 
genes such as proto-oncogenes and tumor suppressor genes. Hence it is not 
surprising that mutations in the proto-oncogenes, tumor-suppressor genes or cell 
cycle checkpoints that are key in controlling this accurate process can lead to 
abnormal cell division. To inhibit abnormal cell division in cancer cells, the different 
anti-cancer drugs that have been developed may target different parts or stages of the 
cell cycle, as discussed in the next section. The drugs can also make use of the 
hallmarks or special characteristics exhibited by cancer cells in order to inhibit tumor 
growth, for e.g. targeting specific genes (e.g. oncogenes) and proteins that are 
involved in signaling the cancer cell to continually divide, inhibiting angiogenesis 
around the tumor to slow or halt the tumor growth, or stimulating the body’s 
suppressed immune system to attack cancer cells. 
 
Oncology Drugs 
The initial drugs that were developed and used to treat many different cancers were 
mainly chemotherapies [33]. Chemotherapy can be given either before or after 
surgery or radiation therapy. When it is given before surgery to shrink the primary 
tumor, this is called neo-adjuvant therapy. When it is given after surgery or radiation 
therapy to eradicate any cancer cells that may still remain in the body and to minimize 
  
11 
recurrence, this is called adjuvant therapy. When chemotherapy is given after the 
cancer has metastasized, this is called chemotherapy in the metastatic setting. When 
chemotherapy or another anti-cancer drug is the first drug given to the patient after 
diagnosis and is the primary or best therapy for the specified cancer, it is called 1st 
line therapy. When chemotherapy or another anti-cancer drug is given to a patient 
after he or she has progressed on the first anti-cancer drug, it is called 2nd line therapy 
and so on. Chemotherapies are not very cell specific and can target both normal and 
cancer cells – they usually target any actively or quickly dividing cells such as cancer 
cells and normal hair, nail and gut cells. The destruction of gut cells in the lining of the 
digestive system is what causes vomiting in many patients on chemotherapy. In 
general, chemotherapies work by targeting and damaging the DNA, RNA or 
microtubules in cells; different chemotherapy drugs can target different phases of the 
cell cycle. The main classes of chemotherapies include alkylating agents, 
anthracyclines, anti-metabolites, anti-microtubule agents and topoisomerase 
inhibitors [34]. Alkylating agents damage DNA, and this stops the cancer cells from 
dividing. They work in all phases of the cell cycle. As an example of an alkylating agent, 
cyclophosphamide forms DNA crosslinks; this interferes with DNA replication, and 
leads to cell death. Anthracyclines are thought to work in multiple ways to inhibit 
cancer [35]. They can inhibit DNA or RNA synthesis by inserting between base pairs 
in the DNA/RNA strand. They can damage DNA by creating free oxygen radicals. They 
can prevent DNA transcription and replication by inhibiting topoisomerase II. They 
can also stop the response to DNA damage by promoting histone eviction from 
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chromatin. They work in all phases of the cell cycle. As an example of an anthracycline, 
daunorubicin can inhibit DNA synthesis by inserting between base pairs in the DNA 
strand. It can also prevent DNA transcription and replication by inhibiting 
topoisomerase II. Finally, it can stop the response to DNA damage by promoting 
histone eviction. Anti-metabolites interfere with DNA and RNA synthesis and hence 
stop cell division. They act during the S phase of the cell cycle. As an example of an 
anti-metabolite, azathioprine inhibits an enzyme necessary for DNA synthesis and 
stops cancer cells from dividing. Mitotic inhibitors, as their name implies, disrupt 
mitosis in the M phase [36]. Most of these mitotic inhibitors disrupt microtubules and 
microtubule dynamics, given their crucial role in mitosis. Taxanes and plant alkaloids 
are examples of mitotic inhibitors. As an example of a taxane, paclitaxel binds to 
tubulin, the major building block of microtubules, stabilizing microtubules and 
preventing their disassembly. Due to this, the chromosomes are unable to form a 
spindle in metaphase. Thus, mitosis is arrested and cancer cells are stopped from 
dividing. As an example of a plant alkaloid, vincristine binds to tubulin, preventing 
microtubule disassembly. This arrests mitosis in metaphase and stops cell division. 
Topoisomerase inhibitors are drugs that disrupt the activity of the topoisomerase 
enzymes, namely topoisomerase I and topoisomerase II, which help separate and 
unwind DNA strands during transcription or replication. They act during the S phase 
and G2 phase of the cell cycle. Examples of topoisomerase I inhibitors include 
irinotecan and topotecan, while examples of topoisomerase II inhibitors include 
doxorubicin and aclarubicin. For example, irinotecan inhibits topoisomerase I, which 
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results in the inhibition of both DNA transcription and replication. One of the ways 
doxorubicin is thought to work is by inhibiting topoisomerase II; this results in 
blocking DNA transcription and replication. 
 
The newer targeted therapies are more specific and usually inhibit cell proliferation 
rather than kill cancer cells [37]. The National Cancer Institute’s (NCI) dictionary 
defines a targeted therapy as: “A type of treatment that uses drugs or other 
substances to identify and attack specific types of cancer cells with less harm to 
normal cells. Some targeted therapies block the action of certain enzymes, proteins, 
or other molecules involved in the growth and spread of cancer cells. Other types of 
targeted therapies help the immune system kill cancer cells or deliver toxic 
substances directly to cancer cells and kill them. Targeted therapy may have fewer 
side effects than other types of cancer treatment. Most targeted therapies are either 
small molecule drugs or monoclonal antibodies.” Early examples of targeted 
therapies are trastuzumab (Herceptin, a monoclonal antibody) for HER2+ breast 
cancer [38] and imatinib (Gleevec, a small molecule drug) for CML [39]. In HER2+ 
breast cancer patients, the HER2 gene is overexpressed in breast cancer cells, which 
means that too many copies of the gene are made. This gene encodes for a protein 
called the HER2 receptor. Due to the presence of too many HER2 receptors on the 
cancer cell’s surface, the signals being sent to the nucleus that direct the cell to divide 
are greatly amplified. This leads to abnormal and limitless cell division. Herceptin is 
a large molecule monoclonal antibody and cannot enter the cell. It attaches itself to 
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the HER2 receptors on the cell surface of breast cancer cells and intercepts these 
signals that are being sent to the cell’s nucleus and that are causing the cell to keep on 
dividing. Thus, by blocking these signals, Herceptin can slow or halt the cancer 
growth.  In most patients with CML, the ABL and BCR genes are fused, forming an 
oncogene called BCR-ABL. This gene encodes for the BCR-ABL protein, which is a 
constitutively active tyrosine kinase. This means that the tyrosine kinase is 
continuously active and promotes unregulated cell division and the initiation of 
cancer. Gleevec is a small molecule tyrosine kinase inhibitor and can enter the cell. It 
binds close to the ATP binding site of BCR-ABL and can decrease the BCR-ABL enzyme 
activity and hence inhibit the uncontrolled proliferation of cancer cells. As another 
example of a targeted therapy, bevacizumab (Avastin) is a monoclonal antibody that 
is used mainly in the treatment of colorectal cancer and lung cancer, and is an 
angiogenesis inhibitor. It slows cancer growth by binding to a protein often 
overexpressed by tumor cells called vascular endothelial growth factor (VEGF) that 
promotes the growth of new blood vessels around the tumor [40]. 
 
An antibody-drug conjugate consists of a cytotoxic agent attached to an antibody, 
with trastuzumab emtansine and brentuximab vedotin being examples [41]. In 
trastuzumab emtansine, the cytotoxic agent DM1 is attached to trastuzumab. 
Trastuzumab targets HER2+ cancer cells and so the cytotoxin DM1 is also delivered 
only to these cancer cells. DM1 then enters the cells, binds to tubulin and stops cell 
division [42]. In brentuximab vedotin, the cytotoxic agent monomethyl auristatin E 
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(MMAE) is attached to the antibody cAC10. cAC10 binds to CD30, which is commonly 
found on the surface of cancer cells. MMAE is then released into the tumor cell, where 
it blocks tubulin polymerization and stops cell division.  
  
Hormonal therapy can be effective in treating cancers that may be hormonally driven 
such as breast, prostate and endometrial cancer [43, 44]. These hormone therapies 
commonly block or remove the hormones that encourage cancer growth. Selective 
Estrogen Receptive Modulators (SERMs) such as tamoxifen to treat estrogen receptor 
positive (ER+) breast cancer and anti-androgens such as flutamide and bicalutamide 
to treat prostate cancer are examples of hormonal therapies. Tamoxifen binds to the 
estrogen receptor and blocks the action of estrogen, thus inhibiting cancer growth 
that is fueled by the action of estrogen, such as in ER+ breast cancer. The anti-
androgens flutamide and bicalutamide bind to the androgen receptor and block the 
action of androgen, thus inhibiting prostate cancer growth that is fueled by the action 
of androgen. Aromatase inhibitors such as letrozole and anastrozole for the treatment 
of ER+ breast cancer are also examples of hormonal therapies. These drugs bind to 
the aromatase enzyme and suppress the conversion of androgens to estrogens by the 
aromatase enzyme; this results in slowing or stopping cancer growth in ER+ breast 
cancer patients.  
 
The field of cancer immunotherapy uses the body’s own immune system to attack the 
cancer cells. In most cancer patients, the immune system is severely compromised 
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and does not function normally because of the presence of an immuno-suppressive 
environment around cancer cells. Immunotherapy can work, in general, by either 
stimulating the body’s immune system to help fight cancer or providing the immune 
system with antibodies to help fight cancer. With regard to re-activating the body’s 
immune system and the development of immunotherapies, a crucial role is currently 
being played by the programmed death 1 (PD-1) receptor protein, that is expressed 
on the surface of activated T cells, and its ligands, programmed death ligand 1 (PD-
L1) and programmed death ligand 2 (PD-L2). T cells are lymphocytes that are active 
participants in the body’s immune response and can recognize and attack cancer cells. 
Many cancer cells produce excess PD-L1 and or PD-L2 which can bind to PD-1, 
inactivating the T cells and preventing them from attacking the tumor. Nivolumab, for 
example, is an anti-PD-1 monoclonal antibody and immunomodulator approved for 
the treatment of melanoma and squamous non-small cell lung cancer that prohibits 
PD-L1 and PD-L2 from binding to the PD-1 receptor on T cells [45]. This enables the 
T cells to be activated and attack the tumor.  
 
Immunotherapy generally consists of three main groups: cell-based therapies (e.g. 
cancer vaccines), antibody therapies and cytokine therapies [46, 47, 48]. An example 
of a cancer vaccine is Provenge, which is used to treat prostate cancer and which 
stimulates the body’s immune system to attack the prostate cancer cells. Some 
antibody therapies such as Herceptin are examples of immunotherapies. Monoclonal 
antibodies, which are man-made versions of immune proteins, can work as 
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immunotherapies in different ways as follows: by a) attaching to cancer cells and 
blocking the signaling pathway that causes abnormal growth and division e.g. 
Herceptin b) attaching to cancer cells and then attracting immune cells to attack these 
cancer cells e.g. alemtuzumab or c) provoking the immune system via the inhibition 
of immune system checkpoints e.g. nivolumab, ipilimumab [49]. Examples of cytokines 
are Interleukins and Interferons such as interleukin-2 (IL-2) and interferon- (IFN-
). Since these cytokines modulate the immune response and can aid anti-tumor 
activity, these cytokines can be used as drugs to stimulate an immune response and 
treat cancer e.g. use of high-dose IL-2 therapy in the treatment of renal cell carcinoma 
and melanoma.  
 
Oncology Clinical Trials and Cancer Treatments 
Before a new anti-cancer drug can be brought to the market, it must undergo rigorous 
clinical testing in humans via clinical trials to evaluate its safety and efficacy [50, 51] 
(Figures 3 and 4). Traditional clinical trials in humans typically consist of Phase I, II 
and III trials, while the newer adaptive designs are more flexible and do not always 
have three phases, such as a seamless Phase I/II trial where phases I and II are 
combined or a seamless Phase II/III trial where phases II and III are combined. 
Patients must provide written informed consent to participate in these clinical trials 
and strict eligibility criteria are followed for patient selection. However, before 
testing the drug in humans, in vitro studies as well as animal studies of the drug are 
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carried out to obtain a preliminary understanding of its adverse effects and to help 
determine an initial safe dose of the drug in humans. These initial pre-clinical studies 
may also aim to understand the pharmacokinetic (PK) and pharmacodynamic (PD) 
properties of the drug i.e. the effect of the body on the drug and the effect of the drug 
on the body respectively. A Phase I study or trial, conducted on a small group of say 
15–30 patients, focuses on drug safety (adverse events of the drug), drug dosing 
(what dose and route of administration e.g. oral or IV may be the best for the study 
drug), as well as the PK/PD properties of the drug in humans [52]. Sometimes 
biomarker studies may also be conducted as part of a Phase I study. The efficacy of 
the drug may be observed in Phase I trials but is not traditionally their focus. Based 
on the safety properties of the drug and the results of the Phase I trial, the drug is then 
tested in a Phase II setting. A Phase II trial typically enrolls 100s of patients and 
focuses on observing trends in the safety and efficacy of the drug. If the drug shows 
acceptable safety properties and shows positive trends in efficacy, the drug is tested 
in a Phase III setting. A Phase III trial is large and can enroll 1000s of patients. It is 
typically a randomized parallel-arm superiority trial, where patients are randomized 
to the standard of care (SOC) in one arm and to the new study drug in the other arm, 
and the aim is to demonstrate the superiority of the study drug to the SOC. In most 
cases, obtaining market approval of the study drug entails showing regulators the 
results of such a Phase III randomized clinical trial (RCT), since an RCT is the gold 
standard for clinical testing. Based on the results of the Phase III RCT, the sponsor 
company can submit the drug to the regulatory agency for approval. The regulatory 
  
19 
agency, using a panel of experts, carefully analyzes the risk to benefit ratio of the drug 
and decides accordingly. Once the cancer drug is approved in a country/region, it 
becomes available to all the patients there who require it. 
 
Personalized cancer therapy seems to be where the future of cancer treatment lies. 
This implies that the treatment regimen, which may include targeted therapies, 
immunotherapies, cell based therapies (for e.g. injecting T cells into the body to fight 
cancer) and combination therapies [53, 54], is tailored specifically to fight the 
individual’s cancer, knowing its genetic signature. Personalizing cancer therapy will 
also involve biomarker studies to understand the subpopulation of patients who may 
be the best responders to the drug. This, in turn, implies that the target population of 
each drug will become increasing more specific, and its testing will involve 
conducting multi-site, highly global trials to enable recruiting an adequate number of 
trial subjects. Innovative therapies of the future could include therapies that inhibit 
telomerase activity so that cancer cells cannot divide indefinitely [55, 56], or 
therapies that target cancer stem cells – cancer stem cells, which are tumorigenic, are 
found in certain tumors and hematologic cancers, and targeting them may prevent 
metastasis and lead to tumor inhibition [57, 58]. Novel delivery strategies for cancer 
therapeutics that have been developed or are being developed are resulting in or may 
result in more effective treatments [59]. All this could allow many cancers to morph 
from a deadly disease to a chronic manageable one sometime in the foreseeable 
future. 
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Figure 3 Clinical Trials Process (taken from  
http://www.mdanderson.es/sites/default/files/editor/elcancer/TRATAR/Trials%2
0Process%20ING.jpg) 
 
 
Figure 4 Clinical Trials Process (taken from  
https://www.linkedin.com/pulse/significance-process-evaluation-clinical-trials-
joshua-ebenezer) 
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Aims and Scope of this Thesis 
This statistical thesis mainly focuses on the design, statistical operating 
characteristics and interpretation of early phase oncology trials. While the later phase 
oncology trials, i.e. Phase III, typically have statistical endpoints such as overall 
survival and progression free survival, these endpoints are not the focus of early 
phase oncology trials. These early phase trials focus on finding the right safe dose to 
be used in the later stage trials. Due to the toxic nature of anti-cancer drugs and due 
to ethical concerns, cancer patients who have exhausted standard treatment options 
are generally recruited for this purpose, in contrast to many other therapeutic areas 
where healthy volunteers can be used in early phase trials. The high toxicity of these 
anti-cancer agents makes it imperative to minimize the possibility of giving patients 
unsafe or fatal doses. At the same time, it is also crucial to minimize the probability of 
giving patients sub-therapeutic or inefficacious doses. Thus, a careful study of drug 
toxicity or dose limiting toxicities (DLTs) and a determination of the maximum 
tolerated dose (MTD) is the focus of most Phase I oncology trials.  
 
In this thesis, we first carefully study the statistical operating characteristics, 
including accuracy of MTD selection, percentage of patients assigned to the MTD, 
over-dosing, under-dosing, trial DLT rate, of eleven rule-based and model-based 
Phase 1 oncology designs that target or pre-specify a DLT rate of ~0.2 for three sets 
of true DLT probabilities. These DLT probabilities are generated at common dosages 
from specific linear, logistic, and log-logistic dose-toxicity curves. The simulations 
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performed in this thesis are intended to provide considerable information on design 
property trade-offs, and the means to explore additional settings. These simulations 
include studying the performance of the designs for different target DLT rates. Not 
every design allows specifying the target DLT rate – for those designs where the 
target DLT rate can be specified, the rate specified should depend on the severity of 
the disease. Designs where the target DLT rate cannot be changed should also be 
selected with the disease severity in mind.  Previous works compare a very limited 
number of specific Phase 1 oncology designs. We fill this gap by comparing the 
performance of several designs that target the same DLT rate for the same true 
underlying DLT probabilities, and provide a practical aid in choosing a Phase I design 
for a particular setting or for developing a new Phase I oncology design.  
 
Phase III oncology trials typically dose patients at the MTD that is determined from 
the corresponding Phase I trial. However, the sample size of the corresponding Phase 
I oncology trial is very limited and it is difficult to accurately predict the MTD with 
such a small number of patients. Using the wrong dose for safety and/or efficacy in a 
Phase III trial can have serious consequences for the development of the oncology 
drug in terms of cost, time and resources. Thus, it may be worthwhile to accurately 
determine the optimal drug dose for safety and efficacy in an early phase trial itself. 
Hence, we next study the effect of cohort size and sample size on the accuracy of dose 
selection in early phase oncology designs. We then propose a new design with a larger 
sample size that encompasses the objectives of both safety and efficacy and is easier 
  
23 
to implement than the existing designs. Designs such as the seamless Phase 1/2 
SEARS design, a seamless 2-step Phase 1/2 design, designs to find the optimal 
biological dose and the Eff-Tox design among others have been proposed earlier to 
evaluate both drug toxicity and efficacy as an alternative to the standard approach of 
a Phase 1 followed by a Phase 2 trial. Instead, we propose the 20+20 accelerated 
titration design, a simple rule-based integrated Phase 1/2 trial design that selects an 
optimal dose for toxicity and efficacy via Bayesian decision rules at the end. We 
incorporate stopping rules within dose levels in this design to allow more flexible 
decision-making. In our simulations, we generate the true DLT rates at each dose 
based on a logistic dose-toxicity curve and the true response rates based on a manual 
dose-response curve since the true response rate of an anti-cancer drug may not 
always increase with an increase in dose. We finally compare the accuracy of optimal 
dose selection of this design with that of other Phase 1/2 strategies such as the Eff-
Tox design, Optimal Biological Dose Isotonic design as well as a 3+3 Phase 1 design 
followed by a Phase 2 design. 
 
We have also extended the TEQR and mTPI dose-finding oncology designs to choose 
an optimal dose for both safety and efficacy by considering correlated Bernoulli 
distributions for the true underlying toxicity and efficacy rates. In our simulations, we 
assume that the true DLT rates increase monotonically with an increase in dose but 
do not assume that the true response rates increase monotonically with an increase 
in dose; we allow multiple types of curves for dose response (monotonically 
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increasing, plateau, or umbrella-shaped). In this context, we apply isotonic regression 
to determine a dose that is optimal for safety and efficacy.  Finally, we compare the 
accuracy of optimal dose selection of the extended TEQR and mTPI designs with that 
of the Eff-Tox design and of the Optimal Biological Dose Isotonic design. 
 
In summary, through the work in this dissertation, we:  
a) have obtained a comprehensive understanding of the statistical operating 
characteristics of several commonly used early phase oncology trial designs. 
b) have understood the effect of sample and cohort size on the accuracy of dose 
selection in some early phase oncology designs. 
c) have proposed some new early phase oncology designs with a larger sample 
size that consider both toxicity and efficacy in dose selection and that are 
improvements over the existing early phase designs. 
It is thus hoped that the statistical characterization of early phase oncology designs 
has been furthered by this dissertation. 
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CHAPTER TWO3 
Introduction 
Phase I trials of a new anti-cancer drug are usually single arm, open label studies 
conducted on a small number (10s) of cancer patients, many of whom do not respond 
any longer to the standard treatment. Due to the toxic nature of many anti-cancer 
drugs as well as due to ethical reasons, cancer patients are enrolled in Phase I 
oncology trials, as opposed to the healthy volunteers used in Phase I trials in other 
therapeutic areas.  
 
The main aim of a Phase I oncology trial is to investigate and understand the toxic 
properties (safety) of the new anti-cancer drug; the drug’s efficacy is not traditionally 
the focus, although the drug’s efficacy is often observed and monitored by the 
oncologist. With regard to safety, the trial helps investigators determine the right 
dose and dosing interval as well as the best route of administration of the new drug. 
In order to determine the right dose, an endpoint such as Phase 1 dose limiting 
toxicities (DLTs) in the first cycle is often considered.  
 
For each dose finding Phase I trial, a set of pre-defined adverse events, typically only 
those possibly related to taking the study drug, constitutes the DLTs for that trial. 
Patients are traditionally monitored for DLTs during the first cycle of administration 
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of the new anti-cancer drug; however, more recent trials may monitor DLTs for a 
longer period and may include toxicities in the DLT definition that are not included in 
the conventional definition of DLTs [60]. The starting dose in these dose finding trials 
is usually a very conservative dose based on animal studies of the drug, and the 
subsequent increasing doses to be administered are pre-specified. The number of 
patients with DLTs in each dose level is used to determine the Maximum Tolerated 
Dose (MTD). For a single anti-cancer drug being tested, the MTD is usually the highest 
dose level at which the observed DLT rate is equal to or below a specified percent. 
Phase II patients are generally dosed at the MTD determined in the corresponding 
Phase I trial. The above method for MTD selection is more applicable to cytotoxic 
agents where the toxicity and efficacy are assumed to increase monotonically with 
dose than to some modern molecularly targeted therapies where the MTD may not 
be reached even at higher doses due to their low toxicity; in such cases, another 
appropriate dosing endpoint may need to be considered such as the dose at which the 
key pharmacokinetic and pharmacodynamics parameters are optimal [60, 61]. 
 
Dose finding Phase I oncology designs can be broadly categorized [62, 63, 64, 65] as 
rule based (such as the 3+3 design) or model based (such as the CRM [66] and Eff-
Tox designs [67]). The 3+3 design has been the workhorse dose finding design for 
Phase I oncology trials for a long time. It is still commonly used due to its simplicity 
and ease of implementation. However, depending on the target DLT rate of interest, 
it can be slow and inaccurate in estimating the MTD and can lead to a large portion of 
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patients receiving sub-therapeutic doses that do not produce any clinically 
meaningful response [68]. Hence, other designs, including model-based designs, have 
been explored in recent years [69, 70, 71].  
 
The establishment of the MTD for various Phase 1 oncology designs is the main focus 
of this paper. In this work, we explore extensions of the 3+3 design as well as the 
model based mTPI [72], TEQR [73], BOIN [74], CRM [66, 62] and EWOC [75, 76] 
designs and compare their performance. There is no unique criterion to evaluate 
these designs since the performance of each design depends on the true DLT 
probability at each dose and the target DLT rate of the design. Hence, we 
systematically compare several statistical operating characteristics for the true DLT 
rates generated at the same doses by three different dose-toxicity curves. In addition, 
we explore the effect of starting the trial at different dose levels below the true MTD 
on the accuracy of MTD selection in these designs. The 3+3 design and its extensions 
we consider target a DLT rate of ~0.2, and we specify a target DLT rate of 0.2 for the 
model based designs we consider. Although the results in this paper focus on a target 
DLT rate of 0.2, we explain in the discussion section the implications of targeting 
other DLT rates such as 0.1 and 0.33 with the A+B designs considered and discuss 
other A+B designs that target these rates. We also study the performance of the model 
based designs considered when the target DLT rate specified is 0.1 and 0.33. In 
contrast to previous works that compare a limited number of specific designs [77], 
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our comprehensive comparison across several designs should serve as a practical aid 
in applying these Phase I oncology designs or in developing new ones.  
 
Methods 
Rule Based Designs 
We consider the 3+3 design, which targets a DLT rate of ~0.2 [78], as well as its 
various extensions that target a DLT rate of ~0.2. We also include the simple 
accelerated titration design and the 3+3+3 design in our study (Table 1) [79, 80, 81]. 
We then investigate several of their statistical operating characteristics, such as the 
accuracy of MTD selection among others. The formal definition of the MTD is that it is 
the dose for which Probability(DLT|dose=d)=target probability.  
For the A+B designs [82] that allow only escalation, the algorithm that we follow is 
[80]: 
1) If out of A patients assigned to dose level i, the number of DLTs observed is ≤x, 
then assign A patients to dose level i+1.  
2)   If the number of DLTs observed out of A patients at dose level i is >x and <y, 
then assign B more patients to dose level i. If out of A+B patients, the number 
of DLTs observed is ≤z, then add A patients to dose level i+1. Otherwise stop 
the trial. 
3) If the number of DLTs observed out of A patients at dose level i is ≥y, then stop 
the trial. 
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We then estimate the MTD to be the dose level immediately below the last dose level 
examined. For the standard 3+3 design (Table 1), which is a special case of the general 
A+B design, this implies that the MTD is estimated to be the highest dose in which 
fewer than 33% of patients experience a DLT. 
 
For the A+B designs that also allow de-escalation, the algorithm that we follow is: 
1) Implement the rules given above for the corresponding escalation only design 
and let i be the dose level where the number of DLTs exceeds that allowed by 
the design. Then, ensure that A+B patients have been dosed at dose level i-1. If 
yes, dose level i-1 is estimated to be the MTD. 
2)  If not, add B more patients at dose level i-1.  
a) If out of the A+B patients at dose level i-1, the number of DLTs observed is 
≤z, then dose level i-1 is estimated to be the MTD even if A+B patients have 
not been dosed at dose level i-2. 
b) If out of the A+B patients at dose level i-1, the number of DLTs observed is 
>z and A+B patients have been dosed at dose level i-2, then dose level i-2 
is estimated to be the MTD. If A+B patients have not been dosed at dose 
level i-2, then add B more patients and continue the process. 
For the 3+3 design with de-escalation, the MTD is estimated to be the highest dose in 
which fewer than 33% of patients experience a DLT, and in which at least six 
participants have been treated with the study drug. 
 
  
30 
For the rule-based designs where no de-escalation is allowed, Table 1 describes the 
dose finding rules; the specific x, y, and z for each A+B design can be determined based 
on the description of these designs in Table 1. To provide a preliminary idea of the 
properties of these designs, we depict in Figure 5 the probability of not escalating for 
a single step for various true DLT rates for the escalation only designs considered. For 
example, for the 3+3 design that allows only escalation, we can escalate at each step 
or dose level if 1) 0 out of 3 patients experience a DLT or if 2) 1 out of 6 patients 
experiences a DLT; the probability of escalating at each step or dose level is q3+3pq5 
and not escalating at each step is 3p2q+p3+9p2q4+9p3q3+3p4q2, where p is the 
probability of experiencing a DLT at the current dose level and q=1-p. Using these two 
probabilities and extending the framework to any number of steps, we can then 
calculate analytically the probability of selecting any dose level as the MTD for the 
3+3 as well as other A+B designs that allow only escalation (see Lin, 2001 [83] and 
Appendix Table 1). This reference [83] also provides analytic formulae for the 
probability of MTD selection for the 3+3 and other A+B designs that allow de-
escalation as well.  
 
Model Based Designs or Designs that Allow Specification of the Target DLT rate 
In terms of model-based designs, we consider the Modified Toxicity Probability 
Interval (mTPI), Toxicity Equivalence Range (TEQR), Bayesian Optimal Interval 
Design (BOIN), Continual Reassessment Method (CRM) and Escalation with Overdose 
Control (EWOC) designs and explore their statistical operating characteristics. For 
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these designs, we can choose the DLT rate that each design will target; we specify a 
target DLT rate of 0.2 for all of them, in order to compare their performance with the 
performance of the 3+3 design and its extensions that target a DLT rate of 0.2. Note 
that although the TEQR design is not a model based design, it allows the specification 
of the target DLT rate. 
 
The mTPI design is described in detail in the reference by Ji and others [72]. The mTPI 
design is a Bayesian dose finding design that uses the posterior probability in guiding 
dose selection. The mTPI design uses a statistic for the decision rules called the unit 
probability mass (UPM), defined as the ratio of the probability mass of the interval 
and the length of the interval [72]. The toxicity probability scale is divided into three 
portions: (0, pT-1) corresponding to under-dosing, [pT-1, pT+2] corresponding to 
proper dosing and (pT+2, 1) corresponding to over-dosing. Here pT is the target 
probability of dose limiting toxicity and 1 and 2 are used to define the interval for 
the target DLT rate. The rules for escalating, staying at the same dose or de-escalating 
depend on which of these portions has the highest UPM for that dose level, based on 
a beta-binomial distribution with a beta(1,1) prior [72, 73]. For example, the next 
cohort of patients will be treated at the next higher dose level if the UPM is the largest 
for the under-dosing interval. The trial stops if dose level 1 is too toxic or if the 
maximum sample size is reached or exceeded. 
 
The TEQR design is a frequentist version of the mTPI design and is described in detail 
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in the reference by Blanchard and Longmate [73]. This design is not based on the 
posterior probability but on the empirical DLT rate. The unit interval is divided into 
three portions: (0, pT-1), [pT-1, pT+2] and (pT+2,1). The rules for escalating, staying 
at the same dose or de-escalating depend on which of these portions contains the 
empirical DLT rate for that dose level – if the empirical DLT rate lies between 0 and 
pT-1, we escalate; if it lies in the interval [pT-1, pT+2], we stay at the same dose; if it 
lies above pT+2, we de-escalate. In both the mTPI and TEQR design, we stay at the 
current dose if the current dose is safe but the next higher dose is too toxic based on 
the data. A trial using the TEQR design stops if dose level 1 is too toxic or when a dose 
level achieves the selected MTD sample size. In a trial using the TEQR or the mTPI 
design, the MTD is determined to be the highest dose level with a DLT rate that is 
closest to (and below) the target DLT rate after applying isotonic regression at the 
end of the trial.  
 
The concept of the BOIN design is similar to that of the TEQR design in terms of 
dividing the toxicity probability scale into three intervals and using these intervals 
along with the empirical DLT rate to guide dose finding [74]. In contrast to the TEQR 
and mTPI designs, where the interval for the target DLT rate is fixed and is 
independent of the dose level and the number of patients that have been treated at 
that dose level, the BOIN design is more general and permits this interval to vary with 
the dose level and the number of patients that have been treated at that dose level. In 
this design, the probability of patients being assigned to very toxic doses or to sub-
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therapeutic doses is low. A trial using the BOIN design usually stops at the pre-
planned sample size but the design allows the incorporation of early stopping rules. 
 
The CRM design and its variations are well-known and are described in several 
references [84, 85, 86, 87]. This design uses the DLT information obtained from all 
the previous patients to determine the dose level to which the next patient (or cohort 
of patients [87]) is assigned. The first patient may be given a dose whose DLT rate is 
expected to be close to the target DLT rate based on information from previous 
studies, although caution usually dictates starting at a lower dose level. The dose 
given to each subsequent patient is decided by the DLT data of all the previous 
patients in conjunction with a dose-toxicity model for e.g. a one parameter logistic 
model with parameter “a”. The estimates of “a” in the dose-toxicity model are updated 
using Bayesian methods after the DLT information from each patient is obtained. For 
example, after n patients are enrolled, 𝑎?̂? = ∫ 𝑎 𝑓(𝑎|Ω𝑛)𝑑𝑎,
∞
0
 
where  𝑓(𝑎|Ω𝑛) = 𝐿Ω𝑛(𝑎)𝑔(𝑎)/ ∫ 𝐿Ω𝑛(𝑎)𝑔(𝑎)𝑑𝑎
∞
0
; 
𝑓(𝑎|Ω𝑛) is the posterior density of a, g(a) is the prior distribution for a, 𝐿Ω𝑛(𝑎) is the 
likelihood function, and Ω𝑛 are the DLT data after n patients [88]. The dose-toxicity 
model is then used to recommend the dose level for the next patient, typically the 
dose with a DLT rate closest to but less than the updated DLT estimate from the 
model, subject to not skipping over untested doses. The stopping point for this 
process is usually the pre-determined sample size of the trial or an observation of no 
  
34 
change in dose assignment for a sequence of n patients. 
  
The EWOC design is a Bayesian adaptive dose finding design, whose unique feature is 
over-dose control i.e. the posterior probability of treating patients at doses above the 
MTD, given the data, cannot be greater than a certain pre-specified probability  [75, 
76]. In mathematical terms, we specify a prior distribution for (0, ), where 0 is 
probability of DLT at the minimum dose and  is the MTD dose, and let n() be the 
marginal posterior cdf of  given Dn (DLT data after n patients). The first patient 
receives the dose x1, and conditional on the event of no DLT at x1, the (n+1)th patient 
receives the dose xn+1=-1n(), which implies that the posterior probability of 
exceeding the MTD is equal to  [76]. The design also minimizes the under-dosing of 
patients. This means that the MTD is generally reached rapidly, and after the initial 
cohorts of patients, the remaining cohorts of patients are treated at dose levels 
reasonably close to the MTD. In this design, it is also possible to add a stopping rule 
for excessive toxicity for e.g. the trial will be stopped early if three consecutive DLTs 
are observed or if the posterior probability at the minimum dose exceeds a certain 
pre-defined value. 
 
Simulations of Rule Based Designs 
For our simulations in SAS of the 3+3 design and its extensions, we use a Bernoulli 
random generator, along with the probability of a DLT at different doses generated 
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by a dose-toxicity curve, to randomly assign each patient a DLT or not depending on 
the probability of a DLT at the assigned dose. We then implement the assignment 
rules of each design and follow each simulated trial to its conclusion. For example, for 
the designs that allow only escalation, we escalate until the number of DLTs at the last 
dose level examined exceeds that allowed by the specific design, and the MTD is then 
estimated to be one dose level below the last dose level examined. We perform these 
simulations 10000 times for each combination of design and dose-toxicity curve. The 
increase in dose at a new dose level beyond dose level 1 for each dose-toxicity curve 
investigated is based on the modified Fibonacci series (2, 1.67, 1.5, 1.4, 1.33, 1.33, 1.33 
etc.), as commonly used in many oncology trials [84].  
 
A logistic dose-toxicity curve is often used to describe the underlying relation 
between dose and toxicity in cytotoxic agents [81]. Hence, we specify the true DLT 
probability at each dose based on a specific logistic curve. In addition to the logistic 
curve, we consider a specific log logistic and a linear dose-toxicity curve to study the 
performance sensitivity of these designs to the true DLT probabilities generated by 
these different dose-toxicity curves. Table 2 shows the true DLT rates at each dose 
level for each of the three dose-toxicity curves. For determining the two unknown 
coefficients of each dose-toxicity curve, we use the DLT rates at two different doses – 
namely we assume a true DLT rate of 0.01 at dose level 1 of 100 units and a DLT rate 
of 0.2 at the true MTD (dose level 3) of 334 units. We assume a DLT rate of 0.2 at the 
MTD because the 3+3 design targets a DLT rate between 0.2 and 0.25 [78]. Hence this 
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choice of 0.2 allows a fair comparison of the simulation results from the 3+3 design 
with those from other A+B designs whose approximate target DLT rate is 0.2 (various 
A+B designs target DLT rates other than 0.2; see Table 4.1 of Chapter 4 in the 
reference by Ting [89]). However, we also study the performance of these designs to 
different target DLT rates, such as 0.1 and 0.33. 
 
We choose the following broad range of statistical operating characteristics to 
compare and evaluate the dose finding schemes considered for these three dose-
toxicity curves: the accuracy of MTD selection, the average number of dose levels 
examined and its standard deviation, the maximum and median number of dose 
levels examined, the mean and median number of patients and the median number of 
DLTs per trial, the mean number of patients dosed at the MTD, the mean percentage 
of patients dosed at the MTD, above the MTD and below the MTD, the average number 
of patients and DLTs at each dose level, the average trial DLT rate and the average 
DLT rate at the MTD. Further, we investigate the effect of the location of the starting 
dose relative to the true MTD on the accuracy of MTD selection for the chosen logistic 
and log-logistic dose-toxicity curves for e.g. when we start our trial simulation at dose 
level -3, -2 or -1 instead of at dose level 1 (see Table 2; these low doses double each 
time). In addition, we use three linear dose-toxicity curves with different offsets to 
investigate the effect of the location of the starting dose relative to the true MTD on 
the accuracy of MTD selection for the 3+3 design. Our SAS programs, available on 
request, are presently able to provide results for six designs (3+3, 2+4, 4+4 a, 5+5 a, 
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3+3+3, and simple accelerated titration designs) and three dose-toxicity curves 
(linear, logistic, log-logistic). However, the programs are simple and flexible and can 
be extended to other A+B designs as well as any other dose-toxicity curve.  
 
Simulations of Model Based Designs or Designs that Allow Specification of the Target 
DLT Rate 
We use R code provided by Ji et al. [72] to implement the mTPI design. The program 
requires the following inputs: number of simulations, target probability of dose 
limiting toxicity pT and 1 and 2 that help define the lower and upper bound of the 
interval for the target DLT rate respectively, sample size, cohort size, starting dose 
and the true DLT rate at each dose.  
 
We use the R package TEQR to implement the TEQR design. The program requires 
the following inputs: number of simulations, target probability of dose limiting 
toxicity pT and 1 and 2 that help define the lower and upper bound of the interval 
for the target DLT rate respectively, DLT probability deemed to be too toxic, desired 
sample size at the MTD, cohort size, maximum number of cohorts, starting dose and 
the true DLT rate at each dose.  
 
We use the R package BOIN to implement the BOIN design. The program requires the 
following inputs: number of simulations, target probability of dose limiting toxicity 
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pT, cohort size, number of cohorts, starting dose, cut off to eliminate an overly toxic 
dose for safety and the true DLT rate at each dose. Although the design allows the 
possibility of rules for stopping prior to reaching the planned sample size, we did not 
implement these early stopping rules, to permit fair comparisons between designs. 
 
We use a CRM trial simulator to implement the various scenarios for the CRM design. 
The program requires the following inputs: maximum sample size, cohort size, 
number of doses, starting dose, target probability of dose limiting toxicity, stopping 
probability (the trial is stopped if the probability that the lowest dose is more toxic 
than the target is greater than this value) and the true DLT rates at the various doses. 
The probability of DLT at dose i is modeled as piexp(), where pi is a constant and  is 
distributed a priori as a normal random variable with mean 0 and variance 2. The 
initial default prior probabilities of DLT used in the software are given in Appendix 
Table 3. The trial stops when the planned sample size is reached or if the lowest dose 
is too toxic. 
 
We use a web based program to implement the EWOC design. The program requires 
the following inputs: target probability of dose limiting toxicity, maximum acceptable 
probability of exceeding the target dose (), variable  increment, cohort size, sample 
size, minimum dose, maximum dose, number of dose levels and the true probability 
of DLT at each dose. Although the EWOC design allows the possibility of rules for 
stopping prior to reaching the planned sample size, the current implementation of the 
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EWOC design does not include early stopping rules. 
 
The parameters used for mTPI, TEQR, BOIN, CRM and EWOC designs are shown in 
Appendix Tables 2, 3, 4 and 5. Note that the sample size is an output of the rule-based 
A+B designs as well as the TEQR design. For the mTPI, BOIN, CRM and EWOC designs, 
we use the same sample size that the TEQR design yields for each of the three sets of 
true DLT rates. 
 
Results 
Comparison of Operating Characteristics for Designs that Target or Specify a DLT rate 
of 0.2 
For all the simulation results in this section, dose level 1 is the lowest dose (see Table 
2) and dose level 3 is the true MTD. 
For the logistic dose-toxicity curve constructed, there is a very clear separation 
between the true DLT rate at the MTD and the rates at the dose levels below and 
above it: the DLT rate of 0.2 at the MTD versus 0.04 at the dose level below and 0.71 
at the dose level above (Table 2). The DLT rate of 0.2 at dose level 3 aligns with the 
range of toxicity rates that the escalation-only A+B designs target (Table 1) and is the 
target DLT rate specified for the model-based designs. Hence all the designs pick dose 
level 3 as the MTD the largest percentage of times in our simulations, while 
incorrectly picking the other dose levels substantially less frequently (Table 3; also 
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see Appendix Table 1 for exact analytic results for MTD selection for the 3+3 design 
and its extensions). The 4+4a design with and without de-escalation, the mTPI design, 
the CRM design and the 3+3+3 design correctly pick dose level 3 as the MTD ~79%, 
~80%, ~76%, ~76% and ~76% percent of the time respectively (Table 3 and Figure 
6). The median number of patients enrolled in the trial ranges from 6 for the simple 
accelerated titration design to 25 for the 5+5 a design. As expected, with the 3+3 
design, about half of the patients are given doses below the MTD. The BOIN design 
and the 5+5 a design with and without de-escalation also treat a large percentage of 
patients at doses below the MTD – about 50%, 48% and 49% respectively. On the 
other hand, the simple accelerated titration design over-doses a large percentage of 
patients (~43%). The model based designs generally treat a large percentage of 
patients at the MTD. The average trial DLT rate ranges from 0.17 for the TEQR design 
to 0.4 for the simple accelerated titration design; the median number of DLTs per trial 
ranges from 2 for the 2+4 design without de-escalation to 5 for the 4+4a design with 
de-escalation and the 5+5 a design, among the extensions of the 3+3 design 
considered.  
 
For the log-logistic dose-toxicity curve constructed, there is a clear separation 
between the true DLT rate at the MTD and the rates at the dose levels below and 
above it: the DLT rate of 0.2 at the MTD versus 0.06 at the dose level below and 0.42 
at the dose level above (Table 2). Although this separation is not as large as it is in the 
logistic dose-toxicity curve considered, all the designs still pick dose level 3 as the 
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MTD more frequently than they pick any other dose level. The CRM, mTPI, BOIN and 
5+5 a with and without de-escalation designs correctly pick dose level 3 as the MTD 
~74%, ~63%, ~59%, ~58% and ~58% percent of the time respectively (Table 4). 
The median number of patients enrolled in the trial ranges from 7 for the simple 
accelerated titration design to 30 for the 5+5 a design with de-escalation. For this 
dose-toxicity curve, about 49% of patients are given doses below the MTD in the 3+3 
design. The BOIN, TEQR and 5+5 a design with and without de-escalation also treat a 
large percentage of patients at doses below the MTD – about 50%, 47%, 47% and 
47% respectively. On the other hand, the simple accelerated titration design over-
doses a large percentage of patients (~47%). The model based designs generally treat 
a large percentage of patients at the MTD. The average trial DLT rate ranges from 0.17 
for the TEQR design to 0.34 for the simple accelerated titration design; the median 
number of DLTs per trial ranges from 2 for the simple accelerated titration design, 
reflecting the very small sample size for this design, to 5 for the 4+4 a design and the 
5+5 a design with de-escalation, among the extensions of the 3+3 design considered. 
 
For the linear dose-toxicity curve constructed, the DLT rate at dose level 3 is 0.2 and 
the DLT rate at dose level 4 is 0.34 (Table 2). Although this separation is even smaller 
than that in the logistic and log-logistic dose-toxicity curves considered, all the 
designs except the accelerated titration design (which picks dose level 3 as the MTD 
27% of the time versus dose level 4 as the MTD 29% of the time) pick dose level 3 as 
the MTD more frequently than any other dose level. The CRM, mTPI, 5+5 a with and 
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without de-escalation and TEQR designs correctly pick dose level 3 as the MTD but 
only ~54%, ~45%, ~45%, ~45% and ~45% percent of the time respectively (Table 
5). The median number of patients enrolled in the trial ranges from 8 for the simple 
accelerated titration design to 30 for the 5+5 a design with de-escalation. For this 
dose-toxicity curve, about half of the patients are given doses below the MTD in the 
3+3 design. The BOIN, TEQR, CRM, mTPI designs and the 5+5 a design with and 
without de-escalation also treat a large percentage of patients at doses below the 
MTD – about 58%, 50%, 50%, 48%, 48% and 48% respectively. On the other hand, 
the simple accelerated titration over-doses a large percentage of patients (~49%). 
The model based designs generally treat a large percentage of patients at the MTD. 
The average trial DLT rate ranges from 0.16 for the TEQR design to 0.31 for the simple 
accelerated titration design; the median number of DLTs per trial ranges from 2 for 
the simple accelerated titration design to 5 for the 4+4 a and 5+5 a designs, among 
the extensions of the 3+3 design. 
 
Results for the accuracy of MTD selection for the 3+3 design for all the three dose-
toxicity curves considered are presented in Figure 7; results for some of the other 
designs are presented graphically in Appendix Figures 1–3. 
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Effect of Starting the Trial at Lower Dose Levels on the Accuracy of MTD Selection 
In the previous section, our simulations are started at dose level 1 for all the rule-
based designs, and dose level 3 is the true MTD for all the designs. This means that it 
takes only two escalations from the starting dose to reach the true MTD in the 
escalation only designs. However, the accuracy of MTD selection could depend on 
where the starting dose is located relative to the true MTD, for example if it is located 
six dose levels below the true MTD versus two, because some dose finding designs 
may be slow to escalate while others may be fast to do so. Thus, we investigate the 
effect of starting at lower dose levels on the accuracy of MTD selection in the 3+3 
design and its extensions that allow only escalation, using the logistic dose-toxicity 
curve in Table 2. We find that the number of patients on the trial and the percentage 
of patients who are under-dosed, both of which are outputs of the program for the 
rule-based designs, increase when we start at the lower doses, but the accuracy of 
MTD selection is largely unaffected for all these designs (Table 6). We find similar 
results for the model based designs. We also find similar results for the log-logistic 
dose-toxicity curve in Table 2 to those described for the logistic dose-toxicity curve. 
The result that the location of the starting dose relative to the true MTD does not 
affect the accuracy of MTD selection may not be surprising since the true DLT rates 
at dose level -1, -2 and -3 are very small for the logistic and log-logistic dose-toxicity 
curves used. 
 
In general, the accuracy of MTD selection will be affected when the true DLT rates at 
  
44 
these lower dose levels are much greater than 0.01 (say 0.1). We have demonstrated 
this for the 3+3 design using three linear dose-toxicity curves with different offsets 
(see Appendix Table 8 and Appendix Figure 4). In practice, the starting dose of the 
trial is usually an extremely conservative estimate based on animal studies, and the 
DLT rates at the first few dose levels are expected to be very low4. In this case, the 
accuracy of MTD selection should not be affected even when the true MTD is several 
doses above the starting dose in the rule-based escalation only designs considered, 
and we can enroll patients at the same low starting dose for these designs. 
 
Discussion 
In this work, we have systematically compared via simulations the statistical 
operating characteristics of various Phase I oncology designs, namely the 3+3 design 
and its extensions that target a DLT rate of ~0.2 as well as the mTPI, TEQR, BOIN, 
CRM and EWOC designs with a pre-specified target DLT rate of 0.2, for three sets of 
true DLT rates (generated for the same doses from a specific linear, logistic and log-
logistic dose-toxicity curve). Although this is not an exhaustive comparison of all the 
current Phase 1 oncology designs, we have covered multiple commonly used ones. 
The 3+3 design is very simple and easy to implement and hence is still commonly 
                                                        
4 While this is generally true, there are cases where the true DLT rate at low doses may not be 
close to zero, such as the following:  1) Phase 1 dose-finding trials sometimes consider all 
causality DLTs 2) The phrase “adverse events possibly related to study drug” in the definition of 
a DLT is considered to be “adverse events related to study drug”, and it is often difficult to 
conclude whether an adverse event is due to the disease or the study drug. 3) The Phase 1 trial 
escalates a new drug added to an existing regimen that has toxicities. 
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used. However, our simulations show, not unexpectedly, that it under-doses a large 
percentage of patients, and is also not the design that picks the MTD most accurately 
for any of the dose-toxicity curves examined, with or without de-escalation. 
  
All the designs examined select the MTD fairly accurately when there is a clear 
separation between the true DLT rate at the MTD and the rates at the dose level 
immediately below and above it, as is the case for the DLT rates generated using the 
chosen logistic dose-toxicity curve. However, when this separation is small, as is the 
case for the DLT rates generated using the chosen linear dose-toxicity curve, the 
accuracy of MTD selection is much lower. The separations in these true DLT rates 
depend, in turn, not only on the functional form of the dose-toxicity curve but also on 
the investigated dose levels and the parameter set-up. The considered A+B designs 
with de-escalation generally pick the MTD more accurately than the corresponding 
escalation-only design for the true DLT rates generated using the chosen log-logistic 
and linear toxicity curves, but not for the logistic one. Some of the other rule based 
designs examined pick the MTD more accurately than the 3+3 design, depending on 
the true DLT rate at each dose. For example, the 5+5 a design is as accurate as the 
model based designs in picking the MTD for the true DLT rates generated using the 
chosen log logistic and linear dose-toxicity curves but requires enrolling a larger 
number of patients compared to the other designs considered (~30 patients) and 
under-doses a large percentage of patients (~48%) for these dose-toxicity curves. 
Among the designs investigated, the simple accelerated titration design over-doses a 
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large percentage of patients. Over-dosing of patients in oncology trials is an important 
issue that needs to be considered carefully in terms of study design since the toxicities 
at the higher doses can be very harmful to patients. The EWOC design explicitly takes 
this into consideration; in this design, one can control the expected proportion of 
patients receiving doses above the MTD by pre-specifying the maximum acceptable 
probability of exceeding the target dose. Although some model-based designs can be 
more difficult to implement than rule based designs, the model based designs studied, 
mTPI, TEQR, BOIN, CRM and EWOC designs, perform well and assign the maximum 
percentage of patients to the MTD, and also have a reasonably high probability (given 
the small sample size) of picking the true MTD. The results for the Bayesian designs 
such as mTPI and EWOC may depend on the choice of the prior distribution, but our 
simulations have used the default prior for the software implementations and we 
have not performed any sensitivity analyses by changing the prior distributions in 
these designs. 
 
In our simulations, we assumed a true DLT rate of 0.2 at the MTD (dose level 3) 
because it has been shown that the standard 3+3 design targets a toxicity rate 
between 0.2 and 0.25 [78]. However, when a DLT rate of 0.1 is specified as the target 
DLT rate, the various A+B designs considered would not, in general, select the MTD 
accurately because 0.1 is not within their target range, and when a DLT rate of 0.33 
or 0.4 at the MTD is assumed, A+B designs that target a higher DLT rate would pick 
the MTD correctly more often than the 3+3 design. For example, for the linear dose-
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toxicity curve in Table 2, dose level 2 is the true MTD if the target DLT rate is 0.1. In 
this case and for the extensions of the 3+3 design considered, percentages for correct 
MTD identification for dose level 2 are lower than those for dose level 3 and range 
from 14% (accelerated titration design) to 29% (5+5 a with target range 0.2–0.25); 
percentage for 3+3 is 27% (target range 0.17–0.26). If we consider a 5+5 design that 
targets a DLT range of 0.1–0.15 (see Table 4.1 of Chapter 4 of the reference by Ting 
[89]), it selects dose level 2 as the MTD ~43% of the time, which is much higher than 
the percentages with which the 3+3 and the other A+B designs with a target DLT rate 
of ~0.2 select dose level 2 as the MTD (results for this 5+5 design are not included in 
any table). Dose level 4 is the true MTD if the target DLT rate is 0.33. If we consider 
the 4+4 b design (target range 0.38–0.44) and 5+5 b design (target range 0.3–0.35) 
(see Table 4.1 of Chapter 4 of the reference by Ting [89]), they both select dose level 
4 as the MTD ~40% of the time (results not shown here). This is much higher than 
the percentages with which the 3+3 and the other A+B designs with a target DLT rate 
of ~0.2 select dose level 4 as the MTD for the chosen linear dose-toxicity curve 
(percentages for correct MTD identification range from 20% to 31%). Results for the 
accuracy of MTD selection for the model based designs for the linear dose-toxicity 
curve given in Table 2 and for the target DLT rates of 0.1 and 0.33 are provided in 
Appendix Tables 6 and 7 respectively. The accuracy of MTD selection decreases as the 
target DLT rate increases from 0.1 to 0.33 for the mTPI, TEQR, BOIN and CRM designs, 
but not for the EWOC design, for the chosen linear dose-toxicity curve. Our 
simulations for the A+B and model based designs show that for designs where the 
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approximate DLT rate targeted by the design is known, it is critical to pick a design 
that is aligned with the true DLT rate of interest.  
 
We also showed that as long as the true DLT rates at the first few dose levels are very 
low, the accuracy of MTD selection is largely unaffected by the number of escalations 
it takes to reach the true MTD, for the rule-based escalation only designs considered 
that target a DLT rate of ~0.2. 
 
For the standard 3+3 design, our simulations, where the starting dose is two levels 
below the true MTD, show that the maximum number of dose levels examined varies 
between 5 for the logistic dose-toxicity curve and 7 for the linear and log-logistic 
dose-toxicity curves considered, while the median number of dose levels examined is 
4 for all the three dose-toxicity curves. In comparison, a literature review of 41 trials 
that were performed using the standard 3+3 design found that the median number of 
dose levels examined was 6 (range 2–12 dose levels), about 45% of the patients were 
under-dosed and about 20% of the patients were over-dosed [90]. These empirical 
results are consistent with our simulation findings that the 3+3 design under-doses 
about 50% of the patients and over-doses about 22% of the patients on the trial, for 
all the three dose-toxicity curves. The average number of patients enrolled in trials 
that are based on the 3+3 design is, however, much higher in the literature review 
with a mean of 44 patients than in our simulations, where we found a mean of ~14 
patients for all the three dose-toxicity curves. However, this literature review is based 
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on trials of targeted anti-cancer agents that reached the MTD and we do not know the 
exact percentage of trials that included expansion cohorts, and if the initial cohorts 
started at very low doses; hence, the above comparisons are not exact. Nevertheless, 
it is clear from clinical trial data as well as our simulations that Phase I trials are very 
small and thus may not provide good estimates of the MTD. If we consider designs 
with a higher average sample size, say 50–60 patients, they will have a much higher 
accuracy of MTD selection. In the future, it may be worthwhile investing in the 
enrollment of a larger number of patients even in a Phase I trial to obtain more 
accurate estimates of the right dose to be used for later Phase trials, although there is 
always a trade-off between costs (lower number of patients) and more accurate 
estimates (higher number of patients). 
Conclusions 
In conclusion, our comprehensive study compares and contrasts the 3+3 design with 
multiple other Phase I oncology designs with an approximate target DLT rate of 0.2 
for various scenarios of true underlying DLT rates, in order to understand which 
designs pick the true MTD most accurately, which under-dose and over-dose the 
maximum percentage of patients, which assign the maximum number and percentage 
of patients to the MTD cohort, which explore the maximum number of dose levels and 
enroll the most number of patients in each case. Our SAS programs are flexible and 
can be extended to include other A+B designs, other dose-toxicity curves as well as 
other evaluation criteria. The summaries in this paper provide considerable 
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information on design property trade-offs, and the means to explore additional 
settings. These may be useful aids in choosing a Phase I design for a particular setting. 
  
5
1
 
Table 1 Designs Investigated that are Extensions of the 3+3 Design that Allow Only Escalation 
Design Assignment Rule Ways to Escalate Approximate Range 
for Toxicity Rate 
Targeted by the 
Design (Table 4.1, 
Chapter 4, Ting, 
2006 [89]; Storer, 
2001 [78]) 
3+3  If 0 out of 3 enrolled patients have a DLT, then escalate to 
the next dose level and enroll 3 more; if 1 out of 3 
patients has a DLT, then add 3 more patients at the same 
dose level; if 2 or more patients out of 3 or 6 patients 
experience a DLT, then stop the trial. The MTD is one 
dose level below.  
0/3 =0% or 
1/6=16.7% 
i.e. can escalate if 
we observe 0 DLTs 
out of 3 patients, or 
1 DLT out of 6 
patients 
0.17<<0.26 
or 
0.2<<0.25 
 
2+4 If 0 out of 2 enrolled patients have a DLT, then escalate to 
the next dose level and enroll 2 more; if 1 out of 2 
patients has a DLT, then add 4 more patients at the same 
dose level; if 2 or more patients out of 2 or 6 patients 
experience a DLT, then stop the trial. The MTD is one 
dose level below. 
0/2=0% or 
1/6=16.7% 
i.e. can escalate if 
we observe 0 DLTs 
out of 2 patients, or 
1 DLT out of 6 
patients 
0.17<<0.26 
4+4 a If 0 out of 4 enrolled patients have a DLT, then escalate to 
the next dose level and enroll 4 more; if 1 or 2 out of 4 
patients have a DLT, then add 4 more patients at the 
same dose level; if 3 or more patients out of 4 or 8 
experience a DLT, then stop the trial. The MTD is one 
dose level below. 
0/4=0% or 
1/8=12.5% or 
2/8=25% 
i.e. can escalate if 
we observe 0 DLTs 
out of 4 patients, or 
1 DLT out of 8 
0.25<<0.31 
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patients, or 2 DLTs 
out of 8 patients  
5+5 a If 0 out of 5 enrolled patients have a DLT, then escalate to 
the next dose level and enroll 5 more; if 1 or 2 out of 5 
patients have a DLT, then add 5 more patients at the 
same dose level; if 3 or more patients out of 5 or 10 
experience a DLT, then stop the trial. The MTD is one 
dose level below. 
0/5=0% or 
1/10=10% or 
2/10=20%  
 
i.e. can escalate if 
we observe 0 DLTs 
out of 5 patients, or 
1 DLT out of 10 
patients, or 2 DLTs 
out of 10 patients 
0.2<<0.25 
3+3+3 If 0 out of 3 enrolled patients have a DLT, then escalate to 
the next dose level and enroll 3 more; if 1 out of 3 
patients has a DLT, then add 3 more patients at the same 
dose level; if 2 out of 6 patients have a DLT then add 3 
more patients at the same dose level; if 2 or more 
patients out of 3 patients experience a DLT or 3 or more 
out of 6 or 9 patients experience a DLT, then stop the 
trial. The MTD is one dose level below. 
0/3=0% or 
1/6=16.7% or 
2/9=22.2%  
i.e. can escalate if 
we observe 0 DLTs 
out of 3 patients, or 
1 DLT out of 6 
patients, or 2 DLTs 
out of 9 patients 
 
Simple 
Accelerated 
Titration 
Design 
Successively assign a single patient at each dose level 
until the patient has a DLT.  Then switch to the 3+3 
design (i.e. add 2 more patients to the dose level at which 
a DLT is first seen and then follow the rules of the 3+3 
design). 
  
The table above provides the rules for the escalation only designs but we also allow de-escalation in the 3+3, 2+4, 4+4 a, 
and 5+5 a designs and follow the algorithm described in the methods section. The designs that also allow de-escalation 
will target a slightly lower DLT rate than their counterparts that allow only escalation. One method to estimate the 
approximate target DLT rate of each design that also allows de-escalation is to run simulations for each design using 
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several different dose-toxicity curves and then perform the following calculation: one needs to compute the sum of the 
product of the true DLT rate at each dose and the probability that that dose is selected as the MTD from simulations for 
each scenario and then find the average of this value across the various scenarios (dose-toxicity curves). Based on our 
results for the logistic, log-logistic and linear dose-toxicity curves in Table 3-5, we find that the approximate target DLT 
rate of the 3+3 design with de-escalation is 0.17, of the 2+4 design with de-escalation is 0.18, of the 4+4 a design with de-
escalation is 0.21 (which is why we also included the 4+4 a design, even though its target DLT rate for the escalation only 
case is a little higher than 0.2), and of the 5+5 a design with de-escalation is 0.17. The 3+3+3 design targets an 
approximate DLT rate of 0.21. 
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Table 2 DLT Rates at Different Doses for the Three Dose-toxicity Curves (also see Appendix Figure 5) 
  Linear Dose-toxicity 
DLT rate= min 
(-0.071197+0.000811966*dose,1) 
Logistic Dose-toxicity 
Log(DLT rate/(1-DLT 
rate)) =-5.96641+ 
0.013713*dose 
Log-Logistic Dose-toxicity 
Log(DLT rate/(1-DLT rate)) 
=-16.8485+2.66078*log(dose) 
Dose 
Level 
Dose DLT Rate DLT Rate DLT Rate 
-3 12.5 
units 
 0.00303 0.00004 
-2 25  0.0036 0.0003 
-1 50  0.00506 0.0016 
1 100  0.01 0.01 0.01 
2 200 0.09 0.04 0.06 
3 334 0.2 0.2 0.2 
4 501 0.34 0.71 0.42 
5 701.4 0.50 0.97 0.64 
6 932.86 0.69 1 0.79 
7 1240.71 0.94 1 0.89 
8 1650.14 1 1 0.95 
9 2194.69 1 1 0.97 
10 2918.93 1 1 0.99 
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Table 3 Simulation Results: Logistic Dose-toxicity: Log(DLT rate/(1-DLT rate)) =-5.96641+ 0.013713*dose 
Design % of times 
that dose 
level 3 is 
selected as 
the MTD 
 
% of times 
that doses 
below the 
MTD (dose 
levels 1 and 
2) are 
selected as 
the MTD 
 
% of times 
that doses 
above the 
MTD (dose 
levels 4 and 
above) are 
selected as 
the MTD 
Average 
Number of 
Dose Levels 
Examined 
Std of Dose 
Levels 
Examined 
Max Dose 
Levels 
Examined 
Median 
Dose Levels 
Examined 
Average 
Number of 
Patients per 
Trial 
Median 
Number of 
Patients 
per Trial 
Median 
Number of 
DLTs per 
Trial 
Average 
Sample 
Size at 
MTD 
Average % 
of pts dosed 
at MTD 
Average 
% of pts 
under- 
dosed 
Average 
% of pts 
over- 
dosed 
3+3* 68.05 
(64.32) 
29.78 
(34.75) 
2  
(0.76) 
3.7 
 
0.54 
 
5 
 
4 
 
13.06 
(15.53) 
12  
(15) 
3  
(3) 
4.1 
(5.6) 
31.43 
(35.87) 
50.30 
(48.47) 
18.26 
(15.66) 
2+4* 69.62 
(64.67) 
23.54 
(34.47) 
6.77 
(0.77) 
3.8 
 
0.56 
 
5 
 
4 
 
10.48 
(14.59) 
10  
(14) 
2  
(3) 
3.22 
(5.75) 
30.86 
(40.17) 
43.23 
(39.69) 
25.90 
(20.14) 
4+4 a* 79.65 
(78.79) 
19.39 
(20.45) 
0.96  
(0.75) 
3.8 
 
0.42 
 
5 
 
4 
 
19.23 
(21.63) 
20  
(20) 
4  
(5) 
6.24 
(7.86) 
32.67 
(36.68) 
46.08 
(44.13) 
21.26 
(19.19) 
5+5 a* 69.19 
(67.5) 
30.68 
(32.43) 
0.13  
(0.05) 
3.7 
 
0.47 
 
5 
 
4 
 
23.14 
(26.12) 
25  
(25) 
5  
(5) 
8.05 
(9.67) 
34.96 
(37.13) 
48.83 
(48.26) 
16.21 
(14.61) 
3+3+3 75.9 21.77 2.3 3.8 0.47 5 4 13.96 15 3 4.59 32.25 47.72 20.03 
Simple 
accelerated 
titration 
62.98 14.51 22.43 4.1 0.64 6 4 7.14 6 3 1.88 24.90 32.06 43.04 
               
mTPI 76.1 23 0.85 5  5 5 21 (max) 21 (max)  10.1    47.88 41.9 10.22 
TEQR 70 27 1 5  5 5 21.78 21  9.5 43.66 46.74 9.6 
BOIN 72.3 25.4 2.3 5  5 5 21 (max) 21 (max) 3.4 (mean) 8.6 41.15 49.76 9.09 
CRM 76 21 3 5  5 5 21 (max) 21 (max) 3.6 (mean) 9.8 46.88 43.97 9.15 
EWOC 70.45 9.7 19.85 5  5 5 21 (max) 21 (max)  10.1 48.04 40.06 11.9 
The bold highlighting shows the designs predicted by simulations to pick the MTD most accurately, to enroll the largest and smallest number of patients, to dose 
the maximum percentage of patients at the MTD, to under-dose the maximum percentage of patients, and to over-dose the maximum percentage of patients. Note 
also that the sum of columns 2 to 4 may add up to <100% because the remaining small percentage of times, no dose level is selected as the MTD.   
* The numbers shown in brackets are for a corresponding design that allows dose de-escalation.  
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Table 4 Simulation Results: Log-Logistic Dose-toxicity: Log(DLT rate/(1-DLT rate)) =-16.8485+2.66078*log(dose) 
Design % of 
times that 
dose level 
3 is 
selected 
as the 
MTD 
 
% of times 
that doses 
below the 
MTD (dose 
levels 1 
and 2) are 
selected as 
the MTD 
 
% of times 
that doses 
above the 
MTD (dose 
levels 4 
and above) 
are 
selected as 
the MTD 
Average 
Number of 
Dose 
Levels 
Examined 
Std of 
Dose 
Levels 
Examined 
Max Dose 
Levels 
Examined  
Median 
Dose 
Levels 
Examined 
Average 
Number 
of 
Patients 
per Trial 
Median 
Number of 
Patients 
per Trial 
Median 
Number of 
DLTs per 
Trial 
Average 
Sample 
Size at 
MTD 
Average 
% of pts 
dosed 
at MTD 
Average 
% of pts 
under- 
dosed 
Average 
% of pts 
over- 
dosed 
3+3* 
49.45 
(50.55) 
31.66 
(35.95) 
18.72 
(13.38) 
3.8 
 
0.8 
 
7 
 
4 
 
14.2 
(16.73) 
15  
(15) 
3  
(3) 
4.00 
(5.18) 
28.72 
(31.16) 
48.61 
(47.44) 
22.67 
(21.4) 
2+4* 
45.8 
(50.89) 
24.48 
(33.94) 
29.6 
(15.05) 
4.1 
 
0.87 
 
8 
 
4 
 
11.89 
(16.29) 
12  
(16) 
3  
(3) 
3.16 
(5.19) 
27.49 
(32.71) 
40.05 
(37.8) 
32.46 
(29.49) 
4+4 a* 
56.73 
(57.76) 
20.26 
(20.69) 
23.01 
(21.54) 
4 
 
0.7 
 
6 
 
4 
 
21.96 
(24.23) 
20  
(24) 
5  
(5) 
6.18 
(7.4) 
29.09 
(31.3) 
42.78 
(41.49) 
28.13 
(27.21) 
5+5 a* 
58.07 
(58.09) 
31.38 
(33.18) 
10.54 
(8.71) 
3.8 
 
0.65 
 
6 
 
4 
 
25.54 
(28.43) 
25  
(30) 
4  
(5) 
7.96 
(9.37) 
31.95 
(33.38) 
46.85 
(46.63) 
21.21 
(19.99) 
3+3+3 53.96 22.43 23.56 4 0.74 7 4 15.89 15 3 4.55 28.9 44.54 26.56 
Simple 
accelerated 
titration 36.32 15.67 47.95 4.5 1.05 9 4 8.11 7 2 1.87 22.93 29.81 47.25 
               
mTPI 63.15 22.45 14.35 7  7 7  24 (max) 24 (max)  10.0 41.67 40.49 17.85 
TEQR 57 32 8 7  7 7 22.71 24  8.6 37.78 46.98 15.24 
BOIN 59.2 28 12.7 7  7 7 24 (max) 24 (max) 3.7 (mean) 8.9 37.08 50 12.92 
CRM 74 18 8 7  7 7  24 (max) 24 (max) 4.0 (mean) 10.1 41.92 43.42 14.67 
EWOC 57.1 9.7 33.2 7  7 7  24 (max) 24 (max)  11.4 47.32 22.92 29.76 
         
The bold highlighting shows the designs predicted by simulations to pick the MTD most accurately, to enroll the largest and smallest number of patients, to dose 
the maximum percentage of patients at the MTD, to under-dose the maximum percentage of patients, and to over-dose the maximum percentage of patients. Note 
also that the sum of columns 2 to 4 may add up to <100% because the remaining small percentage of times, no dose level is selected as the MTD.   
* The numbers shown in brackets are for a corresponding design that allows dose de-escalation. 
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Table 5 Simulation Results: Linear Dose-toxicity: DLT rate=min(-0.071197+0.000811966*dose, 1) 
Design % of times 
that dose 
level 3 is 
selected as 
the MTD 
 
% of times 
that doses 
below the 
MTD (dose 
levels 1 and 
2) are 
selected as 
the MTD 
% of times 
that doses 
above the 
MTD (dose 
levels 4 and 
above) are 
selected as 
the MTD 
Average 
Number of 
Dose Levels 
Examined 
Std of Dose 
Levels 
Examined 
Max Dose 
Levels 
Examined 
Median 
Dose Levels 
Examined 
Average 
Number 
of 
Patients 
per Trial 
Median 
Number 
of 
Patients 
per Trial 
Median 
Number 
of DLTs 
per Trial 
Average 
Sample 
Size at 
MTD 
Average 
% of pts 
dosed at 
MTD 
Average 
% of pts 
under- 
dosed 
Average 
% of pts 
over- 
dosed 
3+3* 
37.49 
(39.86) 
34.6 
(37.62) 
27.72 
(22.39) 
3.9 
  
1.01 
 
7  
 
4 
  
14.75 
(17.22) 
15  
(18) 
3  
(3) 
3.85 
(4.76) 
26.44 
(27.73) 
49.64 
(48.67) 
23.92 
(23.60) 
2+4* 
34.59 
(39.72) 
26.88 
(33.93) 
38.42 
(26.27) 
4.2 
 
1.1 
 
7 4 12.52 
(16.9) 
12  
(16) 
3  
(3) 
3.08 
(4.63) 
25.52 
(28.2) 
40.75 
(38.7) 
33.73 
(33.1) 
4+4 a* 
40.56 
(41.94) 
21.47 
(21.68) 
37.97 
(36.36) 
4.2 
 
0.92 
 
7 
 
4 
 
23.64 
(25.78) 
24  
(24) 
5  
(5) 
6.07 
(6.97) 
26.73 
(27.96) 
42.52 
(41.28) 
30.75 
(30.76) 
5+5 a* 
44.59 
(45.44) 
33.92 
(35.13) 
21.48 
(19.41) 
3.8 
 
0.85 
 
6 
 
4 
 
26.85 
(29.63) 
25  
(30) 
5  
(5) 
7.66 
(8.74) 
29.24 
(29.88) 
47.87 
(47.9) 
22.89 
(22.23) 
3+3+3 39.56 24.73 35.63 4.1 0.97 7 4 16.99 18 3 4.43 26.57 44.55 28.89 
Simple 
accelerated 
titration 26.69 16.99 56.26 4.7 1.26 8 5 8.67 8 2 1.85 21.5 29.94 48.57 
               
mTPI 45.3 28.6 26.05 7  7 7  21 (max) 21 (max)  6.9 32.71 47.99 19.29 
TEQR 45 37 15 7  7 7 22.88 21  7.4 32.12 49.78 18.09 
BOIN 40.4 38.1 21.6 7  7 7 21 (max) 21 (max) 
3.0 
(mean) 
6.1 29.05 57.62 13.33 
CRM 54 24 22 7  7 7 21 (max) 21 (max) 3.3 
(mean) 
7.2 34.43 49.57 16.00 
EWOC 40.35 8.90 50.75 7  7 7  21 (max) 21 (max)  8.5 40.39 23.81 35.81 
The bold highlighting shows the designs predicted by simulations to pick the MTD most accurately, to enroll the largest and smallest number of patients, to dose 
the maximum percentage of patients at the MTD, to under-dose the maximum percentage of patients, and to over-dose the maximum percentage of patients. Note 
also that the sum of columns 2 to 4 may add up to <100% because the remaining small percentage of times, no dose level is selected as the MTD.   
* The numbers shown in brackets are for a corresponding design that allows dose de-escalation. 
 
  
  
5
8
 
Table 6 Simulation Results: Logistic Dose-toxicity: Log(DLT rate/(1-DLT rate)) =-5.96641+ 0.013713*dose: Effect of Starting at Lower Doses on the Accuracy of 
MTD Selection 
Design Median 
Sample 
Size 
when 
Starting 
Dose is 
Dose 
Level -3 
Accuracy of 
MTD 
Selection 
when 
Starting 
Dose is Dose 
Level -3 (% 
of Times 
Dose Level 3 
is Selected 
as MTD) 
% of Patients 
Underdosed 
when Starting 
Dose is Dose 
Level -3 
Median 
Sample 
Size 
when 
Starting 
Dose is 
Dose 
Level -2 
Accuracy of 
MTD 
Selection 
when 
Starting 
Dose is Dose 
Level -2 (% 
of Times 
Dose Level 3 
is Selected 
as MTD) 
% of Patients 
Underdosed 
when Starting 
Dose is Dose 
Level -2 
Median 
Sample 
Size when 
Starting 
Dose is 
Dose Level 
-1 
Accuracy of 
MTD 
Selection 
when 
Starting 
Dose is Dose 
Level -1 (% 
of Times 
Dose Level 3 
is Selected 
as MTD) 
% of Patients 
Underdosed 
when Starting 
Dose is Dose 
Level -1 
Median 
Sample 
Size 
when 
Starting 
Dose is 
Dose 
Level 1 
Accuracy of 
MTD 
Selection 
when 
Starting 
Dose is 
Dose Level 
1 (% of 
Times Dose 
Level 3 is 
Selected as 
MTD) 
% of Patients 
Underdosed 
when Starting 
Dose is Dose 
Level 1 
3+3 21 67.79% 70.84% 18 67.11% 66.16% 15 67.82% 59.74% 12 68.05% 50.30% 
2+4 16 70.45% 63.96% 14 70.51% 59.06% 12 69.76% 52.45% 10 69.62% 43.23% 
4+4 a 32 79.59% 67.02% 28 79.54% 62.21% 24 79.53% 55.66% 20 79.65% 46.08% 
5+5 a 40 69.48% 69.18% 35 69.05% 64.48% 30 69.80% 58.22% 25 69.19% 48.83% 
3+3+3 24 75.92% 68.45% 21 75.85% 63.66% 18 76.09% 57.14% 15 75.9% 47.72% 
Accelerated 
Titration 
9 63.35% 52.96% 8 63.79% 47.60% 7 63.00% 41.04% 6 62.98% 32.06% 
             
mTPI 30 
(max) 
77.3% 59.71% 
27 
(max) 
77.5% 54.49% 24 (max) 77.8% 48.72% 
21 
(max) 
76.1% 41.9% 
TEQR 30 70% 62.91% 27 69% 59.17% 24 71% 54.22% 21 70% 46.74% 
BOIN 30 
(max) 
72.2 65.89% 
27 
(max) 
71% 62.08% 24 (max) 72% 57.5% 
21 
(max) 
72.3% 49.76% 
CRM 30 
(max) 
75% 60.88% 
27 
(max) 
76% 56.2% 24 (max) 76% 50.73% 
21 
(max) 
76% 43.97% 
EWOC 30 
(max) 
70.2% 52.76% 
27 
(max) 
70.85% 45.76% 24 (max) 65.3% 47.4% 
21 
(max) 
70.45% 40.06% 
The sample size is an output for the A+B escalation only designs. For the model based designs, the sample size is an output for the TEQR design and we use the same 
sample size obtained from the TEQR design for the other model based designs. For the CRM design, a prior DLT rate of 0.01, 0.05 and 0.1 are used at dose levels -1, 
-2 and -3.  
  
5
9
 
Figure 5 The probability of not escalating at each step for different true DLT rates for the escalation only designs 
considered that are extensions of the 3+3 design and that target a DLT rate of ~0.2. 
Legend: Figure 5 depicts the probability of not escalating at each step for different true DLT rates for the escalation only 
designs considered that are extensions of the 3+3 design and that target a DLT rate of ~0.2. These probabilities are derived 
analytically based on the decision rules of each design as given in Table 1. 
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Figure 6 The percentage of times each design considered selects the MTD (Dose Level 3) for the true DLT rates generated 
from the logistic dose-toxicity curve given in Table 2.  
 
Legend: Figure 6 depicts the percentage of times each design considered selects the MTD (Dose Level 3) for the true DLT rates generated 
from the logistic dose-toxicity curve given in Table 2. These percentages are from simulations and the results are shown in Tables 3-5.  
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Figure 7 The percentage of times that the 3+3 design selects each dose level as the MTD for the true DLT rates given in 
Table 2.  
 
 
3+3 logistic implies the 3+3 design with the DLT rates generated from the logistic dose-toxicity curve in Table 2 and similarly for 
the others. 
P=Mean Sample Size and D=Mean Number of DLTs at each dose level (from 10000 simulations). 
 
Legend: Figure 7 depicts the percentage of times that the 3+3 design selects each dose level as the MTD for the true DLT rates given in Table 
2, generated from the three dose-toxicity curves. These percentages are from simulations and the results are shown in Tables 3–5.
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Appendix Chapter 2 
Appendix Table 1: Analytic Results for MTD Selection: 
Logistic Dose-toxicity Curve: 
Dose 
Level 
Probability of 
DLT 
Probability of Being the Highest Dose Level Examined  
  3+3 2+4 4+4 a 5+5 a 3+3+3 
1 0.01 0.00 0.00 0.00 0.00 0.00 
2 0.04 0.02 0.01 0.00 0.01 0.01 
3 0.2 0.29 0.23 0.19 0.30 0.21 
4 0.71 0.68 0.70 0.79 0.69 0.76 
5 0.97 0.02 0.07 0.01 0.00 0.02 
 
Log-Logistic Dose-toxicity Curve: 
Dose 
Level 
Probability of 
DLT 
 Probability of Being the Highest Dose Level Examined 
  3+3 2+4 4+4 a 5+5 a 3+3+3 
1 0.01 0.00 0.00 0.00 0.00 0.00 
2 0.06 0.04 0.03 0.01 0.02 0.02 
3 0.2 0.28 0.22 0.19 0.30 0.21 
4 0.42 0.50 0.46 0.57 0.58 0.53 
5 0.64 0.17 0.25 0.22 0.10 0.22 
6 0.79 0.01 0.04 0.01 0.00 0.01 
 
Linear Dose-toxicity Curve: 
Dose 
Level 
Probability of 
DLT 
  Probability of Being the Highest Dose Level Examined 
  3+3 2+4 4+4 a 5+5 a 3+3+3 
1 0.01 0.00 0.00 0.00 0.00 0.00 
2 0.09 0.08 0.06 0.03 0.05 0.04 
3 0.2 0.27 0.21 0.19 0.29 0.21 
4 0.34 0.38 0.34 0.40 0.45 0.39 
5 0.5 0.23 0.27 0.32 0.20 0.29 
6 0.69 0.05 0.10 0.06 0.02 0.07 
7 0.94 0.00 0.01 0.00 0.00 0.00 
These are exact analytic results for MTD selection for extensions of the 3+3 design 
that allow only escalation, and the results are very close to those provided in Tables 
3–5 for MTD selection, which are based on simulations. The rows highlighted in bold 
show the probability of dose level 3 being chosen as the MTD for the various designs 
and dose-toxicity curves. 
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Appendix Table 2: Parameters for the mTPI and TEQR Designs: 
Parameter mTPI Design TEQR Design 
Number of simulations 2000 2000 
Target toxicity 
probability pT 
0.2 0.2 
1 0.05 0.05 
2 0.05 0.05 
Starting dose Dose level 1 Dose level 1 
Cohort size 3 3 
Sample size Same as the median 
sample size obtained from 
TEQR design 
Median sample size is 
automatically determined 
(not an input) 
Number of dose levels Same as the maximum 
dose levels examined 
(obtained from 
simulations) for the 3+3 
design 
Same as the maximum 
dose levels examined 
(obtained from 
simulations) for the 3+3 
design 
DLT probability 
deemed to be too toxic 
to allow further study 
at that dose level 
NA 0.34 
Desired sample size at 
MTD 
NA 12 
Maximum number of 
cohorts 
NA 30 
True DLT rate at each 
dose level 
Values from Table 2 for 
each dose-toxicity curve 
Values from Table 2 for 
each dose-toxicity curve 
The mTPI software (R code) is available at: 
http://health.bsd.uchicago.edu/yji/software2.htm 
R code for the TEQR design was developed using the package TEQR. 
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Appendix Table 3: Parameters for the BOIN Design: 
Parameter BOIN Design 
Number of 
simulations 
2000 
Target toxicity 
probability pT 
0.2 
The interval for the 
target toxicity 
probability 
Used the Default Interval Determined by the design, which 
is (0.16, 0.24) for pT=0.2, and is very close to the interval 
(0.15, 0.25) used for the other model based designs. 
Starting dose Dose level 1 
Cohort size 3 
Sample size Same as the median sample size obtained from TEQR 
design (the sample size is not a direct input of the program 
but the number of cohorts is an input and we input the 
number of cohorts such that the number of cohorts*cohort 
size is the desired sample size). 
Number of cohorts Desired sample size/cohort size 
Cut off to eliminate 
an overly toxic dose 
for safety 
0.95 
True DLT rate at 
each dose level 
Values from Table 2 for each dose-toxicity curve 
R code for the BOIN design was developed using the package BOIN. 
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Appendix Table 4: Parameters for the CRM Design Used in CRMTrialSimulator: 
Parameter CRM Design 
Number of simulations 2000 
Max sample size Same as the median sample size 
obtained from the TEQR design 
Cohort size 3 
Number of dose levels planned Same as the maximum dose levels 
examined (obtained from simulations) 
for the 3+3 design 
Starting dose Dose level 1 
Target toxicity probability 0.2 
True DLT rate at each dose level Values from Table 2 for each dose-
toxicity curve 
CRM Inputs:  
The probability of toxicity at dose i is 
modeled as piexp(), where pi is a 
constant and  is distributed a priori as 
a normal random variable  
 is normally disturbed with mean 0 and 
variance 2 
Prior probabilities of toxicity used are 
the defaults in the program 
at dose level 1=0.15, at dose level 2=0.25, 
at dose level 3=0.3, at dose level 4=0.45, 
at dose level 5=0.51, at dose level 6=0.56, 
at dose level 7=0.6 
Stopping probability (the trial is 
stopped if the probability that the 
lowest dose is more toxic than the 
target is greater than this value) 
0.9 
The software can be found at: 
https://biostatistics.mdanderson.org/SoftwareDownload/SingleSoftware.aspx?Soft
ware_Id=13 
After the first cohort, each successive cohort is given the dose whose posterior 
probability of toxicity given the data collected thus far is closest to the target, subject 
to one additional requirement: one cannot skip over an untried dose. If the method 
would otherwise skip over an untried dose, the lowest untried dose is given instead. 
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Appendix Table 5: Parameters for the EWOC Design Used in Web-EWOC 
Simulator: 
Parameter EWOC Design 
Number of simulations 2000 
Sample size Same as the median sample size 
obtained from the TEQR design 
Cohort size 3 
Number of dose levels planned Same as the maximum dose levels 
examined (obtained from simulations) 
for the 3+3 design 
Starting dose Dose level 1 
Target probability of dose limiting 
toxicity 
0.2 
Probability of exceeding target dose () 0.25 
Variable  increment (resource to 
control the dose escalation rate in the 
beginning of the trial) 
0.04 
Minimum dose and Maximum dose 100 and 500 are the default values (the 
allowable range is 0 to 500) and the 
doses are equally spaced 
True DLT rate at each dose level Values from Table 2 for each dose-
toxicity curve 
Prior distribution ρ0  ∼ Uniform(0, 0.2) (the prior for ρ0, the 
probability of DLT at the minimum dose, is 
Uniform(0, 0.2)) 
γ ∼ Uniform(100, 500) (the prior for the 
maximum tolerated dose γ is  
Uniform(100, 500)) 
 
The EWOC software is available at:  
https://biostatistics.csmc.edu/ewoc/ewocWeb.php 
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Appendix Table 6: Simulation Results: Linear Dose-toxicity: DLT rate=min (-0.071197+0.000811966*dose, 1) – Target DLT rate=0.1 for the Model-
Based Designs and Dose Level 2 is the True MTD: 
Design % of 
times that 
dose level 
2 is 
selected 
as the 
MTD 
 
% of times 
that doses 
below the 
MTD (dose 
level 1) are 
selected as 
the MTD 
% of times 
that doses 
above the 
MTD (dose 
levels 3 and 
above) are 
selected as 
the MTD 
Average 
Number 
of Dose 
Levels 
Examined 
Std of 
Dose 
Levels 
Examined 
Max Dose 
Levels 
Examined 
Median 
Dose 
Levels 
Examined 
Average 
Number 
of 
Patients 
per Trial 
Median 
Number 
of 
Patients 
per Trial 
Median 
Number 
of DLTs 
per 
Trial 
Average 
Sample 
Size at 
MTD 
Average 
% of pts 
dosed at 
MTD 
Average 
% of pts 
under- 
dosed 
Average 
% of pts 
over- 
dosed 
3+3 26.85 7.75 65.21 3.9  1.01 7  4  14.75  15  3  3.6 24.75 20.91 54.34 
               
mTPI 55.75 13.7 30.5 7  7 7 24 
(max) 
24 
(max) 
 9.5 39.4 22.76 37.84 
TEQR 50 15 31 7  7 7 22.81 24  8.8 38.58 23.63 37.79 
BOIN 55.9 14.5 29.5 7  7 7 24 
(max) 
24 
(max) 
2.9 
(mean) 
9.6 39.83 26.97 33.2 
CRM 57 24 20 7  7 7 24 
(max) 
24 
(max) 
2.3 
(mean) 
8.9 37.03 36.24 26.73 
EWOC 43.35 4.15 52.5 7  7 7 24 
(max) 
24 
(max) 
 8.1 33.93 17.87 48.19 
The sum of columns 2 to 4 may add up to <100% because the remaining small percentage of times, no dose level is selected as the MTD.   
The default interval for the target DLT rate in the R package is used for the BOIN design. 
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Appendix Table 7: Simulation Results: Linear Dose-toxicity: DLT rate=min (-0.071197+0.000811966*dose, 1) – Target DLT rate=0.33 for the Model-
based Designs and Dose Level 4 is the True MTD: 
Design % of times 
that dose 
level 4 is 
selected as 
the MTD 
 
% of times 
that doses 
below the 
MTD (dose 
levels 3 
and 
below) are 
selected as 
the MTD 
% of times 
that doses 
above the 
MTD (dose 
levels 5 
and above) 
are 
selected as 
the MTD 
Average 
Number of 
Dose 
Levels 
Examined 
Std of Dose 
Levels 
Examined 
Max Dose 
Levels 
Examined 
Median 
Dose 
Levels 
Examined 
Average 
Number 
of 
Patients 
per Trial 
Median 
Number 
of 
Patients 
per Trial 
Median 
Number 
of DLTs 
per 
Trial 
Average 
Sample 
Size at 
MTD 
Average 
% of pts 
dosed at 
MTD 
Average 
% of pts 
under- 
dosed 
Average 
% of pts 
over- 
dosed 
3+3 22.77 72.09 4.95 3.9  1.01 7  4  14.75  15  3  2.8 19.14 71.76 9.1 
               
mTPI 44.1 42.2 13.7 7  7 7 24 (max) 24 (max)  6.0 24.98 67.16 7.86 
TEQR 31 65 4 7  7 7 24.57 24  6.1 24.75 65.73 9.52 
BOIN 43.2 39.5 17.2 7  7 7 24 (max) 24 (max) 
5.1 
(mean) 
6.0 25 65.83 9.17 
CRM 
53 32 15 
7  7 7 24 (max) 24 (max) 
5.7 
(mean) 
7.2 30 59.38 10.63 
EWOC 48.15 11.05 40.8 7  7 7 24 (max) 24 (max)  8.0 33.44 43.27 23.29 
The sum of columns 2 to 4 may add up to <100% because the remaining small percentage of times, no dose level is selected as the MTD.   
The default interval for the target DLT rate in the R package is used for the BOIN design. 
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Appendix Table 8: Effect of the location of the starting dose relative to the true MTD on the accuracy of MTD 
selection for the 3+3 design for the three linear dose-toxicity curves with different offsets shown in Appendix 
Figure 4: 
                                          Starting dose level relative to true MTD 
 
 
 
 
 
 
-6 implies that the starting dose is 6 dose levels below the true MTD, and similarly for the others. We observe that for an 
offset of 0 (when the true DLT rate=0 for the first 6 dose levels), the accuracy of MTD selection is not affected by how 
many dose levels below the true MTD the starting dose level is located i.e. the percentage of times (out of 10000 
simulations) that dose level 6 (true MTD) is selected as the MTD  is constant (~30% ) for the different starting dose 
locations relative to the true MTD. However for an offset of 0.1 (when the true DLT rate=0.1 for the first 6 dose levels), 
the accuracy of MTD selection is affected by how many dose levels below the true MTD the starting dose level is located. 
 
Appendix Table 9: Accuracy of MTD selection in the 3+3 design when the true DLT rate at one of the dose levels 
falls within the target DLT rate interval (0.17–0.26) and when more than one of the true DLT rates  fall within 
the target DLT rate interval 
Dose 
Level  
DLT 
Rate 
Accuracy of 
MTD Selection 
DLT 
Rate 
Accuracy of 
MTD Selection 
DLT 
Rate 
Accuracy of 
MTD Selection 
DLT 
Rate 
Accuracy of 
MTD Selection 
1 0.01 1.5% 0.01 23.01% 0.01 25.09% 0.01 1.58% 
2 0.04 28.28% 0.17 32.06% 0.18 46.46% 0.04 41.33% 
3 0.2 68.05% 0.26 43.63% 0.36 27.60% 0.26 55.23% 
4 0.71 2% 0.71 1.16% 0.71 0.7% 0.71 1.68% 
5 0.97 0% 0.97 0% 0.97 0% 0.97 0% 
This table provides an example of when the exact target DLT rate is not one of the true DLT rates.  
The second column contains the true DLT rates based on the logistic dose-toxicity curve in Table 2. The 3+3 design targets 
a DLT rate of ~0.2 with an interval of (0.17, 0.26). For the columns where the true DLT rate at exactly one of the dose 
Background 
DLT Rate 
-6 -5 -4 -3 -2 
.1 21.27% 23.91% 26.43% 29.24% 32.36% 
.05 26.41% 28.22% 28.05% 29.45% 29.69% 
0 29.86% 31.07% 30.44% 30.9% 30.38% 
  
7
0
 
levels falls within this interval (i.e. columns 2, 6 and 8), that dose level is the true MTD. However, for column 4, the true 
DLT rates at two of the dose levels fall within this interval, and both these dose levels can be considered the true MTD. In 
this case, the accuracy of MTD selection is 75.69% (=32.06%+43.63%). For columns 3, 7 and 9, the accuracy of MTD 
selection is highlighted in blue. Note also that the sum of each column in columns 3, 5, 7 and 9 may add up to <100% 
because the remaining small percentage of times, no dose level is selected as the MTD.  Also see Appendix Figure 6. 
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Appendix Figure 1: 
 
 
5+5 a logistic implies the 5+5 a design with the true DLT rates given in Table 2, generated from the logistic dose-toxicity curve, and 
similarly for the others. 
P=Mean Sample Size and D=Mean Number of DLTs at each dose level (from 10000 simulations). 
The figure depicts the percentage of times that the 5+5 a design selects each dose level as the MTD for the true DLT rates given in 
Table 2, generated from the three dose-toxicity curves. These percentages are from simulations and the results are shown in Tables 
3–5. 
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Appendix Figure 2: 
 
mTPI logistic implies the mTPI design with the true DLT rates given in Table 2, generated from the logistic dose-toxicity 
curve, and similarly for the others. P=Mean Sample Size at each dose level (from 10000 simulations). 
The figure depicts the percentage of times that the mTPI design selects each dose level as the MTD for the true DLT rates 
given in Table 2, generated from the three dose-toxicity curves. These percentages are from simulations and the results 
are shown in Tables 3–5. 
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Appendix Figure 3: 
 
CRM logistic implies the CRM design with the true DLT rates given in Table 2, generated from the logistic dose-toxicity curve, and 
similarly for the others.  
P=Mean Sample Size at each dose level (from 10000 simulations). 
The figure depicts the percentage of times that the CRM design selects each dose level as the MTD for the true DLT rates given in 
Table 2, generated from the three dose-toxicity curves. These percentages are from simulations and the results are shown in Tables 
3–5. 
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Appendix Figure 4: 
 
 
The figure depicts three linear dose-toxicity curves with different offsets that are used to investigate the effect of the 
location of the starting dose relative to the true MTD on the accuracy of MTD selection for the 3+3 design. 
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Appendix Figure 5: 
 
This plot depicts the dose-toxicity curves that correspond to the true DLT rates in Table 2. The separation between the true DLT 
rate at the MTD and that at the level below and above it is large for the logistic dose-toxicity curve, but is much smaller for the 
linear dose-toxicity curve. For the log-logistic dose-toxicity curve, the separation between the true DLT rate at the MTD and that 
at the level below and above it is in between that of the logistic and linear dose-toxicity curves. 
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Appendix Figure 6: 
 
 
 
This figure depicts the dose-toxicity curves that correspond to the true DLT rates in Columns 2, 4, 6 and 8 of Appendix Table 9. 
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CHAPTER THREE 
  
Introduction 
In a Phase 1 oncology clinical trial, the safety of the investigational drug is studied and 
the maximum tolerated dose (MTD) of the study drug to be used in a Phase 2 trial is 
determined [91, 77]. In a Phase 2 trial, in addition to safety, the efficacy of the drug is 
investigated. The number of patients enrolled in a Phase 1 trial is usually very small 
(say 15–30 patients), while the number of patients enrolled in a Phase 2 trial is larger 
(say 50–100).  
 
With such a small number of patients, Phase 1 dose-finding oncology trials do not 
accurately select the MTD. The 3+3 design that is still frequently used in many Phase 
1 dose-finding oncology trials has been shown to be inaccurate in determining the 
MTD and to under-dose a large number of patients [68].  Furthermore, the efficacy of 
an anti-cancer agent may not always increase with an increase in dose, and can peak 
at any dose level [92,93]. Thus, Phase 1 trials may not target the optimal dose taking 
into consideration both toxicity and response. Assessment of both dose limiting 
toxicities (DLTs) and efficacy responses in a reasonably sized, larger trial has the 
potential for a more accurate determination of a suitable dose, compared to a Phase 
1 followed by a Phase 2 trial.   
 
The criticality of selecting the right safe dose and the optimal dose for toxicity and 
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efficacy has been illustrated in several cases. In the paper by Markman [94], the drug 
pegylated liposomal Doxorubicin (PLD), which is used to treat platinum resistant 
ovarian cancer, and its dosage are discussed. The dose of PLD explored in initial 
clinical trials as well as the dose approved by the FDA was 50 mg/m2 (every 28 days). 
However clinical experience has clearly shown that this dose leads to substantial 
adverse effects in patients, while a lower dose of 40 mg/m2 is equally efficacious but 
leads to fewer adverse effects, as emphasized by Ferrandina [95]. As other examples, 
the reference by Schilsky [96] provides a summary in Table 1 of some approved 
oncology drugs along with their approved dosages and states that for many of these 
drugs, the dose that is clinically administered is often lower or higher than the dosage 
that was approved by the regulatory authority. The dose that is commonly used in a 
Phase III oncology trial is the MTD determined from a small number of patients 
treated in an earlier dose-finding Phase I trial, as Phase II oncology trials do not 
typically evaluate multiple doses. If the MTD obtained from the Phase I trial is not 
right, this can have enormous cost and resource repercussions for the development 
of an oncology drug. If the dose administered to patients in the Phase III trial is too 
high, the trial can fail because of many early drop-outs due to adverse events. On the 
other hand, If the dose administered to patients is inefficacious, it may not be possible 
to determine from the Phase III trial results whether the drug does not work at all or 
whether just the dosage was wrong. All this may result in having to conduct another 
new Phase III trial with the optimal dose. Thus, conducting small early phase trials 
and rapidly moving on to a Phase III trial may not be a good strategy in the long run, 
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and it may be worthwhile to spend more time in the early phase trials to thoroughly 
investigate and accurately determine the optimal drug dose for safety and efficacy. 
 
Hence, in this paper, we propose a simple integrated Phase 1/2 trial design called the 
“20+20 accelerated titration design” that evaluates both safety and efficacy with a 
somewhat larger sample size. The motivation for exploring a larger rule-based design 
comes from the substantial effect of sample size and/or cohort size on the accuracy 
of dose selection in various early phase oncology designs. With 35–50 patients, the 
safety of the drug and the MTD can be evaluated with greater accuracy than with 15–
30 patients, and the efficacy of the study drug can also be investigated in this larger 
sample. Thus, a single, larger study could serve to determine a dose that is optimal for 
both safety and efficacy.  
 
Designs such as 1) the seamless Phase 1/2 SEARS design [97, 98], 2) a seamless 2-
step Phase 1/2 design [99, 100], 3) designs to find the optimal biological dose [93, 
101] and 4) the Eff-Tox design [67, 102] among others [103, 104, 105, 106] have been 
proposed to evaluate both drug toxicity and efficacy in early phase studies; a recent 
reference by Yuan covers Bayesian designs for Phase I/II trials in detail [107]. In fact, 
our proposed rule-based 20+20 accelerated titration design is similar in concept to 
the Eff-Tox design. The Bayesian decision rules incorporated in our design at the end 
of the trial for selecting an optimal dose for efficacy and safety are the same as those 
used in the Eff-Tox design for determining the dose level to which the next cohort of 
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patients should be assigned, based on the number of DLTs and responses in previous 
patients. However, unlike these other designs, our rule based design is easily 
implemented without the assistance of a statistician during the conduct of the trial. 
In addition, our design does not require the challenging selection of three points to 
define the trade-off function contour used to determine the optimal dose for the next 
cohort of patients in the Eff-Tox design.  In the Eff-Tox design, if the trade-off contour 
is not sufficiently steep, the design can get stuck at a lower dose and then fail to find 
an optimal dose for the assignment of the next cohort of patients (Eff-Tox tutorial5). 
 
In summary, we first systematically study the role of sample size and cohort size on 
the accuracy of dose selection in the Continual Reassessment Method (CRM), Eff-Tox 
and some rule-based designs. We then use this information to propose a design that 
is large enough to allow accurate dose selection for toxicity and that selects an 
optimal dose for both toxicity and efficacy via Bayesian decision rules at the end. In 
particular, we propose the 20+20 accelerated titration design. We use simulations to 
study the statistical operating characteristics of the 20+20 accelerated titration 
design and compare its performance with that of the Eff-Tox design by Thall et al. [67, 
102] and the Optimal Biological Dose (OBD) Isotonic design by Zang et al. [101]. We 
show via simulated examples that it performs as well as or better than the Eff-Tox 
                                                        
5 
https://biostatistics.mdanderson.org/softwaredownload/ProductSupportFiles/EffTox/EffToxU
sersGuide.pdf 
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design and the OBD Isotonic design in these situations. We also demonstrate that the 
proposed design performs better than a 3+3 Phase 1 design followed by a Phase 2 
design. 
 
Methods 
Effect of Sample Size/Cohort Size on the Accuracy of MTD or Optimal Dose Selection 
We first study via simulations the effect of sample and/or cohort sizes on the accuracy 
of MTD selection in the CRM as well as the rule based designs such as the 3+3, 5+5 a, 
10+10 and 20+20 designs, using a logistic dose-toxicity curve, which is often 
employed to describe the relation between dose and toxicity [84]; we also study the 
effect of sample size and cohort size on the accuracy of optimal dose selection in the 
Eff-Tox design [67] [see Simulation Section for details]. We describe each design 
studied in this paper in brief below. 
 
Design Descriptions 
The CRM design is a Bayesian design, where the cumulative DLT data along with a 
pre-specified dose-toxicity model, frequently a one or two parameter logistic model, 
are used to assign the next patient(s) to a dose level [66, 84]. After the DLT evaluation 
period of each patient (or cohort of patients), the parameters of the dose-toxicity 
model are updated. The patient(s) is assigned to the dose level whose DLT rate is 
closest to but less than the estimated DLT rate from the updated model. The stopping 
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point of the trial is usually the pre-specified sample size. 
 
The Eff-Tox design is also a Bayesian design. It considers the trade-off between the 
probabilities of drug toxicity and efficacy to determine the optimal dose for each new 
cohort of patients. The joint probability ab of efficacy and toxicity at each dose is 
calculated in terms of the marginal probabilities of efficacy and toxicity (E and T). 
The equation for ab in terms of E and T and its role in computing the dose level with 
maximum desirability based on the cumulative DLT and efficacy data are detailed in 
Thall et al. [102]. Before each new cohort of patients is enrolled, the desirability of 
each dose level is calculated; the dose level with the maximum desirability is the dose 
level to which the next cohort of patients is assigned. The stopping point of the trial 
is usually the pre-specified sample size. 
 
In the paper by Zang et al. [101], three designs are proposed to estimate the optimal 
biological dose (OBD), namely the OBD logistic design, the OBD Isotonic design and 
the OBD locally-logistic design. The authors recommend the OBD Isotonic design or 
the OBD locally-logistic design for use in practice, based on their robust operating 
characteristics from simulation studies. We focus only on the OBD Isotonic design in 
this paper due to the reasonable run-time for 10000 simulations for the OBD Isotonic 
design compared to that for the OBD locally-logistic design. The details of the OBD 
Isotonic design are provided in the reference by Zang et al.. To determine the OBD, an 
admissible set, which is the set of doses satisfying a safety criterion similar to that 
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used in the Eff-Tox design, is first defined. The OBD is then the lowest dose with the 
highest response rate within the admissible set of doses, while still being safe. The 
stopping point of the trial is usually the pre-specified sample size. 
 
The 3+3 and 5+5a rule based designs target a DLT rate  of ~0.2 (see Table 4.1 of 
Chapter 4 of the reference by Ting, 2006 [89] and Table 1 of Ananthakrishnan, 2017 
[108]).  
3+3 Design:  Enroll 3 patients at the lowest dose level. 
• If 0 out of 3 enrolled patients have a DLT, then escalate to the next dose level and 
enroll 3 more. 
• If 1 out of 3 patients has a DLT, then add 3 more patients at the same dose level; if 
2 or more patients out of 3 or 6 patients experience a DLT, then stop the trial.  
• The MTD is one dose level below the last dose level examined. 
 
5+5 a Design:  Enroll 5 patients at the lowest dose level. 
• If 0 out of 5 enrolled patients have a DLT, then escalate to the next dose level and 
enroll 5 more. 
• If 1 or 2 out of 5 patients have a DLT, then add 5 more patients at the same dose 
level; if 3 or more patients out of 5 or 10 patients experience a DLT, then stop the 
trial.  
• The MTD is one dose level below the last dose level examined. 
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The 10+10 and 20+20 designs we construct are such that they target a DLT rate  of 
~0.2, (see the Appendix for the target DLT interval of the 20+20 design).  
10+10 design:  Enroll 10 patients at the lowest dose level.  
• If <=2 patients out of 10 experience a DLT, then enroll 10 patents in the next 
higher dose level.  
• If 3 or 4 patients experience a DLT, then enroll 10 more patients in the same 
dose level.  
• If <=4 patients out of 20 experience a DLT, then enroll 10 patients in the next 
higher dose level.  
• If 5 or more patients out of 10 or 20 patients experience a DLT at a dose level, 
then stop the trial.  
• The MTD is one dose level below the last dose level examined. 
 
20+20 design:  Enroll 20 patients at the lowest dose level.  
• If <=6 patients out of 20 experience a DLT, then enroll 20 patents in the next 
higher dose level.  
• If 7 or 8 patients experience a DLT, then enroll 20 more patients in the same 
dose level.  
• If <=8 patients out of 40 experience a DLT, then enroll 20 patients in the next 
higher dose level.  
• If 9 or more patients out of 20 or 40 patients experience a DLT at a dose level, 
then stop the trial.  
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• The MTD is one dose level below the last dose level examined. 
 
Proposed Design 
We propose the 20+20 accelerated titration design that is intended to be a simple rule 
based design during the conduct of the study, and which enrolls larger sample sizes 
than standard Phase 1 designs and incorporates Bayesian decision rules for optimal 
dose selection at the end of the trial. As mentioned, the 20+20 design targets a DLT 
rate of ~0.2, similar to the 3+3 design, but our proposed 20+20 accelerated titration 
design has additional safety stopping rules which decrease the target DLT rate of the 
20+20 part of the design.  
 
The schematic of the 20+20 accelerated titration design is shown in Figure 8 and the 
design is described here. The 20+20 accelerated titration design starts in the 
accelerated titration phase by enrolling patients in cohorts of size 3.  
• The first cohort of 3 patients is assigned to the lowest dose level and subsequent 
cohorts of size 3 continue to be assigned to increasing dose levels as long as none 
of the 3 patient cohorts experience a DLT.  
• When one or more patients in a cohort of size 3 experiences a DLT, then the design 
switches from the accelerated titration phase into the 20+20 design phase, where 
20 patient cohorts are enrolled in batches of 6 or 8 patients (To limit the number of 
patients that are exposed to the study drug at once, we implement stopping rules 
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after every 6 or 8 patients i.e. after patient 6, 14, 20 etc.).  
In other words, in our proposed design, 1 or more DLTs in a cohort of 3 patients 
leads to enrolling 3 new patients at that same dose level for an initial total of 6 
patients.  
o If 4 or more out of these first 6 patients have a DLT, then the trial is stopped. 
o If <4 patients out of these first 6 patients have a DLT, then 8 more patients 
are treated at the same dose level.  
▪ If out of the 14 patients, 9 or more patients have a DLT, then the 
trial is stopped. 
▪ If out of the 14 patients, 8 or less patients have a DLT, then 6 more 
patients are treated at the same dose level. 
• If out of the 20 patients, 6 or less patients have a DLT, then 
initially 6 patients are treated at the next higher dose level 
and the process is continued, but if out of the 20 patients, 9 
or more have a DLT, then the trial is stopped. 
• If out of the 20 patients, 7 or 8 patients have a DLT, then the 
same dose level is expanded, and 6 more patients are treated 
at the same dose level. 
o If out of 26 patients, more than 8 patients have a 
DLT, then the trial is stopped.  
o If out of 26 patients, no more than 8 patients have a 
DLT, then 8 more patients are treated at the same 
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dose level. 
▪ If out of 34 patients, more than 8 patients 
have a DLT, then the trial is stopped.  
▪ If out of 34 patients, no more than 8 patients 
have a DLT, then 6 more patients are treated 
at the same dose level. 
• If out of 40 patients, more than 8 
patients have a DLT, then the trial is 
stopped. 
• If out of 40 patients, no more than 8 
patients have a DLT, then initially 6 
patients are treated at the next higher 
dose level and the process is 
continued. 
Thus, we can escalate to the next dose level if 6 or less out of 20 patients in a dose 
level experience a DLT or 8 or less out of 40 patients in a dose level experience a DLT, 
similar to the escalation rules of the 20+20 design. However, we can also escalate if 
out of the first 14 patients in a dose level, we observe 0 DLTs and 0 responses, since 
no more than 6 DLTs can be observed in the last 6 patients and the dose is not 
efficacious. Also, note that a safety committee that can stop the trial at its discretion 
at any point should be implemented.  
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At the end of the trial, a dose that is acceptable for safety and efficacy is chosen using 
the following Bayesian decision rules on the posterior probabilities of pi and qi, which 
are the toxicity and efficacy probabilities at dose i: 
 Pr(pi<pTP|data) > a and Pr(qi>pEP|data) >b  
pTP and pEP are the upper limit for toxicity and lower limit for efficacy respectively, 
whose values are pre-specified for the study based on discussions with the clinician, 
and “a” and “b” are small probability cut-offs6. In this paper, we use pTP=0.33, pEP=0.5 
and a=b=0.1. We also assume that both pi and qi follow a Jeffreys prior Beta(0.5, 0.5), 
which is a uniform prior from 0 to 1 [98]. The posterior distributions of pi and qi are 
then Beta(0.5+xi, 0.5+ni-xi) where xi is the number of DLTs or responses respectively 
at dose level i out of ni patients at that dose level. These Bayesian decision rules are 
the same as those used in the Eff-Tox design to assign new cohorts of patients a dose, 
and they ensure that doses that are too toxic or that are too inefficacious are not 
selected.  
 
If more than one dose is found to be acceptable for safety and efficacy in a trial using 
the Bayesian decision rules above, then the following criteria can be used, in the 
suggested order of preference, to choose a single dose level: a) the value of a pre-
specified utility function evaluated at each dose level or b) the percentage of patients 
                                                        
6 The cutoff probabilities are typically 0.1 or smaller in value 
(https://biostatistics.mdanderson.org/softwaredownload/ProductSupportFiles/EffTox/EffTox
UsersGuide.pdf), and we use the upper limit of 0.1 for all the simulations in this paper.  
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who respond but do not have a DLT at each dose level or c) the empirical odds ratio 
(OR)7 at each dose level. In this case, we would select the dose that has the maximum 
value for the utility function or that has the largest percentage of patients with a 
response but no DLT or that has the smallest value for the empirical odds ratio. We 
provide an example utility function for criterion a) and show the calculation for the 
empirical OR for criterion c) below. 
One possible utility function would be the fraction of responders (out of the total patients) 
in the dose level minus a constant ‘c’ times the fraction of patients with DLTs. Other more 
complex utility functions that consider additional factors such as trial cost could be used 
as well, but here we use the following simple utility function. So, for dose level i, the 
following formula is used:  
utilityi=ri – c*di, where c is a constant that can vary between 0 and 1, ri is the fraction of 
patients having a response, and di is the fraction of patients with a DLT. This utility 
function was also employed in Ivanova et al.  [109]. 
The calculation for the odds ratio is based on the numbers of subjects, the number of 
responses, and the number of DLTs at a dose level. The following formula is used:  
𝑂𝑅𝑖 =
number of DLTs at dose i∗(number of patients at dose i – number of responses at dose i) 
number of responses at dose i∗(number of patients at dose i – number of DLTs at dose i)
  
 
                                                        
7 http://www2.ims.nus.edu.sg/Programs/011wclinic/files/guosheng_ppt.pdf 
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Design Characteristics and Comparisons 
We then compare the results for accuracy of optimal dose selection of the 20+20 
accelerated titration design to those of the Eff-Tox design and the OBD Isotonic design 
for various scenarios of true toxicity and efficacy rates. We also compare the results 
of the 20+20 accelerated titration design to those of a 3+3 Phase 1 design followed by 
a Phase 2 design. 
 
Simulations 
1) Effect of sample size and cohort size on the accuracy of MTD or dose selection 
a) For the rule-based designs, we use the statistical package SAS to simulate and study 
the effect of sample size on the accuracy of MTD selection, as described in 
Ananthakrishnan et al. [108]. 
b) For the CRM design, we use the R package CRM to study the effect of sample size 
and cohort size on the accuracy of MTD selection with the input parameters given 
in the Appendix. 
c) For the Eff-Tox design, we use the Eff-Tox design package from the MD Anderson 
Cancer Center to study the effect of sample size and cohort size on the accuracy of 
dose selection with the input parameters given in the Appendix. 
 
2) 20+20 accelerated titration design 
We create our own SAS program to simulate the proposed 20+20 accelerated titration 
design. We start by generating two correlated binary random variables X1~ 
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Bernoulli(p) and X2~ Bernoulli(q) for toxicity and efficacy respectively as follows. We 
first generate X1 with success probability p.  If X1 = 1, we generate X2 with probability 
q1, and if X1=0, we generate X2 with probability q2. r is the correlation coefficient 
between X1 and X2. Here,  
q1 = q + (r/p) * sqrt(p*(1-p)*q*(1-q))  
q2 = (q - q1*p)/(1-p)  
The correlation coefficient r is restricted and can lie only between  
max (−(
(𝑝𝑞)
(1−𝑝)(1−𝑞)
)
1
2 , −(
(1−𝑝)(1−𝑞)
(𝑝𝑞)
)
1
2 )  and  min ((
(𝑝 (1−𝑞))
(1−𝑝)(𝑞)
)
1
2 , (
((1−𝑝)𝑞)
(𝑝)(1−𝑞)
)
1
2)  [110]. 
From the above equations, it can be seen that if the correlation coefficient r=0 then 
q1=q2=q.  
 
In simulations to study the statistical operating characteristics of the 20+20 
accelerated titration design, we generate the true DLT rate at each dose level (pi) 
using a logistic dose-toxicity curve because the toxicity of an anti-cancer agent 
typically increases with an increase in dose; the two coefficients of the logistic dose 
toxicity curve are calculated using the parameters in Table 7.  However, we select the 
true response rate at each dose level (qi) manually because the efficacy of an anti-
cancer agent may not always increase with an increase in dose, and can peak at any 
dose level [92, 93]. In Table 8, we select the true response rates such that the true 
response rate peaks at dose level 4. However, different dose-response curves can be 
investigated (see results in the Appendix for the 20+20 accelerated titration design 
for other scenarios of true underlying response rates). 
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Using SAS, we simulate the 20+20 accelerated titration design proposed 10000 times 
along with the true DLT and response rates in Table 8, correlation coefficient r=0, and 
the stopping rules described in the Methods section. We start with a correlation 
coefficient r of 0 in our simulations for simplicity, but calculations with other non-
zero correlation coefficients are discussed briefly in the Results Section and the 
Appendix. For each simulated trial, we estimate the number of patients, the number 
of DLTs and the number of responses in each dose level. We then use the Bayesian 
decision rules described, to select an acceptable dose for toxicity and efficacy at the 
end of each simulated trial. We also estimate the value of the utility function at each 
dose, the percentage of patients at each dose who respond but do not have a DLT and 
the empirical odds ratio at each dose, for use in optimal dose selection.  
 
Results 
Effect of Sample and Cohort Size on Dose Selection 
a) Phase 1 designs (safety) 
Table 9 shows the percentage of times that the true MTD (dose level 4) is selected 
by various rule based designs that allow only escalation and that target a DLT rate 
of ~0.2. These results are for the true DLT rates shown in Table 8 and are based on 
10000 simulations for the rule-based designs. The accuracy of MTD selection, the 
median and maximum sample sizes are outputs of the simulations for these rule-
based designs. For comparison, we also include in Table 9 the results of two 
specific cases of the CRM design using the input parameters given in the Appendix 
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(further scenarios for the CRM design are shown in Table 10). As can be seen, the 
accuracy of MTD selection increases with an increase in sample size for all the 
cases considered. For the 20+20 design, the accuracy of MTD selection is very high 
(~90%), but the median number of patients enrolled in the trial is also high (100). 
 
All the results in Table 10 for the CRM design are based on 2000 simulations for 
the input parameters given in the Appendix. The sample size and cohort size are 
inputs and the accuracy of MTD selection is an output of these simulations. As in 
Table 9, the percentage of times that the true MTD (dose level 4) is selected 
increases with an increase in sample size. For a sample size of 50 and a cohort size 
of 5 for example, the true MTD (dose level 4) is selected ~82% of the time. It is 
also observed that the cohort size, given the same total sample size, does not have 
a large effect on the accuracy of MTD selection in the CRM design, if the cohort 
size is a small percentage of the total sample size. 
  
b) Eff-Tox design (safety and efficacy) 
The effect of sample size and cohort size on dose selection in the Eff-Tox design 
can be seen using the example in Table 11, which is based on an example in the 
Eff-Tox website  
https://biostatistics.mdanderson.org/softwaredownload/ProductSupportFiles/EffT
ox/EfftoxTutorial.html. All the results in Table 11 are based on 10000 simulations 
using the input parameters given in the Appendix for the Eff-Tox design. We expect 
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dose level 5, the dose level with the highest trade-off value between the 
probabilities of efficacy and toxicity in Table 11, to be selected most frequently. 
However, we observe that when the sample size is small (18) and the cohort size is 
3, dose level 4 is selected more frequently than dose level 5. With an increase in 
sample size to 99 and the same cohort size of 3, dose levels 4 and 5 are selected 
with equal frequency.  With a sample size of 99 but a cohort size of 9, dose level 5 
is selected more than twice as frequently as dose level 4. Hence, cohort size appears 
to be an important criterion in dose selection in the Eff-Tox design. 
 
In summary, based on these examples of the rule-based, CRM and Eff-Tox designs, the 
accuracy of MTD or dose selection improves dramatically with an increase in sample 
size for all the cases and designs considered. Larger cohort sizes may result in a small 
reduction in the accuracy of MTD selection for the CRM design, but could improve 
dose selection in the Eff-Tox design. Thus, cohort size and sample size are crucial 
parameters to consider and explore, while designing an early phase oncology trial.  
 
Simulation Results for the 20+20 Accelerated Titration Design 
From the simulation results in the previous section, we observe that the 20+20 design 
has a high probability of selecting the MTD accurately due to its larger sample size 
than the other A+B designs. Our simulations yield a median sample size of 100 for the 
20+20 design for the true DLT rates in Table 8. This larger sample size allows us to 
consider addressing drug efficacy in addition to drug safety. However, the sample size 
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of the 20+20 design is relatively large for an integrated Phase 1/2 trial, and a sample 
size closer to 50 would be more reasonable. Therefore, we propose the 20+20 
accelerated titration design, as our simulations yield a mean sample size of 42 and a 
median sample size of 35 for this design for the true DLT and response rates in Table 
8. 10+10 accelerated titration or 15+15 accelerated titration designs yield even 
smaller mean sample sizes and result in less accuracy in dose selection, and hence 
were not considered further. Our results for the 20+20 accelerated titration design, 
which considers both drug toxicity and efficacy in selecting an optimal dose, are 
shown in Table 12. 
 
Our simulation results in Table 12 for the 20+20 accelerated titration design show 
that for the true DLT and response rates in Table 8, dose level 4 is the dose that 
satisfies the Bayesian decision rules for safety and efficacy most frequently. Dose level 
4 is chosen as the dose level that is acceptable for safety and efficacy in ~76% of the 
simulation runs in this case (also see Figure 9). In an actual trial, if more than one 
dose level satisfies these two Bayesian decision rules, other criteria such as the value 
of the utility function at each dose level, the percentage of patients at each dose level 
with a response but no DLT and the ORi can be used to choose a single dose level, as 
mentioned earlier. In our example, dose level 4 has the maximum value of the utility 
function most frequently and has the maximum value for the average percentage of 
patients with a response but no DLT. The minimum value for the ORi from the 
simulations is at dose level 1, not at dose level 4, but there are very few responders in 
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dose level 1 (see the first footnote to Table 12). Hence, based on these results of the 
20+20 accelerated titration design, our final selection for optimal dose is dose level 4 
for this example. 
Results for the 20+20 accelerated titration design for various other scenarios of true 
toxicity and efficacy rates are shown in the Appendix. 
 
In general, the results in Table 12 can be investigated for different values of the 
correlation coefficient r. However, r is restricted and can take on only certain values. 
For the example in Table 12, the highest positive correlation that can be used for the 
10000 simulation runs to yield results with no errors due to the chosen value of r is 
0.08, and those results do not differ substantially from the results shown in Table 12 
for r=0. The highest value that r can take will differ for different combinations of true 
DLT and response rates at each dose (see the Appendix). For a logistic dose-toxicity 
curve and for a monotonically increasing dose-response curve, a higher value of r can 
be used (see the Appendix).  
 
Comparison of the 20+20 Accelerated Titration Design to the Eff-Tox Design and to a 
3+3 Design Followed by a Phase 2 
We compare the performance of our proposed 20+20 accelerated titration design to 
that of the Eff-Tox design for various scenarios of true DLT and response rates that 
are provided as examples in the Eff-Tox program, as shown in Table 13. We do not 
compare those examples that are provided in the Eff-Tox program for which the 
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highest toxicity rate was very low (<=0.1) since the 20+20 part of our design is 
intended to target a DLT rate closer to 0.2. We use a sample size in the Eff-Tox design 
of 99 and cohort size of 9, which is the maximum cohort size allowed in the version 
of the Eff-Tox design software program we used. We also use 0.33 for the probability 
of the upper limit of toxicity and 0.5 for the probability of the lower limit of efficacy, 
identical to the values we use in the same decision rules in the 20+20 accelerated 
titration design at the end of each simulated trial. All the other input parameters used 
in the Eff-Tox design simulations are the same as those given in the Appendix as the 
Input parameters for Table 11.  We also compare the performance of our proposed 
20+20 accelerated titration design to that of the OBD Isotonic design by Zang et al., 
for the same scenarios of true DLT and response rates used in the comparison of the 
20+20 accelerated titration design and the Eff-ox design. All the input parameters 
used in the OBD Isotonic design simulations are given in the Appendix. 
 
For scenario 1 of Table 13, the Eff-Tox design does not select the dose with the highest 
trade-off value between the probabilities of efficacy and toxicity (i.e. dose level 3) 
most frequently as the optimal dose for efficacy and toxicity. The Eff-Tox design 
selects dose level 3, 41% of the time, a little less frequently than it selects dose level 
4 (46% of the time), which has a slightly lower trade-off value. The OBD Isotonic 
design selects dose level 3, 38% of the time, less frequently than it selects dose level 
4 (48% of the time). The 20+20 accelerated titration design selects dose level 3 and 
dose level 4 in 96% and 86% of the simulation runs respectively, as acceptable for 
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toxicity and efficacy. From our simulations of the 20+20 accelerated titration design, 
dose level 3 also has a) the maximum value of the utility function most frequently 
(39%, 53% and 59% of the time for c=0.1, c=0.5 and c=1 respectively), b) the 
maximum value for the average percentage of patients with a response but no DLT 
and c) the minimum value of the ORi. Hence, based on these results of the 20+20 
accelerated titration design, our final selection for this design is dose level 3. 
 
For scenario 2, the Eff-Tox design selects dose level 1, the dose with the highest trade-
off value, 74% of the time, the OBD Isotonic design selects dose level 1 53.1% of the 
time as the optimal dose. The 20+20 accelerated titration design selects dose level 1 
as acceptable for safety and efficacy in ~94 % of the simulation runs. From our 
simulations of the 20+20 accelerated titration design, dose level 1 also has a) the 
maximum value of the utility function most frequently (53%, 72% and 85% of the 
time for c=0.1, c=0.5 and c=1 respectively), b) the maximum value for the average 
percentage of patients with a response but no DLT and c) the minimum value of the 
ORi. Hence, based on these results of the 20+20 accelerated titration design, our final 
selection for this design is dose level 1. 
 
For scenario 3, the Eff-Tox design does not select any dose as optimal for safety and 
efficacy 93% of the time, while the 20+20 accelerated titration design does not select 
any dose level as acceptable for safety and efficacy in 78% of the simulation runs. 
These results for the Eff-Tox design and the 20+20 accelerated titration design of 
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selecting no dose level as optimal or acceptable for safety and efficacy most of the 
time are reasonable, since the true DLT rate at the lowest dose level itself is quite high 
— at a value of 0.3, it is just below the upper limit of 0.33 considered in the Bayesian 
decision rule for safety. The OBD Isotonic design does not perform well in this 
scenario since it always assumes that at least the lowest dose should be safe, and selects 
dose level 1 and dose level 2 as the optimal dose 41% and 42% of the time 
respectively. 
 
Although the comparisons between the 20+20 accelerated titration design and the 
Eff-Tox and OBD Isotonic designs are not exact in terms of cohort size and sample 
size, these examples demonstrate that the 20+20 accelerated titration design can 
select an optimal dose for efficacy and toxicity as robustly as the Eff-Tox design and 
the OBD Isotonic design but is easier to implement.  
 
We also compare the results of the 20+20 accelerated titration design to those of a 
3+3 Phase 1 design followed by a Phase 2 design (Table 14). The 3+3 design picks the 
right dose for safety i.e. the true MTD of dose level 4 only 60% of the time for the true 
DLT rates in Table 8, as seen in Table 9. Hence the probability of selecting the right 
dose for both toxicity and efficacy at the end of Phase 2 is no more than 60%. In 
contrast, as seen in Table 12, the 20+20 accelerated titration design picks dose level 
4 as acceptable for safety and efficacy in ~76% of the simulation runs (76% is also 
the value for the percentage of simulations that select dose level 4 as the optimal dose 
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for toxicity and efficacy using the maximum value of the utility function for c=0.1) for 
the true toxicity and true response rates in Table 8. Since the 3+3 design has a small 
sample size, the accuracy of MTD selection is very low. Our simulations with this and 
other scenarios confirm that we need a larger sample size to select the right safe dose 
with high accuracy before proceeding to a Phase 2 study, so that an optimal dose for 
efficacy and toxicity can be selected with a high probability at the end of Phase 2. 
 
Discussion and Conclusion 
Most Phase 1 dose-finding oncology trials enroll a very small number of patients, and 
often fail to predict the MTD accurately due to the small sample size. We have shown, 
via examples of rule-based and model-based designs, that the accuracy of MTD or 
dose selection in these designs increases considerably with an increase in sample or 
cohort size. Thus, it is crucial to study the effect of sample size and cohort size on the 
accuracy of dose selection while designing an early phase oncology trial. With a larger 
number of patients, the efficacy of the drug can also be assessed in an early phase trial 
itself. 
 
This has led us to propose a simple rule based design that enrolls a larger sample size 
than standard Phase 1 designs, that enables accurate dose selection with respect to 
toxicity and incorporates Bayesian decision rules for optimal dose selection for safety 
and efficacy at the end of the trial. In particular, we propose the “20+20 accelerated 
titration” design, a moderately sized, integrated Phase 1/2 trial design that assesses 
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both safety and efficacy. We note that such a design should not become too large; the 
drawbacks of large seamless Phase 1/2 trials with greater than a few hundred 
patients have been discussed by Mullard [111]. The 20+20 accelerated titration 
design is intended to quickly move up the dose levels through accelerated titration 
but to have large enough sample sizes for doses near the MTD to substantially 
increase the accuracy of MTD selection and to provide assessment of efficacy in 
treatment response. As mentioned, the 20+20 design targets a DLT rate of ~0.2, but 
our proposed 20+20 accelerated titration design has additional safety stopping rules 
which decrease the target DLT rate of the 20+20 part of the design. The stopping rules 
and their timing used in our proposed 20+20 accelerated titration design may be 
altered to create a modified 20+20 accelerated titration design. For example, one 
could implement stopping if there are >=3 DLTs, rather than >=4 DLTs, in the first 6 
patients in a dose level, or one could apply stopping rules after patient 7, 14, 20 etc. 
instead of after patient 6, 14, 20 etc. However, this would further change the 
approximate DLT rate that the 20+20 part of the design targets, and simulations to 
study the operating characteristics of this modified design should be performed. In 
this context, we note that there is a trade-off for using aggressive stopping rules and 
stopping too early for toxicity – it decreases the probability of identifying the optimal 
dose. A safety committee that can stop the trial at its discretion at any point should 
be implemented in all these designs. In our simulations, we generate the true DLT rate 
at each dose level using a logistic dose-toxicity curve; we generate the true response 
rate at each dose level manually, since the efficacy of an anti-cancer drug may not 
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always increase with an increase in dose. Our simulations demonstrate that the 
20+20 accelerated titration design can robustly pick a dose that is optimal for efficacy 
and safety.  
 
We have also created a modified 20+20 accelerated titration design, where the switch 
from the 3+3 design to the 20+20 design occurs when either 1 DLT (grade 3, grade 4 
or grade 5 toxicity) is observed or when 3 low grade toxicities (grade 1 or grade 2) 
are observed, similar to the switch from the 3+3 design to the CRM design in the paper 
by Iasonos [112]. The results for this modified design are very close to those from the 
20+20 accelerated titration design in the settings that we have considered. Hence, we 
have provided results only for the 20+20 accelerated titration design.  
 
The Eff-Tox design is an early phase design for oncology trials that considers both 
drug toxicity and efficacy. The Bayesian decision rules used in the Eff-Tox design to 
assign each new cohort of patients a dose imply that the dose that best optimizes 
efficacy and safety is selected each time. We employ these same decision rules, but 
only at the end of the trial in the 20+20 accelerated titration design. Hence, we have 
compared the performance of the proposed 20+20 accelerated titration design to that 
of the Eff-Tox design for some scenarios of true underlying DLT and response rates. 
We also compared the performance of the 20+20 accelerated titration design to that 
of the OBD Isotonic design proposed by Zang et al. for the same scenarios. Our 
comparisons show that the 20+20 accelerated titration design performs as well as or 
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better than the Eff-Tox design and the OBD Isotonic design for the scenarios 
considered. Our simple rule-based design can also be implemented more easily than 
the Eff-Tox design and the OBD Isotonic design. 
 
We have also compared the results from the 20+20 accelerated titration design to 
those from a 3+3 Phase 1 design followed by a Phase 2 design. Our simulations 
confirm that we need a larger sample size to select the right safe dose with high 
accuracy before proceeding to a Phase 2 study so that a dose that is optimal for 
efficacy and toxicity can be picked with a high probability at the end of Phase 2.  The 
importance of selecting the right safe dose and the optimal dose for toxicity and 
efficacy has been illustrated in several cases. As one example, it is illustrated by 
Markman [94] with the drug PLD, which is used to treat platinum resistant ovarian 
cancer. The dose of PLD explored in initial clinical trials as well as the dose approved 
by the FDA was 50 mg/m2 (every 28 days). However clinical experience has shown 
that this dose leads to substantial adverse effects while a lower dose of 40 mg/m2 is 
equally efficacious but leads to fewer adverse effects. 
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Table 7 Parameters Used to Determine the Coefficients of the Logistic Dose-Toxicity 
Curve 
Parameter Value 
Starting dose 100 units (the remaining doses follow the 
modified Fibonacci series) 
True DLT rate at starting dose 0.01 
True MTD  Dose Level 4 = 501 units 
True DLT rate at MTD 0.2 
 
Table 8 True Underlying DLT and Response Rates 
Dose True probability of toxicity at each dose, generated 
from a logistic curve, whose coefficients are 
calculated using the parameters in Table 7 
Loge(DLT rate/(1-DLT rate)) =-5.39533+ 
0.008002*dose 
True probability of 
response at each 
dose is selected 
manually 
100 
units 
0.01 0.01 
200 0.02 0.05 
334 0.06 0.15 
501 0.2 0.45 
701.4 0.55 0.2 
932.86 0.89 0.05 
 
Table 9 Accuracy of MTD Selection in Some Rule-Based Designs and for Some Cases 
for the CRM Design 
Design Target 
DLT Rate 
% of Times the True 
MTD (Dose Level 4) 
is Selected 
Median Sample Size, 
Maximum Sample 
Size 
Standard 3+3 design 0.17–0.26 60.0% 15, 33 
5+5 a design 0.2–0.25 65.9% 30, 50 
CRM 5, 50 (cohort size of 
5, sample size of 50) 
0.15–0.25 81.6% 
50 (maximum sample 
size, which is an 
input) 
10+10 design 0.2–0.24 74.0% 50, 80 
20+20 design 0.2–0.21 90.1% 100, 140 
CRM 20,120 (cohort size 
20, sample size 120) 
0.15–0.25 90.0% 
120 (maximum 
sample size, which is 
an input) 
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Table 10 Accuracy of MTD Selection in the CRM Design 
Number of Patients on 
the Trial (Maximum 
Sample Size) 
Cohort Size % of Times the True 
MTD (Dose Level 4) 
is Selected 
30 5 69.2% 
40 5 74.5% 
50 5 81.6% 
60 5 82.9% 
   
50 1 81.4% 
50 2 80.9% 
50 5 81.6% 
   
   
120 20 90.0% 
140 20 92.8% 
160 20 95.7% 
   
120 1 95.3% 
120 2 94.5% 
120 4 94.5% 
120 5 94.8% 
120 10 94.1% 
120 20 90.0% 
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Table 11 Accuracy of Dose Selection in the Eff-Tox Design 
Dose Level 1 2 3 4 5 None 
True toxicity rate, true response rate 0.05, 0.2 0.1, 0.4 0.15, 0.6 0.2, 0.8 0.25, 0.95  
       
Utility (Trade-off Value) -0.68 -0.37 -0.04 0.28 0.51  
% dose level selected 
Maximum Sample size=18 
Cohort size=3 
2 4 31 34 29 1 
% dose level selected 
Maximum Sample size=99 
Cohort size=3 
0 1 28 35 35 1 
% dose level selected 
Maximum Sample size=99 
Cohort size=9 
0 1 26 23 49 0 
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Table 12 Results for the 20+20 Accelerated Titration Design 
 Dose Level 1 Dose Level 2 Dose Level 3  Dose Level 4 Dose Level 5  Dose Level 6 
True toxicity, true efficacy rate 0.01, 0.01 0.02, 0.05 0.06, 0.15 0.2, 0.45 0.55, 0.2 0.89, 0.05 
Odds of Toxicity to Efficacy from 
Simulations at Dose Level i (ORi)* 
0.20 0.26 0.35 0.31 7.71 20.05 
Average Number of Patients 3.5 4.5 7.3 14.0 12.2 0.28 
Average Number of DLTs 0.04 0.1 0.45 2.8 6.7 0.25 
Average Number of Responses 0.04 0.22 1.1 6.3 2.4 0.01 
Average Number of Patients with a 
Response but no DLT 
0.04 0.22 1.0 5.0 1.1 0.0 
Decision based on the Bayesian 
Posterior Probabilities (% of times 
out of 10000 simulations each dose 
satisfies the Bayesian decision 
criteria for both toxicity and 
efficacy)** 
2.86% 
 
13.02% 28. 6%  76.08%   1.87%  0%  
% of times out of 10000 simulations 
each dose level is the one with the 
maximum value of the utility 
function 
when c =0.1*** 
when c = 0.5 
when c=1 
 
 
 
 
1.54% 
4.6% 
7.34% 
 
 
 
 
4.46% 
6.66% 
8.64% 
 
 
 
 
11.91% 
16.05% 
20.79% 
 
 
 
 
76.15% 
71.63% 
63.04% 
 
 
 
 
5.93% 
1.06% 
0.19% 
 
 
 
 
0.01% 
0% 
0% 
* Calculated using only those simulations runs with a non-zero denominator for ORi. For the lower dose levels (levels 1 and 2), the 
denominator is zero in many simulation runs since the average number of responses is zero.  
** No dose level is chosen as acceptable for toxicity and efficacy ~15% of the time. The addition of the percentages for dose selection based 
on the Bayesian decision rules can add up to more than 100 since more than one dose level can be chosen as acceptable for toxicity and 
efficacy in each simulation.  
***c=1 gives equal weight to toxicity and efficacy while 0.1 gives a very small weight to toxicity and more weight to efficacy. 
Mean sample size for this example is 41.75; median sample size is 35, minimum sample size is 12 and maximum sample size is 126. 
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Table 13 Comparing the Results of the Eff-Tox Design and the OBD Isotonic Design to those of the 20+20 Accelerated 
Titration Design for Various Scenarios of True Toxicity and Efficacy Rates 
Scenario                                      Dose Level  
  1 2 3 4 5 None 
1 
 True toxicity, true efficacy 
rate  
.05, .10 .10, .30 .15, .60 .30, .62 .45, .65 -  
 Trade-off Value Eff-Tox 
Design 
-0.88 -0.57 -0.04 -0.24 -0.41 -  
 % selected by Eff-Tox 
Design 
0 0 41 46* 11 2 
 % selected by OBD 
Isotonic Design  
3.5 2.1 38.2 48.2 8 0 
 % of times each dose level 
is acceptable for efficacy 
and toxicity in the 20+20 
Accelerated Titration 
Design 
(% of times each dose 
level is the one with the 
maximum value of the 
utility function when c =1) 
23.03**  
(4.88)*** 
49.59  
(15.64) 
95.51  
(58.81) 
86.07  
(18.85) 
29.61  
(2.13) 
0.47  
 
2 
 True toxicity, true efficacy 
rate 
.20, .60 .40, .62 .55, .65 .70, .70 .85, .75 -  
 Trade-off Value Eff-Tox 
Design 
-0.12 -0.40 -0.57 -0.70 -0.83 -  
 % selected by Eff-Tox 
Design 
74 16 2 1 0 7 
 % selected by OBD 
Isotonic Design 
53.1 41.3 5.1 0.5 0 0 
  
1
0
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 % of times each dose level 
is acceptable for efficacy 
and toxicity in the 20+20 
Accelerated Titration 
Design 
(% of times each dose 
level is the one with the 
maximum value of the 
utility function 
when c =1) 
93.77** 
(84.64)*** 
60.27 
(14.63) 
5.59  
(0.71)  
0.02  
(0.02) 
0  
(0) 
3.52  
 
3 
 True toxicity, true efficacy 
rate 
.30, .10 .40, .30 .55, .60 .60, .62 .65, .65 -  
 Trade-off Value Eff-Tox 
Design 
-1.29 -1.04 -0.67 -0.71 -0.73 -  
 % selected by Eff-Tox 
Design 
0 3 4 0 0 93 
 % selected by OBD 
Isotonic Design 
40.7 41.6 15.3 2.2 0.2 0 
 % of times each dose level 
is acceptable for efficacy 
and toxicity in the 20+20 
Accelerated Titration 
Design 
9.30** 13.04 4.08 0.15 0 77.75 
 
* The dose shown in green is the dose level selected by each design as the optimal dose for toxicity and efficacy. 
** These numbers for percentage of times each dose level is acceptable for toxicity and efficacy can add up to more than 100% in the 
20+20 accelerated titration design. For example, in scenario 1, dose levels 3 and 4 are selected in 96% and 86% of the simulation runs. 
This means that both dose levels 3 and 4 are selected in a large percentage of the 10000 simulations because both doses satisfy the 
Bayesian decision rules in those simulations. 
*** The percentages shown in brackets are the percentages that each dose is chosen as the optimal dose for the 20+20 accelerated 
titration design using the utility function, and these percentages add up to 100. 
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Table 14 Results for a 3+3 Phase 1 Design Followed by a Phase 2 Design 
3+3 Phase 1 
followed by Phase 
2; 
Sample Size of 3+3 
Design in Phase 1 
Hypothesis in 
Phase 2 
Sample Size 
for Phase 2 
Total Sample Size Probability of Choosing the Right 
Dose for Toxicity and Efficacy 
Sample Size is ~15 
(median) and ~33 
(max) 
H0=0.4, H1=0.6* 
Power=0.9 
 
52 (1-sided 
alpha =0.05) 
 
 
 
64 (1-sided 
alpha = 0.025) 
~85 (max) (33 
patients for 3+3 
from Table 9 + 52 
for Phase 2) 
 
~97 (max)  
0.6*0.9=0.54 (0.6 is the probability of 
choosing the right dose for toxicity 
from Table 9) and 0.9 is the power in 
Phase 2 for the efficacy endpoint. 
Sample Size is ~15 
(median) and ~33 
(max) 
H0=0.45, H1=0.65 
Power=0.9 
 
52 (1-sided 
alpha =0.05) 
 
63 (1-sided 
alpha = 0.025) 
~85 (max) 
 
 
~96 (max) 
 
0.6*0.9=0.54 
 
Sample Size is ~15 
(median) and ~33 
(max) 
H0=0.5, H1=0.7 
Power=0.9 
 
50 (1-sided 
alpha =0.05) 
 
62 (1-sided 
alpha = 0.025) 
~83 (max) 
 
 
~95 (max) 
 
0.6*0.9=0.54 
*H0: response rate under the null hypothesis; H1: response rate under the alternative hypothesis 
For these calculations, we used the software EAST with the option “Discrete” for endpoint and “One Sample” for 
procedure. The option in EAST that says “Perform Exact Computations” was not used.
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Figure 8 Schematic of 20+20 Accelerated Titration Design 
 
 
  Treat 3 patients at the  
lowest dose level 
If 0 out of 3 patients have a DLT, 
treat 3 patients at the next 
higher dose level. Keep 
escalating until 1 or more DLTs 
out of 3 patients are observed in 
a dose level. 
If 4 or more out of the 6 
patients have a DLT, stop the 
trial.  
If 8 or less out of the 14 patients 
have a DLT, treat 6 more patients 
at the same dose level. 
If 9 or more out of the 14 patients 
have a DLT, stop the trial. 
If 6 or less out of the 20 patients 
have a DLT, treat 6 patients at the 
next higher dose level and 
continue the process*. 
If 9 or more out of the 20 patients 
have a DLT, stop the trial. 
If 1 or more out of 3 patients 
have a DLT, treat 3 more 
patients at the same dose level. 
If 3 or less of the 6 patients 
have a DLT, treat 8 more 
patients at the same dose level. 
If 7 or 8 out of the 20 patients 
have a DLT, treat 6 more patients 
at the same dose level. 
  
1
1
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Note that we can escalate if we see 6 or less DLTs out of 20 patients or 8 or less DLTs out of 40 patients in a dose level, 
but we can also escalate if 0 DLTs and 0 responses are observed in the first 14 patients in a dose level since we cannot 
observe more than 6 DLTs in the last 6 patients and since the dose is not efficacious (otherwise we enroll the next 6 
patients at the same dose level and continue the process). 
 
Figure Legend: Schematic of the 20+20 accelerated titration design. At the end of the trial, the dose that is optimal for 
safety and efficacy is chosen using Bayesian decision rules and other criteria. 
 
 
 
If 8 or less out of the 34 
patients have a DLT, treat 6 
more patients at the same dose 
level. 
If 9 or more out of the 34 
patients have a DLT, stop the 
trial. 
If 8 or less out of the 40 
patients have a DLT, treat 6 
patients at the next higher dose 
level and continue the 
process*. 
If 9 or more out of the 40 
patients have a DLT, stop the 
trial. 
If 8 or less out of the 26 
patients have a DLT, treat 8 
more patients at the same dose 
level. 
If 9 or more out of the 26 
patients have a DLT, stop the 
trial. 
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Figure 9 Percentage of Times Each Dose Level is Selected as Acceptable for Safety and Efficacy in the 20+20 Accelerated 
Titration Design Based on the DLT and Response Rates in Table 8 
 
 
Figure Legend: Percentage of times out of 10000 simulations that each dose level is selected as acceptable for safety and 
efficacy in the 20+20 accelerated titration design based on the DLT and Response Rates in Table 8.  
 
0
10
20
30
40
50
60
70
80
1 2 3 4 5
%
 o
f 
T
im
e
s 
D
o
se
 L
e
v
e
l 
is
 S
e
le
ct
e
d
Dose Level
% of Times Each Dose Level is Selected
% of Times Each Dose Level is
Selected For Safety and Efficacy
  
114 
 
Appendix Chapter 3 
1. Target DLT interval of the 20+20 design 
We have constructed the stopping rules for the 20+20 design such that it targets a 
DLT rate  of ~0.2, similar to the 3+3 design, which targets an approximate DLT rate 
of 0.2 (range of 0.17–0.26) [80, 113]. Other stopping rules and cohort sizes can be 
proposed in order to target other DLT rates. The approximate DLT interval that any 
A+B design targets can be calculated using the following inequality from Ivanova [80].   
CU/(A+B) < < A+B , 
where A+B is the solution to the equation Pr(Bin(A+B, A+B)<=CU)=0.5.  
A+B is the total number of patients a dose level can enroll and the trial is stopped if 
>CU DLTs are observed in A+B patients. 
For our 20+20 design, A+B=40, CU=8, and the inequality becomes: 
0.2<<0.21. 
 
2. Correlation Coefficient r that Can Be Used (for Different Cases of True 
Efficacy and Toxicity Rates) 
Dose Level True toxicity rate True efficacy rate 
1 0.01 0.05 
2 0.02 0.25 
3 0.06 0.3 
4 0.2 0.35 
5 0.55 0.4 
>=6 0.89 0.5 
Maximum positive value of r in this case where both the true DLT and response 
rates are increasing monotonically with an increase in dose is ~0.25. 
  
115 
Dose Level True toxicity rate True efficacy rate 
1 0.01 0.4 
2 0.02 0.35 
3 0.06 0.3 
4 0.2 0.25 
5 0.55 0.15 
>=6 0.89 0.05 
Maximum positive value of r in this case where the true DLT is increasing 
monotonically with an increase in dose but the true response rate is 
monotonically deceasing is 0.08. 
 
3. Input Parameters Used in Simulations for the CRM, Eff-Tox and OBD 
Isotonic Designs 
Input Parameters Used in the R Package CRM for the CRM Design 
A CRM design with a target DLT rate of 0.2, starting dose level of 1 and a 1-parameter 
logistic dose-toxicity model with parameter “a” whose initial value is 1 and fixed 
parameter “b” whose value is 3 is considered. The prior for “a” is exp(-a). The prior DLT 
rate at each of the six dose levels is (0.15, 0.25, 0.3, 0.45, 0.51, 0.56) and the true DLT 
rate at each dose level is as given in Table 8. 
 
Input parameters Used in the Eff-Tox Package for the Eff-Tox Design 
Probability of Toxicity and Efficacy Limits for Dose Acceptability Rules  
Parameter Value 
Prob(tox) upper limit (πT*) 0.30000 
Lower prob cutoff for prob of toxicity (pT,L) 0.10000 
Prob(eff) lower limit (πE*) 0.50000 
Lower prob cutoff for prob of efficacy (pE,L) 0.10000 
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Trade-off Function Elicited Points (3 points to define the trade-off function contour) 
 πE πT 
(π1,E*, 0) 0.50000 0.00000 
(1, π2,T*) 1.00000 0.65000 
(π3,E, π3,T) 0.70000 0.25000 
 
Elicited Means (Prior Toxicity, Prior Efficacy) 
Dose Toxicity Efficacy 
1 0.0200 0.2000 
2 0.0400 0.4000 
3 0.0600 0.6000 
4 0.0800 0.8000 
5 0.1000 0.9000 
 
Input parameters Used in the OBD Isotonic Design 
Cohort size = 9 
Number of cohorts = 11 
phi = upper bound of toxicity rate = 0.33 
ct = threshold for posterior probability of toxicity (any dose with toxicity probability 
larger than ct is excluded from the admissible set of doses) = 0.9 
Number of simulations = 10000 
The true DLT and response rates at each dose level are as given in Table 13. 
The R code given at the following URL was used along with the input parameters 
given above: 
 http://odin.mdacc.tmc.edu/~yyuan/Software/TargetAgent/targetAgentDF.r 
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4. Results for the 20+20 Accelerated Titration Design for Various Scenarios of 
True Toxicity and Efficacy Rates 
a) True Toxicity and Efficacy Rates are Monotonically Increasing with an Increase 
in Dose 
 Dose 
Level 1 
Dose 
Level 2 
Dose 
Level 3 
Dose 
Level 4 
Dose 
Level 5 
Dose 
Level 6 
True toxicity, true efficacy rate 0.01, 
0.01 
0.02, 
0.05 
0.06, 
0.15 
0.2, 
0.45 
0.55, 
0.5 
0.89, 
0.6 
Odds of Toxicity to Efficacy 
from Simulations at Dose Level i 
(ORi)* 
0.20 0.26 0.35 0.31 2.6 3.7 
Average Number of Patients 3.5 4.5 7.3 14.0 12.2 0.28 
Average Number of DLTs 0.04 0.1 0.45 2.8 6.7 0.25 
Average Number of Responses 0.04 0.22 1.1 6.3 6.1 0.17 
Average Number of Patients 
with a Response but no DLT 
0.04 0.22 1.0 5.0 2.7 0.02 
Decision based on the Bayesian 
Posterior Probabilities (% of 
times out of 10000 simulations 
each dose level satisfies the 
Bayesian decision criteria for 
both toxicity and efficacy)** 
2.86% 13.02% 28. 6% 76.08% 15.32% 0% 
% of times out of 10000 
simulations each dose level is 
the one with the maximum 
value of the utility function 
when c =0.1*** 
when c = 0.5 
when c=1 
 
 
 
 
0.31% 
2.13% 
6.05% 
 
 
 
 
1.61% 
5.64% 
8.48% 
 
 
 
 
6.43% 
14.04% 
20.21% 
 
 
 
 
47.01% 
62.19% 
61.13% 
 
 
 
 
42.91% 
15.63% 
4.11% 
 
 
 
 
1.73% 
0.37% 
0.02% 
* Calculated using only those simulations runs with a non-zero denominator for ORi. For the lower 
dose levels (levels 1 and 2), the denominator is zero in many simulation runs since the average 
number of responses is zero.  
** No dose level is chosen as acceptable for toxicity and efficacy ~13% of the time. The addition 
of the percentages for dose selection based on the Bayesian decision rules can add up to more 
than 100 since more than one dose level can be chosen as acceptable for toxicity and efficacy in 
each simulation. 
***c=1 gives equal weight to toxicity and efficacy while 0.1 gives a very small weight to toxicity 
and more weight to efficacy. 
Mean sample size for this example is 41.75; median sample size is35; minimum sample size is 12 
and maximum sample size is 126. 
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b) True Toxicity Rates are Monotonically Increasing with an Increase in Dose and 
True Efficacy Rates Increase with an Increase in Dose but Plateau after Dose 
Level 3 
 
Dose 
Level 1 
Dose 
Level 2 
Dose 
Level 3  
Dose 
Level 4 
Dose 
Level 5  
Dose 
Level 6 
True toxicity, true 
efficacy rate 
0.01, 0.01 0.02, 0.05 0.06, 0.15 0.2, 0.45 0.55, 0.45 0.89, 0.45 
Odds of Toxicity to 
Efficacy from 
Simulations at Dose 
Level i (ORi)* 
0.20 0.26 0.35 0.31 3.13 6.95 
Average Number of 
Patients 
3.5 4.5 7.3 14.0 12.2 0.28 
Average Number of 
DLTs 
0.04 0.1 0.45 2.8 6.7 0.25 
Average Number of 
Responses 
0.04 0.22 1.1 6.3 5.5 0.12 
Average Number of 
Patients with a 
Response but no DLT 
0.04 0.22 1.0 5.0 2.4 0.01 
Decision based on the 
Bayesian Posterior 
Probabilities (% of 
times out of 10000 
simulations each dose 
level satisfies the 
Bayesian decision 
criteria for both toxicity 
and efficacy)** 
2.86% 13.02% 28.6% 76.08% 13.57% 0.0% 
% of times out of 
10000 simulations each 
dose level is the one 
with the maximum 
value of the utility 
function 
when c =0.1*** 
when c = 0.5 
when c=1 
 
 
 
 
 
0.46% 
2.45% 
6.43% 
 
 
 
 
 
2.15% 
6.03% 
8.55% 
 
 
 
 
 
7.32% 
14.71% 
20.44% 
 
 
 
 
 
54.07% 
65.77% 
61.93% 
 
 
 
 
 
35.03% 
10.94% 
2.65% 
 
 
 
 
 
0.97% 
0.10% 
0% 
* Calculated using only those simulations runs with a non-zero denominator for ORi. For the lower 
dose levels (levels 1 and 2), the denominator is zero in many simulation runs since the average 
number of responses is zero.  
**No dose level is chosen as acceptable for toxicity and efficacy ~13% of the time. The addition of 
the percentages for dose selection based on the Bayesian decision rules can add up to more than 
100 since more than one dose level can be chosen as acceptable for toxicity and efficacy in each 
simulation. 
***c=1 gives equal weight to toxicity and efficacy while 0.1 gives a very small weight to toxicity 
and more weight to efficacy. 
Mean sample size for this example is 41.75; median is 35; minimum sample size is 12 and 
maximum sample size is 126. 
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CHAPTER FOUR 
  
Introduction 
Several dose finding oncology designs have been developed over the past years that 
are improvements over the 3+3 design in terms of accuracy of MTD selection as well 
as other operating characteristics such as the percentage of patients under-dosed. 
Here, we focus on two of these relatively recent designs: the TEQR and the mTPI 
designs. The TEQR design is a simple dose finding design where the dose finding 
decisions are based on whether the empirical dose limiting toxicity (DLT) rate lies 
within the target DLT interval or in the interval below or above it [73]. The mTPI 
design [72] uses a similar concept for dosing decisions but provides a Bayesian 
counterpart to the frequentist TEQR design.  
 
Phase I trials are generally very small and the accuracy of MTD selection is low with 
such a small sample size. Hence, we first compare the frequentist TEQR dose-finding 
design and the Bayesian mTPI dose-finding design for accuracy of MTD selection with 
larger sample sizes and identical stopping rules. We then extend the TEQR and mTPI 
designs with a moderately large sample size to choose an optimal dose for both safety 
and efficacy by considering correlated Bernoulli distributions for the true underlying 
toxicity and efficacy rates; we have previously proposed a simple rule-based design 
that incorporates toxicity and efficacy in dose selection, and we now continue this 
work and similarly extend the TEQR and mTPI designs to also include efficacy. In our 
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simulations, we assume that the true DLT rates increase monotonically with an 
increase in dose but we do not assume that the true response rates increase 
monotonically with an increase in dose; we allow multiple types of curves for dose-
response (monotonically increasing, plateau, or umbrella-shaped). In this context, we 
apply a recent update to the isotonic regression method, called nearly-isotonic 
regression, and investigate if it can be used to select a dose that is optimal for both 
safety and efficacy. We also apply isotonic regression on the difference in observed 
response rates between adjacent dose levels and investigate if it can be used to 
improve the accuracy of dose selection for certain dose-response curves. Thus, we 
propose a simple way of extending the mTPI (and TEQR) design to include efficacy, 
using the technique of isotonic regression. This is in contrast to the more complex 
technique of using a statistic called the joint unit probability mass (JUPM) for toxicity 
and efficacy, as proposed by Li et al., to extend the mTPI design to include efficacy 
[114]. We finally compare the accuracy of dose selection of the extended TEQR and 
mTPI designs to that of the Eff-Tox design and the Optimal Biological Dose (OBD) 
Isotonic design. 
 
Methods 
TEQR and MTPI Designs  
The TEQR design is a frequentist design and is based on the empirical DLT rate [73]. 
The toxicity probability scale is divided into three intervals, namely (0, pT-1), [pT-1, 
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pT+2] and (pT+2,1); pT is the target probability of DLT and 1 and 2 are used to define 
the interval for the target DLT rate. The rules for escalating, staying at the same dose 
or de-escalating depend on which of these intervals contains the empirical DLT rate 
for that dose level – if the empirical DLT rate lies between 0 and pT-1, the next cohort 
of patients will be treated at the next higher dose; if it lies in the interval [pT-1, pT+2], 
the next cohort of patients will be treated at the same dose; if it lies above pT+2, the 
next cohort of patients will be treated at a lower dose. The trial stops if dose level 1 is 
too toxic or when a dose level achieves the selected MTD sample size.  
 
The mTPI design is a Bayesian counterpart of the TEQR design and uses the unit 
probability mass (UPM) statistic, defined as the ratio of the probability mass of the 
interval and the length of the interval [72], for the dose finding decisions. The toxicity 
probability scale is again divided into three intervals, namely (0, pT-1), [pT-1, pT+2] 
and (pT+2, 1), and these three intervals correspond to under-dosing, correct dosing 
and over-dosing respectively. The rules for escalating, staying at the same dose or de-
escalating depend on which of these intervals has the highest UPM for that dose level, 
based on a beta-binomial posterior distribution formed from the likelihood of the 
observed DLT data and a beta(1,1) prior. For example, the next cohort of patients will 
be treated at the same dose if the UPM is the largest for the correct dosing interval. 
The trial stops if dose level 1 is too toxic or if the maximum sample size is reached or 
exceeded. In both the mTPI and TEQR design, we stay at the current dose if the 
current dose is safe but the DLT data indicate that the next higher dose is too toxic. 
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Isotonic Regression 
When the true underlying DLT rate (or response rate) increases with an increase in 
dose, the observed DLT (or response) rate is also expected to be a monotonically non-
decreasing function of dose. However, this may not always be what is observed due 
to the small sample size in each dose level in dose-finding oncology trials. Isotonic 
regression is a weighted regression and a smoothing procedure that has been used to 
ensure that the estimated DLT (or response) rate is a monotonically non-decreasing 
function of dose. This then enables us to determine the highest dose level that is 
acceptable for safety and the lowest dose level that is acceptable for efficacy. 
 
In a trial using a standard TEQR or mTPI design, the dose chosen for safety is the 
highest dose level with a DLT rate that is closest to (and below) the pre-specified DLT 
rate (say 0.33) after applying isotonic regression at the end of the trial. In our 
simulated trials of the TEQR or mTPI design that has been extended to evaluate both 
safety and efficacy, isotonic regression is also applied independently to the observed 
response rates at the end of each trial, when the true underlying response rates are 
thought to be monotonically increasing or monotonically non-decreasing with an 
increase in dose. Since the estimated response rates will be monotonically non-
decreasing with an increase in dose after applying isotonic regression, we choose as 
the optimal dose for safety and efficacy the highest dose level where the DLT rate is 
less than or equal to 0.33 after isotonic regression, only if the smoothed response rate 
at that dose level crosses the efficacy threshold (say response rate of 0.4). For 
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example, if dose level 4 is chosen after isotonic regression as the highest dose level 
with a DLT rate <=0.33 and dose level 3 or lower is chosen after isotonic regression 
as the lowest dose level with a response rate >=0.4, then dose level 4 is the optimal 
dose for safety and efficacy since the response rate at dose level 4 will be >=0.4 in this 
case. However, if dose level 3 is chosen for safety after isotonic regression and dose 
level 4 is chosen for efficacy after isotonic regression, then there is no dose level that 
is optimal for safety and efficacy because the efficacy threshold of a response rate of 
0.4 is not crossed at dose level 3, but only at dose level 4. Of course, if dose level 3 is 
chosen for both safety and efficacy after isotonic regression, then dose level 3 is the 
optimal dose for safety and efficacy.  
 
Nearly-isotonic Regression 
When the true response rates are not considered to be strictly monotonically 
increasing with an increase in dose, we can use the method of “nearly-isotonic” 
regression developed by Holger et al. of approximating a sequence of data points with 
a nearly-monotone function [115]. Their method is a modified version of the pool 
adjacent violators algorithm (PAVA), and the formulation of the method includes a 
parameter  that controls the amount of smoothing of the data. In mathematical 
terms, the equation that is considered is the following convex optimization problem 
for each non-negative :  
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?̂?𝜆 = 𝑎𝑟𝑔𝑚𝑖𝑛⏟    
𝛽∈𝑅𝑛
1
2
∑(𝑦𝑖 − 𝛽𝑖)
2 
𝑛
𝑖=1
+  𝜆∑(𝛽𝑖 − 𝛽𝑖+1)+ 
𝑛−1
𝑖=1
  
where  ?̂?𝜆 (= (1, 2,…, n)) is the nearly monotone approximation to the sequence of 
n points y1, y2,…..yn, and x+ indicates the positive part, x+ = x · 1(x > 0). ?̂?𝜆 will vary 
with . When =0, then there is no smoothing at all and the estimates are fit to just 
the observed data points as is; as  gets larger and larger, the regression fit tends 
towards the standard isotonic regression fit. 
 
Finding the Peak of an Umbrella-shaped Dose-Response Curve using Isotonic 
Regression 
When there is a peak in the dose-response curve (umbrella-shaped dose-response 
curve), we apply isotonic regression to the difference in observed response rates 
between adjacent dose levels obtained at the end of each simulated trial. These 
differences function like a derivative. For a convex shaped curve for example, the 
derivative is 0 at the peak, and the sign of the derivative changes from before the peak 
to after the peak. This is the same concept we use to determine the peak of an 
umbrella shaped dose-response curve – we apply isotonic regression at the end of 
each simulated trial to the differences in observed response rates between adjacent 
dose levels, and observe where these differences switch from a negative to a positive 
sign, to determine the peak of the curve. 
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Comparisons of Results for Accuracy of Optimal Dose Selection 
We compare the results for accuracy of optimal dose selection of the extended TEQR 
and mTPI designs to those of the Eff-Tox design and the Optimal Biological Dose 
(OBD) Isotonic design for various scenarios of true toxicity and efficacy rates. The Eff-
Tox design [67, 102] and the OBD Isotonic design [101] are described in Chapter 3. 
 
Simulations 
We generate two correlated binary random variables X1~ Bernoulli(p) and X2~ 
Bernoulli(q) for toxicity and efficacy respectively as follows. We first generate X1 with 
success probability p. If X1=1, we generate X2 with probability q1 and if X1=0, we 
generate X2 with probability q2. q1 and q2 are defined as follows: 
q1 = q + (r/p) * sqrt(p*(1-p)*q*(1-q))  
q2 = (q - q1*p)/(1-p)  
r is the correlation coefficient between X1 and X2 and is restricted to lie between  
max (−(
(𝑝𝑞)
(1−𝑝)(1−𝑞)
)
1
2 , −(
(1−𝑝)(1−𝑞)
(𝑝𝑞)
)
1
2 )  and  min ((
(𝑝 (1−𝑞))
(1−𝑝)(𝑞)
)
1
2 , (
((1−𝑝)𝑞)
(𝑝)(1−𝑞)
)
1
2)  [110]. 
In the equations for q1 and q2, it can be seen that if the correlation coefficient r=0 
then q1=q2=q.  
 
We generate the true DLT rate at each dose level (pi) using a logistic dose toxicity 
curve, whose two coefficients are calculated using the following parameters: true DLT 
rate at starting dose (dose level 1, 100 units) of 0.01 and true DLT rate of 0.2 at the 
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true MTD (dose level 4, 501 units). We generate the true response rate at each dose 
level (qi) manually to follow either a monotonic increase, a plateau, or an umbrella-
shape (Table 15). 
 
We have created our own SAS code to simulate both the extended TEQR and mTPI 
designs. To obtain the statistical operating characteristics for each scenario in the 
results section, we perform 1000 simulations each time. The rules for escalation, de-
escalation or remaining at the same dose for each simulated trial are based on the 
number of observed DLTs. Two different stopping rules are considered in our 
simulations, namely the usual stopping rules for the TEQR design and the mTPI 
design respectively; the simulated trial stops a) when the desired MTD sample size is 
reached or when dose level 1 is too toxic or b) when the desired total sample size is 
reached or when dose level 1 is too toxic. In our simulations of these designs, we have 
also considered the underlying true response rate at each dose level and the resultant 
response of each patient. Although the dose escalation/staying/de-escalation 
decisions are based only on the number of observed DLTs, the response of each 
patient is also observed and noted. At the end of each simulated trial, we choose a 
dose that is optimal for both safety and efficacy based on the observed DLT and 
response rates at each dose level.  
 
The input parameters used in our SAS code for the TEQR and mTPI designs are 
provided in Appendix Table 1. For simplicity, the coefficient of correlation r is set to 
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0 for the simulation results given in the main text. The results can be investigated for 
correlation coefficients other than zero (Appendix Section 2) within the range of 
values that the correlation coefficient can assume. 
 
Results 
Safety Only: Monotonically Increasing True DLT Rates  
Only the monotonically increasing true DLT rates with an increase in dose shown in 
Table 15 are used in the simulations and no efficacy is involved in the results in Tables 
16 and 17; isotonic regression is applied to the observed DLT rates at the end of each 
simulated trial to determine the MTD.  
We use the same stopping rules for the mTPI and TEQR designs and compare them 
for accuracy of MTD Selection.  
a) We use the usual stopping rules of the TEQR design, namely stop the trial when 
the desired MTD sample size is reached or when dose level 1 is too toxic, for both 
the TEQR and mTPI designs and compare their performance for the accuracy of 
MTD selection; dose level 4 is the true MTD in our example. 
b) We use the usual stopping rules of the mTPI design, namely stop the trial when the 
total desired sample size is reached or when dose level 1 is too toxic, for both the 
TEQR and mTPI designs and compare their performance for the accuracy of MTD 
selection; dose level 4 is the true MTD in our example. 
In general, we find that when identical stopping rules are used for both the designs, 
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the Bayesian mTPI design is more accurate than the frequentist TEQR design in 
selecting the true MTD for the scenarios explored, with the same or similar number 
of subjects (Table 16 and Table 17). Also, given the same cohort size, the accuracy of 
MTD selection generally increases when the total sample size is increased. Thus, we 
use a moderate sample size of 50 subjects to evaluate efficacy and safety. 
Safety and Efficacy: Monotonically Increasing True DLT and Response Rates  
The monotonically increasing true DLT and response rates with an increase in dose 
shown in Table 15 are used in the simulations and isotonic regression is applied 
independently to the observed DLT rates and to the observed response rates at the 
end of each simulated trial.  
a) We use the usual stopping rules of the TEQR design, namely stop the trial when 
the desired MTD sample size is reached or when dose level 1 is too toxic, for 
both the extended TEQR and mTPI designs and compare their performance for 
dose selection. The results in Table 18 are based on a MTD sample size of 50 
and a cohort size of 5. 
For this example, both the extended TEQR and mTPI designs select dose level 4 as the 
optimal dose for safety and efficacy with the highest probability (Table 18).  The 
extended mTPI design selects dose level 4 as the optimal dose with a higher 
probability than the extended TEQR design does. 
 
For the extended TEQR design example in Table 18, we also apply isotonic regression 
to the difference in the observed response rates between adjacent dose levels at the 
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end of each simulated trial, to investigate if this technique will help determine the 
dose for efficacy (Appendix Section 3).  
b) We use the stopping rules of the mTPI design, namely stop the trial when the 
total desired sample size is reached or when dose level 1 is too toxic, for both 
the extended TEQR and mTPI designs and compare their performance for dose 
selection. The results in Table 19 are based on a total sample size of 50 and a 
cohort size of 5. 
For this example, both the extended TEQR and mTPI designs select dose level 4 as the 
optimal dose for safety and efficacy with the highest probability (Table 19).  The 
extended mTPI design selects dose level 4 as the optimal dose with a higher 
probability than the extended TEQR design does. 
 
Safety and Efficacy: Monotonically Increasing True DLT Rates and Plateauing 
Response Rates  
The monotonically increasing true DLT and plateauing response rates with an 
increase in dose shown in Table 15 are used in the simulations and isotonic 
regression is applied independently to the observed DLT rates and to the observed 
response rates at the end of each simulated trial. 
a) We use the usual stopping rules of the TEQR design, namely stop the trial when 
the desired MTD sample size is reached or when dose level 1 is too toxic, for both 
the extended TEQR and mTPI designs and compare their performance for dose 
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selection. The results in Table 20 are based on a MTD sample size of 50 and a 
cohort size of 5. 
For this example, both the extended TEQR and mTPI designs select dose level 4 as the 
optimal dose for safety and efficacy with the highest probability (Table 20).  The 
extended mTPI design selects dose level 4 as the optimal dose with a higher 
probability than the extended TEQR design does. 
For the extended TEQR design example in Table 20, we also apply isotonic regression 
to the difference in the observed response rates between adjacent dose levels at the 
end of each simulated trial, to investigate if this technique will help determine the 
dose for efficacy (Appendix Section 4).  
b) We use the stopping rules of the mTPI design, namely stop the trial when the total 
desired sample size is reached or when dose level 1 is too toxic, for both the 
extended TEQR and mTPI designs and compare their performance for dose 
selection. The results in Table 21 are based on a total sample size of 50 and a cohort 
size of 5. 
For this example, both the extended TEQR and mTPI designs select dose level 4 as the 
optimal dose for safety and efficacy with the highest probability (Table 21).  The 
extended mTPI design selects dose level 4 as the optimal dose with a higher 
probability than the extended TEQR design does. 
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Safety and Efficacy: Monotonically Increasing True DLT Rates and Umbrella-Shaped 
Dose-Response Curve  
The monotonically increasing true DLT rates with an increase in dose and the 
umbrella-shaped true response rates shown in Table 15, where the response rate 
peaks at dose level 4, are used in the simulations; isotonic regression is applied to the 
observed DLT rates and nearly-isotonic regression is applied to the observed 
response rates at the end of each simulated trial. 
a) We use the usual stopping rules of the TEQR design, namely stop the trial when 
the desired MTD sample size is reached or when dose level 1 is too toxic, for both 
the extended TEQR and mTPI designs and compare their performance for dose 
selection. The results in Table 22 are based on a MTD sample size of 50 and a 
cohort size of 5. 
In general, we will not know the exact shape of the underlying dose-response curve 
at the beginning of the trial. However, when the true dose-response curve is thought 
to be umbrella-shaped, the results in Table 22 are obtained when the technique of 
nearly-isotonic regression is applied to the observed response rates. When the true 
underlying response rates possess a peak at a certain dose, the dose level that is 
chosen for efficacy depends on the amount of smoothing performed on the observed 
response rates – this smoothing is controlled by the parameter. In this scenario, 
applying nearly-isotonic regression or isotonic regression directly to the response 
rates does not help identify the peak in the dose-response curve. When the true dose-
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response curve is thought to possess a clear peak, we suggest applying isotonic 
regression to the difference in observed response rates between adjacent dose levels 
to reveal or identify this peak dose level for efficacy, as described in Appendix Section 
5. 
For the extended TEQR design example in Table 22, we also apply isotonic regression 
to the difference in the observed response rates between adjacent dose levels at the 
end of each simulated trial, to help determine the dose at which the response rate 
peaks (Appendix Section 5).   
b) We use the stopping rules of the mTPI design, namely stop the trial when the total 
desired sample size is reached or when dose level 1 is too toxic, for both the 
extended TEQR and mTPI designs and compare their performance for dose 
selection. The results in Table 23 are based on a total sample size of 50 and a cohort 
size of 5. 
In this case, where the true underlying response rates possess a peak at a certain dose, 
the dose level that is chosen for efficacy depends on the amount of smoothing done 
on the observed response rates – this smoothing is controlled by the parameter . In 
this scenario, applying nearly-isotonic regression or isotonic regression directly to 
the response rates does not help identify the peak in the dose-response curve. When 
the true dose-response curve is thought to possess a clear peak, we suggest applying 
isotonic regression to the difference in observed response rates between adjacent 
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dose levels to reveal or identify this peak dose level for efficacy, as described in 
Appendix Section 5. 
 
Comparison of the Accuracy of Optimal Dose Selection for Various Designs 
We compare the accuracy of optimal dose selection of our extended TEQR and mTPI 
designs to that of the Eff-Tox design and that of the OBD Isotonic design by Zang et 
al., for some scenarios of true DLT and response rates. All the input parameters used 
in the Eff-Tox design and OBD Isotonic design simulations are given in Appendix 
Section 6. 
 
We find that among the designs considered, the extended mTPI design selects the 
optimal dose more accurately than the other designs for these scenarios. The 
extended TEQR design performs as well as or slightly worse than the Eff-Tox design 
in terms of accuracy of optimal dose selection in most scenarios. The OBD Isotonic 
design performs well for the case of the umbrella-shaped dose response curve, while 
the Eff-Tox design frequently does not select any dose as optimal for such a dose-
response curve (Table 24). 
 
Discussion and Conclusion 
We have first compared the frequentist TEQR design with the Bayesian mTPI design 
for accuracy of MTD selection, when using the same stopping rules for both designs. 
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In all the scenarios considered, the Bayesian mTPI design is more accurate in 
selecting the true MTD than the frequentist TEQR design, when identical stopping 
rules and the same or similar sample sizes are used for both the designs. Also, given 
the same cohort size, the accuracy of MTD selection generally increases when the 
total sample size is increased. 
 
We then extended the TEQR and mTPI designs to also consider efficacy, in addition to 
safety, in a moderately sized trial. In our extended TEQR or mTPI trial designs, 
isotonic regression is always applied to the observed DLT rates at the end of the trial, 
since the true DLT rate is always assumed to increase with an increase in dose. The 
technique that is most appropriate to apply to the observed response rates depends 
on the drug’s properties (Figure 10). For this, clinical knowledge or judgement about 
the true underlying response rates of the study drug is required to have a good initial 
guess at the true dose-response curve. 
 
When the true underlying response rates are thought to increase monotonically with 
an increase in dose or to first increase monotonically and then plateau after a certain 
dose level, isotonic regression can also be applied to the observed response rates at 
the end of the TEQR or mTPI trial. The optimal dose level for safety and efficacy is 
chosen to be the highest dose level for which the DLT rate after applying isotonic 
regression is below or at the target toxicity rate, only if the threshold for response 
rate is crossed at that dose. If the threshold for response rate is not reached at the 
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highest dose level at which the smoothed DLT rate is below or at the target toxicity 
rate, then no dose level is chosen as optimal for safety and efficacy. 
 
When the underlying true response rates are thought to possess a clear peak 
(umbrella shaped dose-response curve), isotonic regression on the difference in 
observed response rates between adjacent dose levels, along with the sign of these 
differences, can be used to reveal or identify this peak dose level for efficacy. This 
information of the peak dose level for efficacy can then be used in conjunction with 
the dose level picked for safety, to select an optimal dose for safety and efficacy.  For 
example, if the peak dose level identified for efficacy is equal to or lower than the dose 
level selected for safety, then the peak dose level identified for efficacy is chosen as 
the optimal dose for safety and efficacy, assuming that the peak is above the specified 
efficacy threshold – if not, no dose level is chosen as the optimal dose. If the peak dose 
level identified for efficacy is higher than the dose level selected for safety, then the 
lower dose level selected for safety can be chosen as the optimal dose, only if the 
response rate at that dose is greater than or equal to the efficacy threshold – if not, no 
dose is chosen as the optimal dose. In brief, we cannot select a dose that exceeds the 
target toxicity, but if the maximum or peak efficacy of the drug is reached at a lower 
dose, we can use that as the optimal dose assuming the efficacy threshold is crossed 
at that dose (Figure 11). 
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Note that when we use isotonic regression on the difference in response rates 
between adjacent dose levels in the case when there is no peak in the response rates 
(monotonically increasing or plateauing response rates), we find that no dose level is 
selected as the peak frequently. In this case, we can apply isotonic regression on the 
response rates themselves.  
 
We compared the extended TEQR and mTPI design to the Eff-Tox and OBD Isotonic 
design for accuracy of optimal dose selection for some scenarios of true efficacy and 
toxicity rates. For these scenarios and for the designs considered, we found that the 
extended mTPI design selects the optimal dose more accurately than the other 
designs. The extended TEQR design performs as well as or slightly worse than the Eff-
Tox design in terms of the accuracy of optimal dose selection for most of the 
scenarios. The OBD Isotonic design performs well for an umbrella-shaped dose 
response curve, while the Eff-Tox design frequently does not select any dose as 
optimal for such a dose-response curve. 
 
In summary, we have continued to propose designs that incorporate toxicity and 
efficacy in dose selection. In this context, we applied a recent update to the isotonic 
regression method, called nearly- isotonic regression, and investigated if it could be 
used to select a dose that is optimal for both safety and efficacy. We did not find that 
it was necessary to use this update to isotonic regression but found that isotonic 
regression itself applied on the difference in observed response rates between 
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adjacent dose levels could be used to identify the peak of a dose-response curve with 
a clear maximum, such as a convex umbrella-shaped dose-response curve. For other 
dose-response curves, such as monotonically increasing or plateau, applying isotonic 
regression to both the observed DLT and response rates independently can be used 
to determine the optimal dose for toxicity and efficacy. 
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Table 15 Monotonically Increasing True DLT Rates with an Increase in Dose and Different Dose-Response Curves (the true 
probability of response at each dose is selected manually) 
Dose True probability of toxicity at each dose, 
generated from a logistic curve, whose coefficients 
are calculated assuming the true DLT rate at 100 
units to be 0.01 and at 501 units to be 0.2. The 
dose levels follow the modified Fibonacci series. 
Loge(DLT rate/(1-DLT rate)) =-5.39533+ 
0.008002*dose 
Monotonically 
Increasing True 
Response Rates 
Plateauing 
Response Rates 
with an Increase 
in Dose 
 
Umbrella-
Shaped Dose-
Response 
Curve 
100 
units 
0.01 0.1 0.1 0.1 
200 0.02 0.3 0.3 0.3 
334 0.06 0.4 0.4 0.4 
501 0.2 0.45 0.45 0.45 
701.4 0.55 0.55 0.45 0.2 
932.86 0.89 0.6 0.45 0.05 
 
  
  
1
3
9
 
Table 16 Results for Accuracy of MTD Selection: Stopping Rules of the TEQR Design 
Cohort 
Size 
Sample 
Size at 
MTD 
mTPI Accuracy of 
MTD Selection (% 
of Times out of 
1000 Simulations 
Dose Level 4 is 
Selected) 
Median 
Sample 
Size 
Maximum 
Sample 
Size 
TEQR Accuracy of 
MTD Selection (% 
of Times out of 
1000 Simulations 
Dose Level 4 is 
Selected) 
Median 
Sample 
Size 
Maximum 
Sample Sze 
3 30 75.7% 39 75 73.1% 45 84 
4 40 83.4% 56 100 69.5% 52 92 
5 50 85.0% 65 115 63.7% 65 115 
6 60 82.2% 78 132 82.5% 84 132 
10 100 93.4% 130 200 83.7% 130 210 
 
Sample 
Size at 
MTD 
Cohort 
Size 
mTPI Accuracy of 
MTD Selection (% 
of Times out of 
1000 Simulations 
Dose Level 4 is 
Selected) 
Median 
Sample 
Size 
Maximum 
Sample 
Size 
TEQR Accuracy of 
MTD Selection (% 
of Times out of 
1000 Simulations 
Dose Level 4 is 
Selected) 
Median 
Sample 
Size 
Maximum 
Sample Sze 
60 2 79.2% 70 132 43.4% 66 128 
60 3 75.1% 69 147 75.9% 75 135 
60 4 83.9% 76 140 66.6% 72 128 
60 5 87.3% 75 135 62.1% 75 130 
60 6 82.2% 78 132 82.5% 84 132 
60 10 91.3% 90 130 81.6% 90 130 
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Table 17 Accuracy of MTD Selection: Stopping Rules of the mTPI Design 
Cohort 
Size 
Total 
Sample 
Size  
mTPI Accuracy of MTD Selection 
(% of Times out of 1000 
Simulations Dose Level 4 is 
Selected) 
TEQR Accuracy of MTD 
Selection (% of Times out of 
1000 Simulations Dose Level 4 
is Selected) 
3 30 71.5% 66.6% 
4 40 80.3% 68.7% 
5 50 86.2% 64.5% 
6 60 82.7% 81.3% 
10 100 91.5% 82.8% 
 
Total 
Sample 
Size 
Cohort 
Size 
mTPI Accuracy of MTD Selection (% 
of Times out of 1000 Simulations 
Dose Level 4 is Selected) 
TEQR Accuracy of MTD 
Selection (% of Times out of 
1000 Simulations Dose Level 4 
is Selected) 
60 2 78.1% 44.1% 
60 3 76.0% 74.7% 
60 4 85.1% 67.2% 
60 5 86.4% 66.6% 
60 6 82.7% 81.3% 
60 10 90.4% 79.7% 
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Table 18 Results for Accuracy of Dose Selection in the Extended TEQR and mTPI Designs for Monotonically Increasing True 
DLT and Response Rates: Stopping Rules of the TEQR Design 
TEQR Design 
Dose Level % of Times Dose Level is 
Chosen for Toxicity 
% of Times Dose Level is 
Chosen for Efficacy 
Probability of Dose Level 
being Selected as Optimal 
for Toxicity and Efficacy 
No Dose Level is chosen 0% 9.2% 0.28 
1 0.8% 0% 0 
2 3.2% 27.9% 0.01 
3 31.8% 28.1% 0.18 
4 63.7% 26.6% 0.53 
5 0.5% 8.1% 0 
6 0% 0.1% 0 
 
mTPI Design 
Dose Level % of Times Dose Level is 
Chosen for Toxicity 
% of Times Dose Level is 
Chosen for Efficacy 
Probability of Dose Level 
being Selected as Optimal 
for Toxicity and Efficacy 
No Dose Level is chosen 0% 9.9% 0.21 
1 0% 0% 0 
2 0.2% 26.5% 0 
3 14.7% 29.1% 0.08 
4 85.0% 27.3% 0.70 
5 0.1% 7.1% 0 
6 0% 0.1% 0 
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Table 19 Results for Accuracy of Dose Selection in the Extended TEQR and mTPI Designs for Monotonically Increasing True 
DLT and Response Rates: Stopping Rules of the mTPI Design 
TEQR Design 
Dose Level % of Times Dose 
Level is Chosen for 
Toxicity 
% of Times Dose 
Level is Chosen for 
Efficacy 
Probability of Dose Level 
being Selected as Optimal 
for Toxicity and Efficacy 
No Dose Level is chosen 0% 9.4% 0.28 
1 0.6% 0% 0 
2 2.6% 25.4% 0.01 
3 31.3% 32.3% 0.18 
4 64.5% 24.0% 0.53 
5 1.0% 8.9% 0.01 
 
mTPI Design 
Dose Level % of Times Dose 
Level is Chosen for 
Toxicity 
% of Times Dose 
Level is Chosen for 
Efficacy 
Probability of Dose Level 
being Selected as Optimal 
for Toxicity and Efficacy 
No Dose Level is chosen 0% 9.9% 0.23 
1 0% 0% 0 
2 0.3% 25.2% 0 
3 12.7% 30.0% 0.07 
4 86.2% 25.1% 0.69 
5 0.8% 9.6% 0.01 
6 0% 0.2% 0 
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Table 20 Results for Accuracy of Dose Selection in the Extended TEQR and mTPI Designs for Monotonically Increasing True 
DLT Rates and Plateauing True Response Rates: Stopping Rules of the TEQR Design  
TEQR Design 
Dose Level % of Times Dose 
Level is Chosen for 
Toxicity 
% of Times Dose 
Level is Chosen for 
Efficacy 
Probability of Dose Level 
being Selected as Optimal 
for Toxicity and Efficacy 
No Dose Level is chosen 0% 11.5% 0.29 
1 0.8% 0% 0 
2 3.2% 28.0% 0.01 
3 31.8% 27.5% 0.18 
4 63.7% 26.5% 0.52 
5 0.5% 6.3% 0 
6 0% 0.2% 0 
 
mTPI Design 
Dose Level % of Times Dose 
Level is Chosen for 
Toxicity 
% of Times Dose 
Level is Chosen for 
Efficacy 
Probability of Dose Level 
being Selected as Optimal 
for Toxicity and Efficacy 
No Dose Level is chosen 0% 11.2% 0.22 
1 0% 0% 0 
2 0.2% 25.9% 0 
3 14.7% 29.1% 0.08 
4 85.0% 27.0% 0.70 
5 0.1%  6.8% 0 
6 0% 0% 0 
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Table 21 Results for Accuracy of Dose Selection in the Extended TEQR and mTPI Designs for Monotonically Increasing True 
DLT Rates and Plateauing True Response Rates: Stopping Rules of the mTPI Design 
TEQR Design 
Dose Level % of Times Dose 
Level is Chosen 
for Toxicity 
% of Times Dose 
Level is Chosen 
for Efficacy 
Probability of Dose Level 
being Selected as Optimal 
for Toxicity and Efficacy 
No Dose Level is chosen 0% 11.3% 0.28 
1 0.6% 0% 0 
2 2.6% 25.1% 0.01 
3 31.3% 32.3% 0.18 
4 64.5% 23.4% 0.52 
5 1.0% 7.6% 0.01 
6 0% 0.3% 0 
 
mTPI Design 
Dose Level % of Times Dose 
Level is Chosen 
for Toxicity 
% of Times Dose 
Level is Chosen 
for Efficacy 
Probability of Dose Level 
being Selected as Optimal 
for Toxicity and Efficacy 
No Dose Level is chosen 0% 12.1% 0.24 
1 0% 0% 0 
2 0.3% 25.1% 0 
3 12.7% 29.9% 0.07 
4 86.2% 24.3% 0.68 
5 0.8% 8.6% 0.01 
6 0% 0% 0 
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Table 22 Results for Accuracy of Dose Selection in the Extended TEQR and mTPI Designs for Monotonically Increasing True 
DLT Rates and Umbrella-Shaped True Response Rates: Stopping Rules of the TEQR Design 
TEQR Design 
Dose 
Level 
% of Times 
Dose Level 
is Chosen 
for Toxicity 
% of Times 
Dose Level 
is Chosen 
for Efficacy 
(=0) 
% of Times 
Dose Level 
is Chosen 
for Efficacy 
(=0.01) 
% of Times 
Dose Level 
is Chosen 
for Efficacy 
(=0.025) 
% of Times 
Dose Level 
is Chosen 
for Efficacy 
(=0.05) 
% of Times 
Dose Level 
is Chosen 
for Efficacy 
(=0.1) 
% of Times 
Dose Level 
is Chosen 
for Efficacy 
(=0.5) 
% of Times 
Dose Level 
is Chosen 
for Efficacy 
(=1) 
1 0.8% 0% 0% 0% 0% 0% 0% 0% 
2 3.2% 47.1% 34.3% 33.3% 32.4% 31.1% 23.6% 23.5% 
3 31.8% 32.1% 29.3% 27.8% 27.0% 25.5% 19.7% 19.7% 
4 63.7% 14.5% 22.1% 21.0% 19.8% 17.2% 14.6% 14.6% 
5 0.5% 0.3% 0.1% 1.0% 1.0% 1.0% 1.1% 1.1% 
6 0% 0% 0% 0% 0% 0% 0% 0% 
 
mTPI Design 
Dose 
Level 
% of Times 
Dose Level 
is Chosen 
for Toxicity 
% of Times 
Dose Level 
is Chosen for 
Efficacy 
(=0) 
% of Times 
Dose Level 
is Chosen for 
Efficacy 
(=0.01) 
% of Times 
Dose Level 
is Chosen for 
Efficacy 
(=0.025) 
% of Times 
Dose Level 
is Chosen 
for Efficacy 
(=0.05) 
% of Times 
Dose Level 
is Chosen for 
Efficacy 
(=0.1) 
% of Times 
Dose Level 
is Chosen for 
Efficacy 
(=0.5) 
% of Times 
Dose Level 
is Chosen 
for Efficacy 
(=1) 
1 0% 0% 0% 0% 0% 0% 0% 0% 
2 0.2% 45.2% 31.0% 30.5% 30.1% 29.3% 22.4% 22.3% 
3 14.7% 34.9% 31.1% 30.3% 29.6% 28.2% 22.5% 22.5% 
4 85.0% 17.2% 24.5% 22.8% 21.1% 18.3% 15.2% 15.2% 
5 0.1% 0.5% 1.6% 1.6% 1.6% 1.7% 2% 2% 
6 0% 0% 0% 0% 0% 0% 0% 0% 
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Table 23 Results for Accuracy of Dose Selection in the Extended TEQR and mTPI Designs for Monotonically Increasing True 
DLT Rates and Umbrella-Shaped True Response Rates: Stopping Rules of the mTPI Design 
 
TEQR Design 
Dose 
Level 
% of Times 
Dose Level is 
Chosen for 
Toxicity 
% of Times 
Dose Level is 
Chosen for 
Efficacy (=0) 
% of Times 
Dose Level is 
Chosen for 
Efficacy 
(=0.025) 
% of Times 
Dose Level is 
Chosen for 
Efficacy 
(=0.05) 
% of Times 
Dose Level is 
Chosen for 
Efficacy 
(=0.1) 
% of Times 
Dose Level is 
Chosen for 
Efficacy 
(=0.5) 
% of Times 
Dose Level is 
Chosen for 
Efficacy (=1) 
1 0.6% 0% 0% 0% 0% 0% 0% 
2 2.6% 41.7% 29.5% 28.7% 27.3% 20.8% 20.8% 
3 31.3% 38.0% 33.8% 32.0% 29.7% 22.6% 22.6% 
4 64.5% 14.1% 20.7% 18.7% 16.7% 13.5% 13.5% 
5 1.0% 0.4% 1.5% 1.5% 1.5% 1.5% 1.5% 
 
mTPI Design 
Dose 
Level 
% of Times 
Dose Level is 
Chosen for 
Toxicity 
% of Times 
Dose Level is 
Chosen for 
Efficacy 
(=0) 
% of Times 
Dose Level is 
Chosen for 
Efficacy 
(=0.025) 
% of Times 
Dose Level is 
Chosen for 
Efficacy 
(=0.05) 
% of Times 
Dose Level is 
Chosen for 
Efficacy 
(=0.1) 
% of Times 
Dose Level is 
Chosen for 
Efficacy 
(=0.5) 
% of Times 
Dose Level is 
Chosen for 
Efficacy 
(=1) 
1 0% 0% 0% 0% 0% 0% 0% 
2 0.3% 44.6% 30.3% 29.6% 29.1% 21.4% 21.3% 
3 12.7% 36.6% 31.9% 31.0% 29.5% 23.3% 23.3% 
4 86.2% 15% 22.4% 21.1% 18.9% 16% 16% 
5 0.8% 0.5% 1.8% 1.8% 1.9% 2% 2% 
6 0% 0% 0% 0% 0% 0% 0% 
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Table 24 Results for Accuracy of Optimal Dose Selection for Various Designs  
Scenario                                      Dose Level  
  1 2 3 4 5 6 None 
1 
 True toxicity, true efficacy rate  .01, .1 .02, .30 .06, .4 .2, .45 .55, 0.55 .89, .6 -  
 Trade-off Value Eff-Tox Design -0.82 -0.43 -0.30 -0.43 -0.77 -1.2 -  
 % selected by Eff-Tox Design 0 1 41 53* 2 0 3 
 % selected by OBD Design  8 21.6 25.3 36.7 8.3 0 0 
 % selected by Extended mTPI Design  0 0.08 7.01 69.22 0.72 0 23 
 % selected by Extended TEQR Design  0 0.66 18.06 52.7 0.91 0 27.68 
2 
 True toxicity, true efficacy rate  .01, .1 .02, .30 .06, .4 .2, .45 .55, 0.45 .89, .45 -  
 Trade-off Value Eff-Tox Design -0.82 -0.43 -0.30 -0.43 -0.98 -1.51 -  
 % selected by Eff-Tox Design 0 1 42 50 2 0 5 
 % selected by OBD Design  8 21.9 27.4 36.8 5.9 0 0 
 % selected by Extended mTPI Design  0 0.08 6.99 68.36 0.7 0 23.88 
 % selected by Extended TEQR Design  0 0.65 17.97 52.12 0.88 0 28.37 
3 
 True toxicity, true efficacy rate  .05, .10 .10, .30 .15, .60 .30, .62 .45, .65  -  
 Trade-off Value Eff-Tox Design -0.88 -0.57 -0.04 -0.24 -0.41  -  
 % selected by Eff-Tox Design 0 1 47 36 15  0 
 % selected by OBD Isotonic Design  7.6 4.8 37.8 37.1 12.8  0 
 % selected by Extended mTPI Design  0 3.6 49 31.5 1.2  14.6 
 % selected by Extended TEQR Design  0 6 41.5 21.9 1.5  29.2 
4 
 True toxicity, true efficacy rate .20, .60 .40, .62 .55, .65 .70, .70 .85, .75  -  
 Trade-off Value Eff-Tox Design -0.12 -0.40 -0.57 -0.70 -0.83  -  
 % selected by Eff-Tox Design 66 26 3 0 0  5 
  
1
4
8
 
 % selected by OBD Isotonic Design 46.1 41.4 11.3 1.2 0  0 
         
 % selected by Extended mTPI Design  69 7.5 0 0 0  23.5 
 % selected by Extended TEQR Design  57.6 12 0.1 0 0  30.3 
5 
 True toxicity, true efficacy rate .01, .1 .02, .35 .06, .5 .2, .3 .55, 0.2 .89, .05 -  
 Trade-off Value Eff-Tox Design -0.82 -0.33 -0.1 -0.73 -1.48 -2.32 -  
 % selected by Eff-Tox Design 1 1 23 11 5 2 57 
 % selected by OBD Isotonic Design 5.4 19.1 65.5 9.5 0.4 0 0 
 % selected by Extended mTPI Design  0 18.7 65.6 3.1 0 0 12.6 
 % selected by Extended TEQR Design  0 17.7 64.1 3.9 0 0 14.3 
* The dose level marked in green is the dose that is selected most frequently as the optimal dose by each design. 
The TEQR and mTPI designs here use the standard stopping rules of the mTPI design: maximum sample is 
reached or dose level 1 is too toxic. All the designs use a cohort size of 5 and maximum sample size of 50. 
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Figure 10 Schematic to Depict the Concept of Optimal Dose Selection for Various Dose-Response Curves for the Extended 
mTPI and TEQR Designs 
 
 
 
 
Monotonically Increasing or Plateauing Dose-Response Curve                        Umbrella-Shaped Dose-Response Curve 
 
 
 
 
 
 
 
Figure Legend: Schematic of Analysis Method for Different Dose-Response Curves 
  
If the true underlying response 
rates are thought to increase 
monotonically with an increase 
in dose or plateau after a 
certain dose, isotonic 
regression on the observed 
response rates can determine 
the optimal dose for efficacy 
and safety 
In our extended TEQR or mTPI design that 
also considers efficacy, isotonic regression 
is applied to the observed DLT rates at the 
end of the trial.  
If the true underlying response 
rates are thought to peak at a 
certain dose level, isotonic 
regression on the difference in 
observed response rates between 
adjacent dose levels, along with 
the sign of these differences, can 
reveal this peak; the optimal dose 
for efficacy and safety can then be 
determined. 
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Figure 11 Schematic to Depict Optimal Dose Selection in the Extended mTPI and TEQR Designs for Dose-Response Curves 
that Peak at Various Dose Levels 
 
 
Figure Legend: In this example, Dose level 4 is below the target toxicity rate of 0.33 (blue curve with dashes). For the green dose-
response curve with the peak response rate at dose level 3, dose level 3 is chosen as the optimal dose for toxicity and efficacy, 
assuming the peak response rate is above the efficacy threshold at dose level 3. For the brown dose-response curve with the peak 
response rate at dose level 4, dose level 4 is chosen as the optimal dose, assuming the peak response rate is above the efficacy 
threshold at dose level 4. For the purple dose-response curve with the peak response rate at dose level 5, dose level 4 is chosen as 
the optimal dose, only if the response rate at dose level 4 reaches the efficacy threshold – if not, no dose is chosen as the optimal 
dose.  
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Appendix Chapter 4 
1. Input parameters for the mTPI and TEQR Designs 
Appendix Table 1: Parameters for the mTPI and TEQR Designs: 
Parameter mTPI 
Design 
TEQR 
Design 
Number of simulations 2000 2000 
Target toxicity probability pT 0.2 0.2 
1 0.05 0.05 
2 0.05 0.05 
Starting dose Dose level 2 Dose level 2 
DLT probability deemed to be too toxic to allow 
further study at that dose level 
NA 0.34 
Desired sample size at MTD NA 50 
Maximum number of cohorts NA 30 
True DLT rate at each dose level Values from 
Tables 15  
Values from 
Table 15 
True Response rate at each dose level Values from 
Tables 15  
Values from 
Table 15  
We start from Dose Level 2 to allow for immediate de-escalation to dose level 1, if 
required.  
 
2. Results for Dose Selection for the Extended TEQR Design with a Non-Zero 
Correlation Coefficient between the True Toxicity and Efficacy Rates 
 
The monotonically increasing true DLT and response rates with an increase in dose 
shown in Table 15 are used in the simulations and isotonic regression is applied 
independently to the observed DLT and to the observed response rates at the end of 
each simulated trial. 
We use the usual stopping rules of the TEQR design, namely stop the trial when the 
desired MTD sample size is reached or when dose level 1 is too toxic, with a non-
zero correlation coefficient between true toxicity and efficacy rates. The results in 
Appendix Table 2 are based on a sample size at the MTD of 50, a cohort size of 5 and 
a correlation coefficient r=0.22. 
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Appendix Table 2: Results for Dose Selection for the Extended TEQR Design for 
a Non-Zero Correlation between Toxicity and Efficacy 
TEQR Design 
Dose Level % of Times Dose 
Level is Chosen for 
Toxicity 
% of Times Dose 
Level is Chosen for 
Efficacy 
% of Times Dose 
Level is Chosen as 
Optimal for 
Toxicity and 
Efficacy 
No dose is chosen 0% 5% 28%* 
1 0.8% 0% 0% 
2 3.2% 28.4% 0.6% 
3 31.8% 29.7% 17.1% 
4 63.7% 29.0% 53.8% 
5 0.5% 7.9% 0.5% 
* These results for the % of times each dose level is selected as optimal for toxicity 
and efficacy are based on simulations and are not analytic calculations based on the 
% of times each dose level is chosen for toxicity and efficacy, since the correlation 
coefficient r is not 0. 
 
We choose dose level 4 as the optimal dose for safety and efficacy most frequently in 
this case. The results for optimal dose selection are similar to those obtained for the 
“no correlation between the efficacy and toxicity rates” case i.e. r=0 case, with the 
other input parameters and stopping rules remaining the same. 
 
3. Incorporating Safety and Efficacy: True DLT and Response Rates that 
Increase Monotonically with an Increase in Dose 
We use the usual stopping rules of the TEQR design, namely stop the trial when the 
desired MTD sample size is reached or when dose level 1 is too toxic. The results in 
Appendix Table 3 a and b are based on a sample size at the MTD of 50, a cohort size 
of 5 and a correlation coefficient r=0. 
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The monotonically increasing true DLT rates shown in Table 15 are used to produce 
the simulations in Appendix Tables 3 a and 3 b. The response rates with an increase 
in dose shown in Table 15 are used in the simulations in Appendix Table 3 a. Isotonic 
regression is applied to the observed DLT rates and isotonic regression is applied to 
the difference in observed response rates between adjacent dose levels at the end of 
each simulated trial (Appendix Tables 3 a and 3 b). 
 
We calculate the difference in the observed response rates between adjacent dose 
levels at the end of each simulated trial i.e. between dose level 1 and 2, 2 and 3, 3 and 
4 etc. We then investigate where the differences in response rates between adjacent 
dose levels switch from a negative sign to a positive sign after applying isotonic 
regression to these differences, to determine whether there is a peak at a certain dose 
level in the observed response rates. If in a simulation the difference in response rates 
between dose levels 2 and 3 is negative and that between dose levels 3 and 4 is 
positive, then dose level 3, is considered the peak. If the difference in response rates 
between dose levels 1 and 2 is negative, that between dose levels 2 and 3 is zero and 
that between dose levels 3 and 4 is positive, then dose level 3, is the peak. If all the 
differences between adjacent dose levels are negative in a simulation, then no dose 
level chosen as the peak for that simulation. If all the differences between adjacent 
dose levels are positive in a simulation, then dose level 1 is the peak. 
 
In this example, dose level 3 is what is picked most frequently as the peak but it is 
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selected only 23% of the time. Also, note that no dose level is chosen as the peak dose 
level for efficacy 44% of the time. Thus, there is no peak in the observed response 
rates at dose level 3. Based on the true response rates in Table 15, the difference in 
true response rates between adjacent dose levels is always negative and there is no 
peak at dose level 3. Hence, the results in Appendix Table 3 a reflect this underlying 
scenario. 
 
Appendix Table 3 a: Results for Accuracy of Dose Selection for the Extended 
TEQR Design for Monotonically Increasing True DLT and Response Rates Using 
the Difference in Observed Response Rates 
TEQR Design 
Dose Level % of Times Dose 
Level is Chosen 
for Toxicity 
% of Times Dose 
Level is a Peak for 
Efficacy 
No dose level 
is chosen 
0% 44.2% 
1 0.8% 0.1% 
2 3.2% 12% 
3 31.8% 22.9% 
4 63.7% 12.8% 
5 0.5% 7.9% 
6 0% 0.1% 
 
As another example, if the true response rate at dose level 1, 2, 3, 4, 5 and 6 are 0.1, 
0.2, 0.3, 0.4. 0.5 and 0.6 respectively i.e. the difference in true response rates between 
adjacent dose levels is always  -0.1, and isotonic regression is applied to the observed 
differences at the end of each of the 1000 simulations, the results in Appendix Table 
3 b are obtained. It is seen, in this scenario, that dose level 3 is picked as the peak most 
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frequently, but only 16% of the time, and that no dose level is selected as the peak 
53% of the time, reflecting the underlying scenario in true response rates where there 
is no peak.  
 
Appendix Table 3 b: Results for Accuracy of Dose Selection for the Extended 
TEQR Design for Monotonically Increasing True DLT and Response Rates Using 
the Difference in Observed Response Rates 
TEQR  Design 
Dose Level % of Times Dose 
Level is Chosen 
for Toxicity 
% of Times Dose 
Level is a Peak for 
Efficacy 
No dose level is 
chosen 
0% 53.0% 
1 0.8% 0.1% 
2 3.2% 8.2% 
3 31.8% 15.5% 
4 63.7% 15.2% 
5 0.5% 7.9% 
6 0% 0.1% 
 
Hence, in general, when the true response rates are monotonically increasing with an 
increase in dose, applying isotonic regression on the difference in response rates 
between adjacent dose levels will show that no dose level is selected as the peak dose 
most frequently; thus, in this case, applying isotonic regression on the observed 
response rates themselves can help determine the dose to be chosen for efficacy. 
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4. Incorporating Safety and Efficacy: Plateauing True Response Rates with an 
Increase in Dose 
We use the usual stopping rules of the TEQR design, namely stop the trial when the 
desired MTD sample size is reached or when dose level 1 is too toxic. The results in 
Appendix Table 4 a and b are based on a sample size at the MTD of 50, a cohort size 
of 5 and a correlation coefficient r=0. 
 
The monotonically increasing true DLT rates shown in Table 15 are used to produce 
the simulations in Appendix Tables 4 a and 4 b.  The plateauing true response rates 
with an increase in dose shown in Table 15 are used in the simulations in Appendix 
Table 4 a. Isotonic regression is applied to the observed DLT rates and isotonic 
regression is applied to the difference in observed response rates between adjacent 
dose levels at the end of each simulated trial (Appendix Tables 4 a and 4 b).  
 
We calculate the difference in the observed response rates between adjacent dose 
levels at the end of each simulated trial and apply isotonic to these differences. We 
then investigate where these differences switch signs after isotonic regression, to 
help determine whether there is a peak at a certain dose level in the observed 
response rates. In this example, there is no peak 36% of the time, dose level 3 is 
chosen as the peak most frequently, and dose level 4 is chosen as the peak only 18% 
of the time. Thus, there is no clear peak or plateau in response rates at dose level 4.  
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Based on the true underlying response rates in Table 15, there is a plateau from dose 
level 4. However, the results in Appendix Table 4 a do not clearly show that there is a 
peak or plateau in response rates at dose level 4. 
Appendix Table 4 a: Results for Accuracy of Dose Selection for the Extended 
TEQR Design for Monotonically Increasing True DLT Rates and Plateauing 
Response Rates Using the Difference in Observed Response Rates 
TEQR Design 
Dose Level % of Times Dose 
Level is Chosen for 
Toxicity 
% of Times Dose 
Level is a Peak 
for Efficacy 
No dose level 
is chosen 
0% 36.2% 
1 0.8% 0.1% 
2 3.2% 13.5% 
3 31.8% 24.7% 
4 63.7% 18.3% 
5 0.5% 7.0% 
6 0% 0.2% 
 
As another example, if the true response rate at dose level 1, 2, 3, 4, 5 and 6 are 0.1, 
0.35, 0.5, 0,5, 0.5 and 0.5 respectively, and isotonic regression is applied to the 
observed differences at the end of each of the 1000 simulations, the results in 
Appendix Table 4 b show that dose level 3, the dose level that is selected as the peak 
most frequently, is selected only 34% of the time. However, no dose level is selected 
as the peak almost as frequently, at 32% of the time. Thus, the results in Appendix 
Table 4 b do not clearly show that there is a peak or plateau in response rates at dose 
level 3, as present in the true underlying response rates. 
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Appendix Table 4 b: Results for Accuracy of Dose Selection for the Extended 
TEQR Design for Monotonically Increasing True DLT Rates and Plateauing 
Response Rates Using the Difference in Observed Response Rates 
TEQR Design 
Dose Level % of Times Dose 
Level is Chosen 
for Toxicity 
% of Times Dose 
Level is a Peak for 
Efficacy 
No dose level 
is chosen 
0% 31.8% 
1 0.8% 0% 
2 3.2% 11.7% 
3 31.8% 34.2% 
4 63.7% 13.6% 
5 0.5% 8.7% 
 
Hence, applying isotonic regression on the observed response rates themselves in the 
case the response rates plateau with an increase in dose will show that no dose level 
is selected as the peak dose frequently; thus, in this case, when there is no clear peak, 
applying isotonic regression on the observed response rates themselves can help 
determine the dose to be chosen for efficacy. 
 
5. Incorporating Safety and Efficacy: Response Rates that Follow an Umbrella-
Shaped Dose-Response Curve 
We use the usual stopping rules of the TEQR design, namely stop the trial when the 
desired MTD sample size is reached or when dose level 1 is too toxic. The results in 
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Appendix Table 5 a, b and c are based on a sample size at the MTD of 50, a cohort 
size of 5 and a correlation coefficient r=0. 
 
The monotonically increasing true DLT rates with an increase in dose shown in Table 
15 are used to produce the simulations in Appendix Tables 5 a, 5 b and 5 c. The 
umbrella-shaped true response rates shown in Table 15, where the response rate 
peaks at dose level 4, are used in the simulations in Appendix Table 5 a. Isotonic 
regression is applied to the observed DLT rates and isotonic regression is applied to 
the difference in observed response rates between adjacent dose levels at the end of 
each simulated trial (Appendix Tables 5 a, 5 b and 5 c). 
 
We calculate the difference in the observed response rates between adjacent dose 
levels at the end of each simulated trial and apply isotonic to these differences. We 
then investigate where these differences switch signs after isotonic regression, to 
help determine whether there is a peak at a certain dose level in the observed 
response rates. In this example, dose level 3 is chosen slightly more frequently than 
dose level 4 as the peak. Based on the true underlying response rates in Table 15, 
there is a peak at dose level 4. Thus, the results in in Appendix Table 5 a do not reflect 
this peak at dose level 4 as clearly. It is seen from the examples below that when the 
peak in response rates is at a lower dose level, such as at dose level 3, it is revealed 
clearly by this method. In other words, not as many patients are dosed at the higher 
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dose levels compared to at the lower doses, and it is difficult to reveal the peak in 
response rates when it is at these higher dose levels. 
Appendix Table 5 a: Results for Accuracy of Dose Selection for the Extended 
TEQR Design for Monotonically Increasing True DLT Rates and Umbrella-
Shaped Response Rates Using the Difference in Observed Response Rates 
TEQR Design 
Dose Level % of Times Dose 
Level is Chosen for 
Toxicity 
% of Times Dose 
Level is a Peak for 
Efficacy 
No dose level is 
chosen 
0% 22.7% 
1 0.8% 0.1% 
2 3.2% 15.5% 
3 31.8% 32.0% 
4 63.7% 27.6% 
5 0.5% 2.1% 
 
 
If the true response rate at dose level 1, 2, 3, 4, 5 and 6 are 0.1, 0.35, 0.5, 0,3, 0.2 and 
0.05 respectively, and isotonic regression is applied to the observed differences at the 
end of each of the 1000 simulations, the results in Appendix Table 5 b show that dose 
level 3 is chosen as the peak most frequently, consistent with the peak at dose level 3 
in the true underlying response rates. Dose level 3 is selected as the optimal dose 63% 
of the time (Figure 11 explains how the optimal dose is selected at the end of each 
simulation for a dose-response curve with a peak). 
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Appendix Table 5 b: Results for Accuracy of Dose Selection for the Extended 
TEQR Design for Monotonically Increasing True DLT Rates and Umbrella-
Shaped Response Rates Using the Difference in Observed Response Rates 
TEQR Design 
Dose Level % of Times Dose 
Level is Chosen 
for Toxicity 
% of Times Dose 
Level is a Peak for 
Efficacy 
% of Times Dose Level 
is Selected as Optimal 
for Safety and Efficacy 
No dose level 
is chosen 
0% 9% 15.8% 
1 0.8% 0% 0% 
2 3.2% 20% 19.4% 
3 31.8% 62.7% 62.7% 
4 63.7% 5.1% 2% 
5 0.5% 3.2% 0.1% 
 
As a final example, if the true response rate at dose level 1, 2, 3, 4, 5 and 6 are 0.05, 
0.1, 0.45, 0,3, 0.2, 0.05 respectively, and isotonic regression is applied to the observed 
differences at the end of each of the 1000 simulations, the results in Appendix Table 
5 c show that dose level 3 is chosen as the peak most frequently, consistent with the 
peak at dose level 3 in the true underlying response rates. Dose level 3 is selected as 
the optimal dose 63% of the time. 
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Appendix Table 5 c: Results for Accuracy of Dose Selection for the Extended 
TEQR Design for Monotonically Increasing True DLT Rates and Umbrella-
Shaped Response Rates Using the Difference in Observed Response Rates 
TEQR Design 
Dose Level % of Times Dose 
Level is Chosen 
for Toxicity 
% of Times Dose 
Level is a Peak for 
Efficacy 
% of Times Dose Level 
is Selected as Optimal 
for Safety and Efficacy 
No dose level 
is chosen 
0% 15.0% 32% 
1 0.8% 0.3% 0% 
2 3.2% 1.7% 1.4% 
3 31.8% 68.7% 63.4% 
4 63.7% 9.4% 3.1% 
5 0.5% 4.9% 0.1% 
 
 Thus, if the true underlying response rates have a clear peak at a certain dose level 
(umbrella-shaped dose-response curve), isotonic regression on the difference in 
observed response rates between adjacent dose levels, along with the sign of these 
differences, can be used to reveal this peak, and determine an optimal dose for 
toxicity and efficacy (Figure 11). The technique works well when the peak in response 
rates is at a lower dose level rather than a higher dose level where few patients may 
be dosed. 
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6. Input Parameters Used in Simulations for the Eff-Tox and OBD Isotonic 
Designs 
Input parameters Used in the Eff-Tox Package for the Eff-Tox Design 
Probability of Toxicity and Efficacy Limits for Dose Acceptability Rules  
Parameter Value 
Prob(tox) upper limit (πT*) 0.33000 
Lower prob cutoff for prob of toxicity (pT,L) 0.10000 
Prob(eff) lower limit (πE*) 0.40000 
Lower prob cutoff for prob of efficacy (pE,L) 0.10000 
 
Trade-off Function Elicited Points (3 points to define the trade-off function contour) 
 πE πT 
(π1,E*, 0) 0.50000 0.00000 
(1, π2,T*) 1.00000 0.65000 
(π3,E, π3,T) 0.70000 0.25000 
 
Elicited Means (Prior Toxicity, Prior Efficacy) 
Dose Toxicity Efficacy 
1 0.0200 0.2000 
2 0.0400 0.4000 
3 0.0600 0.6000 
4 0.0800 0.8000 
5 0.1000 0.9000 
 
Input parameters Used in the OBD Isotonic Design 
Cohort size = 5 
Number of cohorts = 10 
  
164 
phi = upper bound of toxicity rate = 0.33 
ct = threshold for posterior probability of toxicity (any dose with toxicity probability 
larger than ct is excluded from the admissible set of doses) = 0.9 
Number of simulations = 10000 
The true DLT and response rates at each dose level are as given in Table 24. 
The R code given at the following URL was used along with the input parameters 
given above: 
 http://odin.mdacc.tmc.edu/~yyuan/Software/TargetAgent/targetAgentDF.r 
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DISCUSSION AND CONCLUSIONS 
 In this thesis, we first systematically compared the statistical operating 
characteristics of 11 existing Phase 1 rule-based and model-based oncology dose-
finding designs that target or pre-specify a DLT rate of ~0.2, for three sets of true 
underlying DLT rates. These DLT rates were generated from a specific logistic, log-
logistic and linear dose-toxicity curve at the same dosages. We found that all the 
designs examined select the MTD much more accurately when there is a clear 
separation between the true DLT rate at the MTD and the rates at the dose level 
immediately above and below it, such as for the DLT rates generated using the chosen 
logistic dose-toxicity curve. Not surprisingly, we found that the 3+3 dose-finding 
design under-doses a large percentage of patients and is not very accurate in selecting 
the MTD in all the cases considered. Among the rule-based designs studied, the 5+5 a 
design picked the MTD as accurately as the model based designs for the true DLT rates 
generated using the chosen log-logistic and linear dose-toxicity curves, but required 
enrolling a higher number of patients than the other designs. The model based 
designs, mTPI, TEQR, BOIN, CRM and EWOC designs, performed well on the whole – 
they assigned the maximum percentage of patients to the MTD, and also had a 
reasonably high probability of picking the right dose level as the MTD across the three 
dose toxicity curves examined. We also found that it is critical to pick a design that is 
aligned with the true DLT rate of interest. Thus, the simulation results contained in 
this thesis provide considerable information on design property trade-offs, and the 
means to explore additional settings. However, this is not an exhaustive comparison 
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of all the current Phase 1 oncology designs. We have covered multiple commonly used 
ones but future comparisons or studies could include other dose-finding designs such 
as the Time-to-Event CRM (TITE-CRM) design, the Rolling 6 design, the Bayesian 
Logistic Regression Method (BLRM) and the recently revised mTPI design, called the 
mTPI-2 design, proposed by Ji et al..  
 
 However, the sample size of these Phase I oncology trials is very limited and it 
is difficult to accurately predict the MTD with such a small number of patients. Hence, 
we next studied the effect of sample size and cohort size on the accuracy of dose 
selection in early phase oncology designs, finding that an adequate sample size is 
crucial. We then proposed a new design with a larger sample size that encompasses 
the objectives of both safety and efficacy and that is simpler to implement than the 
existing Phase 1/2 seamless designs. In particular, we proposed the 20+20 
accelerated titration design, a simple rule-based integrated Phase 1/2 trial design 
that selects an optimal dose for toxicity and efficacy via Bayesian decision rules at the 
end. Our simulations of the 20+20 accelerated titration design yielded a mean sample 
size of ~42 patients for the chosen true underlying DLT and response rates and 
stopping rules and showed that with this sample size, the design can robustly pick a 
dose that is optimal for both efficacy and safety. We showed via simulated examples 
that it performed as well as or better than the Eff-Tox design and the Optimal 
Biological Dose Isotonic design for the scenarios considered. It also performed better 
than a 3+3 Phase 1 design followed by a Phase 2 design. Further, this technique used 
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in the 20+20 accelerated titration design of selecting an optimal dose for safety and 
efficacy via Bayesian decision rules at the end of the trial could also be applied more 
generally to other Phase 1 designs in future work. 
 
We also extended the TEQR and mTPI dose-finding oncology designs to choose an 
optimal dose for both safety and efficacy by considering correlated Bernoulli 
distributions for the true underlying toxicity and efficacy rates. In our simulations, we 
assumed that the true DLT rates increase monotonically with an increase in dose but 
did not assume that the true response rates increase monotonically with an increase 
in dose; we allow multiple types of curves for dose response (monotonically 
increasing, plateau, or umbrella-shaped). In this context, we applied isotonic 
regression to determine a dose that is optimal for both safety and efficacy. We showed 
that the extended TEQR and mTPI designs performed as well as or better than the Eff-
Tox design and the Optimal Biological Dose Isotonic design in terms of accuracy of 
optimal dose selection for the scenarios considered. 
 
Several further extensions to this thesis work could be considered. Future work could 
consider: 
1) extending these designs to systematically and rigorously implement rules in their 
dose finding algorithms for late occurring DLTs, i.e. DLTs occurring outside the 
protocol defined observation period of (say) the first 2 cycles of the study drug. It 
would be useful to extend some of these designs such as the TEQR design to 
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account for DLTs occurring outside this window, similar to the TITE-CRM design 
where the timing of  late-onset DLTs is incorporated [116, 117]. In general, it would 
be useful to extend the TEQR and other designs to account for the time that the 
patient is on study before having a DLT for patients who experience a DLT, and 
also to account for patients who do not experience a DLT (see reference [118]). 
2) extending these designs to incorporate PK and/or biomarker data in their dose 
finding algorithms.  
3) extending these dose finding oncology designs to include, in addition to a binary 
endpoint for safety i.e. DLT vs no DLT, a continuous endpoint for efficacy; for 
example, we can include a continuous immune response, as opposed to a binary 
response such as Complete Response/Partial Response (CR/PR) vs no CR/PR, as 
we have done in the 20+20 acceleration titration design and in extending the mTPI 
and TEQR designs.  We would then have to consider how an optimal dose for safety 
and efficacy can be selected taking into account the correlation between a binary 
endpoint for safety and a continuous one for efficacy [119].  
4) extending these early phase designs to combination studies of two drugs for both 
efficacy and toxicity i.e. to determine an optimal dose(s) for efficacy and toxicity 
for a combination of two drugs. This is a challenging but useful problem to tackle 
due to the increasing number of drug combination studies being performed in 
oncology.  
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APPENDIX CHAPTER FOR PROGRAM CODES USED IN THE THESIS 
Codes for Chapter 2  
SAS code for all designs where only escalation is allowed (3+3, 2+4, 4+4 a, 4+4 b, 
5+5 a, 5+5 b, 3+3+3, 3+1+1): 
 
%macro alldesigns(design1, equation1); 
data simi1; 
call streaminit(1); 
 
array a{1000,10}; 
array sumi{1000}; 
array dosel[10000]; 
array dosemtd{10000}; 
array doseover{10000}; 
array doseunder{10000}; 
array dltmtd{10000}; 
array dltover{10000}; 
array dltunder{10000}; 
array dltoverall{10000}; 
array mtddltrate{10000}; 
array mtdpop{10000}; 
array totalpop{10000}; 
array totaldlt{10000}; 
array peopledosel{10}; 
array dltdosel{10}; 
sumd=0; 
sump=0; 
 
 
 
/** program works for 3+3, 2+4, 4+4 a, 4+4 b, 5+5 a, 5+5 b, 3+3+3, or 
3+1+1 designs and 3 dose-toxicity curves **/ 
 
length design $10; 
design="&design1"; 
 
length equation $20; 
equation="&equation1"; 
 
if design='3+3' then do; 
no1=3; 
no2=4; 
no3=6; 
o1= 1; 
o2= 3; 
o3= 1; 
o4= 6; 
o5= 1; 
o6= 6; 
  
170 
end; 
if design='2+4' then do; 
no1=2; 
no2=3; 
no3=6; 
o1= 1; 
o2= 2; 
o3= 1; 
o4= 6; 
o5= 1; 
o6= 6; 
end; 
if design='4+4a' then do; 
no1=4; 
no2=5; 
no3=8; 
o1= 2; 
o2= 4; 
o3= 2; 
o4= 8; 
o5= 2; 
o6= 8; 
end; 
if design='4+4b' then do; 
no1=4; 
no2=5; 
no3=8; 
o1= 2; 
o2= 4; 
o3= 3; 
o4= 8; 
o5= 3; 
o6= 8; 
end; 
 
if design='3+1+1' then do; 
no1=3; 
o1= 2; 
o2= 3; 
o3= 2; 
o4= 4; 
o5= 2; 
o6= 5; 
end; 
if design='3+3+3' then do; 
no1=3; 
no2=4; 
no3=6; 
o1= 1; 
o2= 3; 
o3= 2; 
o4= 6; 
o5= 2; 
o6= 9; 
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if design='5+5a' then do; 
no1=5; 
no2=6; 
no3=10; 
o1= 2; 
o2= 5; 
o3= 2; 
o4= 10; 
o5= 2; 
o6= 10; 
end; 
if design='5+5b' then do; 
no1=5; 
no2=6; 
no3=10; 
o1= 2; 
o2= 5; 
o3= 3; 
o4= 10; 
o5= 3; 
o6= 10; 
end; 
 
/* program can consider one of 3 dose-toxicity curves; change these 
parameters if you want to change the dose-toxicity curve */ 
 
startdose = 100; 
mtddose=334; 
dltrstartdose=0.01; 
dltrmtd=0.2; 
doselevelmtd=3; 
 
if equation='linear' then do; 
 
coeff2=1/(mtddose-startdose)*(dltrmtd-dltrstartdose); 
coeff1= dltrstartdose - startdose*coeff2; 
 
end; 
 
if equation='logistic' then do; 
 
coeff2=1/(mtddose-startdose)*( log(dltrmtd/(1-dltrmtd))-
log(dltrstartdose/(1-dltrstartdose)) ); 
coeff1= log(dltrstartdose/(1-dltrstartdose)) - startdose*coeff2; 
 
end; 
 
if equation='loglogistic' then do; 
 
coeff2=1/(log(mtddose)-log(startdose))*( log(dltrmtd/(1-dltrmtd))-
log(dltrstartdose/(1-dltrstartdose)) ); 
coeff1= log(dltrstartdose/(1-dltrstartdose)) - log(startdose)*coeff2; 
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end; 
 
 
 
do k=1 to 10000; 
 
 
do i1=1 to 1000; 
do j1=1 to 10; 
a[i1,j1]=.; 
sumi[i1]=.; 
end; 
end; 
 
i=0; 
sumi[1]=0; 
peoplec=0; 
atmtd=0; 
belowmtd=0; 
abovemtd=0; 
dltc=0; 
dltatmtd=0; 
dltbelowmtd=0; 
dltabovemtd=0; 
 
dose=100; 
 
/** escalate until the number of DLTs exceeds what is allowed by the 
design **/ 
do until ((sumi[i]>o1 and sumins=o2) or (sumi[i]>o3 and sumins=o4) or 
(sumi[i]>o5 and sumins=o6));  
    i = i+1; 
 sumi[i]=0; 
 sumins=0; 
 
 
if i=1 then frac=1; 
if i=2 then frac=2; 
if i=3 then frac=1.67; 
if i=4 then frac=1.5; 
if i=5 then frac=1.4; 
if i=6 then frac=1.33; 
if i>=7 then frac=1.33; 
dose=dose*frac; 
 
if equation='linear' then dr=min(coeff1+coeff2*dose,1); 
 
if equation='logistic' then dr=exp(coeff1+coeff2*dose)/(1+ 
exp(coeff1+coeff2*dose)); 
 
if equation='loglogistic' then dr=exp(coeff1+coeff2*log(dose))/(1+ 
exp(coeff1+coeff2*log(dose))); 
 
 do j=1 to no1; 
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  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
 end; 
 
if (design='3+3' or design='2+4' or design='3+3+3') then do;  
if sumi[i]=1 then do; 
do j=no2 to no3; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
end; 
end; 
 
if (design='4+4a' or design='5+5a') then do;  
if (sumi[i]=1 or sumi[i]=2) then do; 
do j=no2 to no3; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
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  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
end; 
end; 
 
if (design='4+4b' or design='5+5b') then do;  
if sumi[i]=2 then do; 
do j=no2 to no3; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
end; 
end; 
 
if design='3+3+3' then do; 
if (sumi[i]=2 and sumins=6) then do; 
do j=7 to 9; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
      if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
end; 
end; 
 
if design='3+1+1' then do; 
if ((sumi[i]=1) or (sumi[i]=2)) then do; 
  a[i,4]=rand('Bernoulli', dr); 
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  sumi[i]=sumi[i]+a[i,4]; 
  sumd=sumd+a[i,4]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
 
if ((sumi[i]=2) and (sumins=4)) then do; 
  a[i,5]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,5]; 
  sumd=sumd+a[i,5]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
end; 
 
 
end; 
dosel[k]=i; 
dosemtd[k]=atmtd/peoplec*100; 
doseover[k]=abovemtd/peoplec*100; 
doseunder[k]=belowmtd/peoplec*100; 
dltmtd[k]=dltatmtd/dltc*100; 
dltover[k]=dltabovemtd/dltc*100; 
dltunder[k]=dltbelowmtd/dltc*100; 
 
dltoverall[k]=dltc/peoplec; 
if atmtd ne 0 then mtddltrate[k]=dltatmtd/atmtd; 
else mtddltrate[k]=0; 
mtdpop[k]=atmtd; 
totalpop[k]=peoplec; 
totaldlt[k]=dltc; 
 
end; 
avgd=sumd/10000; 
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avgp=sump/10000; 
ave= mean(of dosel1-dosel10000);  
dev=STD(of dosel1-dosel10000);  
serror=STDERR(of dosel1-dosel10000); 
max= max(of dosel1-dosel10000);  
median= median(of dosel1-dosel10000);  
pctl_25=pctl(25, of dosel1-dosel10000); 
pctl_50=pctl(50, of dosel1-dosel10000); 
pctl_75=pctl(75, of dosel1-dosel10000); 
avgdosemtd=mean(of dosemtd1-dosemtd10000); 
avgdoseover=mean(of doseover1-doseover10000); 
avgdoseunder=mean(of doseunder1-doseunder10000); 
avgdltmtd=mean(of dltmtd1-dltmtd10000); 
avgdltover=mean(of dltover1-dltover10000); 
avgdltunder=mean(of dltunder1-dltunder10000); 
avgdltrate=mean(of dltoverall1-dltoverall10000); 
avgmtddltrate=mean(of mtddltrate1-mtddltrate10000); 
avgmtdpop=median(of mtdpop1-mtdpop10000); 
avgtotalpop=median(of totalpop1-totalpop10000); 
avgtotalpop1=mean(of totalpop1-totalpop10000); 
avgtotaldlt=median(of totaldlt1-totaldlt10000); 
run; 
 
/* print design, highest dose level reached/dose level at which the 
trial stops, dose at highest dose level, dlt rate at the highest dose 
level, factor to multiply present dose to get the next dose level, avg 
(+STD), max and median number of dose levels explored, median and avg 
number of patients on trial, median number of DLTs, avg DLT rate of the 
trial, avg DLT rate at the MTD, median MTD pop, avg percentage of 
patients dosed at MTD, under-dosed and over-dosed, avg number of 
patients and DLTs at each dose level */ 
  
proc print; 
var design i dose dr frac ave dev max median avgtotalpop avgtotalpop1 
avgtotaldlt avgdltrate avgmtddltrate avgmtdpop avgdosemtd avgdoseunder 
avgdoseover peopledosel1-peopledosel10 dltdosel1-dltdosel10; 
run; 
 
data simi2; 
set simi1; 
array v_[*] dosel1-dosel10000; 
array counts[10]; 
call missing (of counts[*]); 
do i = 1 to dim(v_); 
     counts[v_[i]] + 1; 
end; 
if counts1=. then counts1=0; 
if counts2=. then counts2=0; 
if counts3=. then counts3=0; 
if counts4=. then counts4=0; 
if counts5=. then counts5=0; 
if counts6=. then counts6=0; 
if counts7=. then counts7=0; 
if counts8=. then counts8=0; 
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if counts9=. then counts9=0; 
if counts10=. then counts10=0; 
 
run; 
 
/* times out of 10000 that the trial stops at each dose level, from 
which the percentage of times each dose level is choosen as the MTD can 
be determined - the MTD is one dose level below the dose level at which 
the trial stops */ 
proc print;  
var counts1-counts10; 
run; 
 
%mend alldesigns; 
 
%alldesigns(3+3, logistic); 
 
 
SAS code for accelerated titration design: 
 
data simi1; 
call streaminit(1); 
 
array a{1000,6}; 
array sumi{1000}; 
array flag{1000}; 
array dosel[10000]; 
array dosemtd{10000}; 
array doseover{10000}; 
array doseunder{10000}; 
array dltmtd{10000}; 
array dltover{10000}; 
array dltunder{10000}; 
array dltoverall{10000}; 
array mtddltrate{10000}; 
array mtdpop{10000}; 
array totalpop{10000}; 
array totaldlt{10000}; 
array peopledosel{10}; 
array dltdosel{10}; 
 
sumd=0; 
sump=0; 
 
/* program can handle one of 3 dose-toxicity equations */ 
length equation $20; 
equation='logistic'; 
 
startdose = 100; 
mtddose=334; 
dltrstartdose=0.01; 
dltrmtd=0.2; 
doselevelmtd=3; 
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if equation='linear' then do; 
 
coeff2=1/(mtddose-startdose)*(dltrmtd-dltrstartdose); 
coeff1= dltrstartdose - startdose*coeff2; 
 
end; 
 
if equation='logistic' then do; 
 
coeff2=1/(mtddose-startdose)*( log(dltrmtd/(1-dltrmtd))-
log(dltrstartdose/(1-dltrstartdose)) ); 
coeff1= log(dltrstartdose/(1-dltrstartdose)) - startdose*coeff2; 
 
end; 
 
if equation='loglogistic' then do; 
 
coeff2=1/(log(mtddose)-log(startdose))*( log(dltrmtd/(1-dltrmtd))-
log(dltrstartdose/(1-dltrstartdose)) ); 
coeff1= log(dltrstartdose/(1-dltrstartdose)) - log(startdose)*coeff2; 
 
end; 
 
 
do k=1 to 10000; 
 
do i1=1 to 1000; 
do j1=1 to 6; 
a[i1,j1]=.; 
sumi[i1]=.; 
flag[i1]=.; 
end; 
end; 
 
i=0; 
sumi[1]=0; 
 
peoplec=0; 
atmtd=0; 
belowmtd=0; 
abovemtd=0; 
dltc=0; 
dltatmtd=0; 
dltbelowmtd=0; 
dltabovemtd=0; 
 
dose=100; 
 
do until (a[i,1]=1); 
    i = i+1; 
 sumi[i]=0; 
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    if i=1 then frac=1; 
    if i=2 then frac=2; 
    if i=3 then frac=1.67; 
    if i=4 then frac=1.5; 
    if i=5 then frac=1.4; 
    if i=6 then frac=1.33; 
    if i>=7 then frac=1.33; 
 
    dose=dose*frac; 
  
    if equation='linear' then dr=min(coeff1+coeff2*dose,1); 
 
    if equation='logistic' then dr=exp(coeff1+coeff2*dose)/(1+ 
exp(coeff1+coeff2*dose)); 
 
    if equation='loglogistic' then dr=exp(coeff1+coeff2*log(dose))/(1+ 
exp(coeff1+coeff2*log(dose))); 
 
 a[i,1]=rand('Bernoulli', dr); 
 sumi[i]=sumi[i]+a[i,1]; 
 sumd=sumd+a[i,1]; 
 sump=sump+1; 
 peopledosel[i]=sum(peopledosel[i],0.0001); 
 dltdosel[i]=sum(dltdosel[i],a[i,1]/10000); 
      peoplec=peoplec+1; 
 if i=doselevelmtd then atmtd=atmtd+1; 
  if i>doselevelmtd then abovemtd=abovemtd+1; 
 if i<doselevelmtd then belowmtd=belowmtd+1; 
 dltc=dltc+a[i,1]; 
 if i=doselevelmtd then dltatmtd=dltatmtd+a[i,1]; 
  if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,1]; 
 if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,1]; 
end; 
 
/** switch to 3+3 design once a DLT is observed in a patient **/ 
do j=2 to 3; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=atmtd+1; 
   if i>doselevelmtd then abovemtd=abovemtd+1; 
  if i<doselevelmtd then belowmtd=belowmtd+1; 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
 
 
if sumi[i]=1 then do; 
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do j=4 to 6; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=atmtd+1; 
   if i>doselevelmtd then abovemtd=abovemtd+1; 
  if i<doselevelmtd then belowmtd=belowmtd+1; 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
end; 
if sumi[i]=1 then flag[i]=1; 
else flag[i]=0; 
jj1=i; 
 
if flag[jj1]=1 then do; 
do until (sumi[i]>1); 
    i = i+1; 
 sumi[i]=0; 
 
 if i=1 then frac=1; 
    if i=2 then frac=2; 
    if i=3 then frac=1.67; 
    if i=4 then frac=1.5; 
    if i=5 then frac=1.4; 
    if i=6 then frac=1.33; 
    if i>=7 then frac=1.33; 
 
    dose=dose*frac; 
     
 if equation='linear' then dr=min(coeff1+coeff2*dose,1); 
 
    if equation='logistic' then dr=exp(coeff1+coeff2*dose)/(1+ 
exp(coeff1+coeff2*dose)); 
 
    if equation='loglogistic' then dr=exp(coeff1+coeff2*log(dose))/(1+ 
exp(coeff1+coeff2*log(dose))); 
 
 
  
 do j=1 to 3; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
     dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  peoplec=peoplec+1; 
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  if i=doselevelmtd then atmtd=atmtd+1; 
   if i>doselevelmtd then abovemtd=abovemtd+1; 
  if i<doselevelmtd then belowmtd=belowmtd+1; 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
 end; 
  
 if sumi[i]=1 then do; 
 do j=4 to 6; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
     dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=atmtd+1; 
   if i>doselevelmtd then abovemtd=abovemtd+1; 
  if i<doselevelmtd then belowmtd=belowmtd+1; 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
 end; 
 end; 
 
end; 
end; 
 
dosel[k]=i; 
dosemtd[k]=atmtd/peoplec*100; 
doseover[k]=abovemtd/peoplec*100; 
doseunder[k]=belowmtd/peoplec*100; 
dltmtd[k]=dltatmtd/dltc*100; 
dltover[k]=dltabovemtd/dltc*100; 
dltunder[k]=dltbelowmtd/dltc*100; 
dltoverall[k]=dltc/peoplec; 
 
if atmtd ne 0 then mtddltrate[k]=dltatmtd/atmtd; 
else mtddltrate[k]=0; 
mtdpop[k]=atmtd; 
totalpop[k]=peoplec; 
totaldlt[k]=dltc; 
 
end; 
 
avgd=sumd/10000; 
avgp=sump/10000; 
ave= mean(of dosel1-dosel10000);  
dev=STD(of dosel1-dosel10000);  
serror=STDERR(of dosel1-dosel10000); 
max= max(of dosel1-dosel10000);  
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median= median(of dosel1-dosel10000);  
pctl_25=pctl(25, of dosel1-dosel10000); 
pctl_50=pctl(50, of dosel1-dosel10000); 
pctl_75=pctl(75, of dosel1-dosel10000); 
avgdosemtd=mean(of dosemtd1-dosemtd10000); 
avgdoseover=mean(of doseover1-doseover10000); 
avgdoseunder=mean(of doseunder1-doseunder10000); 
avgdltmtd=mean(of dltmtd1-dltmtd10000); 
avgdltover=mean(of dltover1-dltover10000); 
avgdltunder=mean(of dltunder1-dltunder10000); 
avgdltrate=mean(of dltoverall1-dltoverall10000); 
avgmtddltrate=mean(of mtddltrate1-mtddltrate10000); 
avgmtdpop=median(of mtdpop1-mtdpop10000); 
avgtotalpop=median(of totalpop1-totalpop10000); 
avgtotalpop1=mean(of totalpop1-totalpop10000); 
avgtotaldlt=median(of totaldlt1-totaldlt10000); 
run; 
 
/* print highest dose level reached/dose level at which the trial 
stops, dose at highest dose level, dlt rate at the highest dose level, 
factor to multiply present dose to get the next dose level, avg (+STD), 
max and median number of dose levels explored, median and avg number of 
patients on trial, median number of DLTs, avg DLT rate of the trial, 
avg DLT rate at the MTD, median MTD pop, avg percentage of patients 
dosed at MTD, under-dosed and over-dosed, avg number of patients and 
DLTs at each dose level */ 
 
proc print; 
var i dose dr frac ave dev max median avgtotalpop avgtotalpop1 
avgtotaldlt avgdltrate avgmtddltrate avgmtdpop avgdosemtd avgdoseunder 
avgdoseover peopledosel1-peopledosel10 dltdosel1-dltdosel10; 
run; 
 
data simi2; 
set simi1; 
array v_[*] dosel1-dosel10000; 
array counts[10]; 
call missing (of counts[*]); 
do i = 1 to dim(v_); 
     counts[v_[i]] + 1; 
end; 
if counts1=. then counts1=0; 
if counts2=. then counts2=0; 
if counts3=. then counts3=0; 
if counts4=. then counts4=0; 
if counts5=. then counts5=0; 
if counts6=. then counts6=0; 
if counts7=. then counts7=0; 
if counts8=. then counts8=0; 
if counts9=. then counts9=0; 
if counts10=. then counts10=0; 
 
run; 
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/** number of times out of 10000 that the trial stops at each dose 
level, from which the percentage of times each dose level is choosen as 
the MTD can be determined - the MTD is one dose level below the dose 
level at which the trial stops **/ 
proc print;  
var counts1-counts10; 
run; 
 
 
SAS code for 3+3 and 2+4 designs where de-escalation is also allowed: 
 
%macro alldesigns(design1, equation1); 
data simi1; 
call streaminit(1); 
 
array a{1000,6}; 
array sumi{1000}; 
array sumitot{1000}; 
array dosel[10000]; 
array dosemtd{10000}; 
array doseover{10000}; 
array doseunder{10000}; 
array dltmtd{10000}; 
array dltover{10000}; 
array dltunder{10000}; 
array dltoverall{10000}; 
array mtddltrate{10000}; 
array mtdpop{10000}; 
array totalpop{10000}; 
array totaldlt{10000}; 
array peopledosel{10}; 
array dltdosel{10}; 
sumd=0; 
sump=0; 
 
 
 
/** program for either 3+3 or 2+4  design with deescalation **/ 
 
length design $10; 
design="&design1"; 
 
length equation $20; 
equation="&equation1"; 
 
if design='3+3' then do; 
no1=3; 
no2=4; 
no3=6; 
o1= 1; 
o2= 3; 
o3= 1; 
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o4= 6; 
o5= 1; 
o6= 6; 
end; 
if design='2+4' then do; 
no1=2; 
no2=3; 
no3=6; 
o1= 1; 
o2= 2; 
o3= 1; 
o4= 6; 
o5= 1; 
o6= 6; 
end; 
 
startdose = 100; 
mtddose=334; 
dltrstartdose=0.01; 
dltrmtd=0.2; 
doselevelmtd=3; 
 
/* program can handle one of 3 dose-toxicity curves */ 
if equation='linear' then do; 
 
coeff2=1/(mtddose-startdose)*(dltrmtd-dltrstartdose); 
coeff1= dltrstartdose - startdose*coeff2; 
 
end; 
 
if equation='logistic' then do; 
 
coeff2=1/(mtddose-startdose)*( log(dltrmtd/(1-dltrmtd))-
log(dltrstartdose/(1-dltrstartdose)) ); 
coeff1= log(dltrstartdose/(1-dltrstartdose)) - startdose*coeff2; 
 
end; 
 
if equation='loglogistic' then do; 
 
coeff2=1/(log(mtddose)-log(startdose))*( log(dltrmtd/(1-dltrmtd))-
log(dltrstartdose/(1-dltrstartdose)) ); 
coeff1= log(dltrstartdose/(1-dltrstartdose)) - log(startdose)*coeff2; 
 
end; 
 
 
 
do k=1 to 10000; 
 
 
do i1=1 to 1000; 
do j1=1 to 6; 
a[i1,j1]=.; 
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sumi[i1]=.; 
sumitot[i1]=.; 
end; 
end; 
 
i=0; 
gg=0; 
sumi[1]=0; 
sumitot[1]=0; 
peoplec=0; 
atmtd=0; 
belowmtd=0; 
abovemtd=0; 
dltc=0; 
dltatmtd=0; 
dltbelowmtd=0; 
dltabovemtd=0; 
 
dose=100; 
 
do until ((sumi[i]>o1 and sumins=o2) or (sumi[i]>o3 and sumins=o4));  
    i = i+1; 
 sumi[i]=0; 
 sumitot[i]=0; 
 sumins=0; 
 
 
if i=1 then frac=1; 
if i=2 then frac=2; 
if i=3 then frac=1.67; 
if i=4 then frac=1.5; 
if i=5 then frac=1.4; 
if i=6 then frac=1.33; 
if i>=7 then frac=1.33; 
dose=dose*frac; 
 
if equation='linear' then dr=min(coeff1+coeff2*dose,1); 
 
if equation='logistic' then dr=exp(coeff1+coeff2*dose)/(1+ 
exp(coeff1+coeff2*dose)); 
 
if equation='loglogistic' then dr=exp(coeff1+coeff2*log(dose))/(1+ 
exp(coeff1+coeff2*log(dose))); 
 
 do j=1 to no1; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumitot[i]=sumitot[i]+1; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
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  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
 end; 
 
 
if sumi[i]=1 then do; 
do j=no2 to no3; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumitot[i]=sumitot[i]+1; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
end; 
 
 
end; 
 
***; 
gg=i-1; 
 
if gg>=1 then do; 
/** stop if the dose level is 1 or (total number of patients at dose 
level = 6 and total number of DLTs>1)or additional DLTs at dose level 
is 0 or 1.**/ 
do until ( flaggg=1 or (sumitot[gg]=o4 and totdlt>o3) or totdlt in (0 
1)); 
totdlt=0; 
flaggg=.; 
if gg=1 then flaggg=1; 
 
if sumitot[gg]=o2 then do; 
 
 
do jj=no2 to no3; 
if equation='logistic' then do; 
if gg=1 then dr1=0.01; 
if gg=2 then dr1 =0.03828; 
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if gg=3 then dr1=0.2; 
if gg=4 then dr1=0.71172; 
if gg=5 then dr1=0.97471; 
if gg=6 then dr1=0.99892; 
if gg=7 then dr1=0.99998; 
if gg>=8 then dr1=1; 
end; 
if equation='loglogistic' then do; 
if gg=1 then dr1=0.01; 
if gg=2 then dr1 =0.06004; 
if gg=3 then dr1=0.2; 
if gg=4 then dr1=0.42374; 
if gg=5 then dr1=0.64287; 
if gg=6 then dr1=0.79358; 
if gg=7 then dr1=0.89143; 
if gg=8 then dr1=0.94605; 
if gg=9 then dr1=0.97399; 
if gg=10 then dr1=0.98765; 
end; 
if equation='linear' then do; 
if gg=1 then dr1=0.01; 
if gg=2 then dr1 =0.0912; 
if gg=3 then dr1=0.2; 
if gg=4 then dr1=0.3356; 
if gg=5 then dr1=0.49832; 
if gg=6 then dr1=0.68626; 
if gg=7 then dr1=0.93621; 
if gg>=8 then dr1=1; 
end; 
 
  a[gg,jj]=rand('Bernoulli', dr1); 
  sumi[gg]=sumi[gg]+a[gg,jj]; 
  sumitot[gg]=sumitot[gg]+1; 
  totdlt=a[gg,jj]+totdlt; 
  sumd=sumd+a[gg,jj]; 
  sump=sump+1; 
  peopledosel[gg]=sum(peopledosel[gg],0.0001); 
  dltdosel[gg]=sum(dltdosel[gg],a[gg,jj]/10000); 
  peoplec=peoplec+1; 
  if gg=doselevelmtd then atmtd=sum(atmtd,1); 
   if gg>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if gg<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[gg,jj]; 
  if gg=doselevelmtd then dltatmtd=dltatmtd+a[gg,jj]; 
   if gg>doselevelmtd then dltabovemtd=dltabovemtd+a[gg,jj]; 
  if gg<doselevelmtd then dltbelowmtd=dltbelowmtd+a[gg,jj]; 
end; 
 
end; 
 
if gg>1 then gg=gg-1; 
 
end; 
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end; 
 
 
***; 
if gg=0 then dosel[k]=20; 
else if gg=1 and flaggg=1 and totdlt in (0 1) then dosel[k]=gg; 
else if gg=1 and flaggg=1 and totdlt in (2 3 4) then dosel[k]=20; 
else if gg=1 and totdlt in (0 1) then dosel[k]=gg+1; 
else if gg=1 and totdlt in (2 3 4) then dosel[k]=gg; 
else if gg>1 and totdlt in (0 1) then dosel[k]=gg+1; 
else if gg>1 and totdlt in (2 3 4) then dosel[k]=gg; 
 
dosemtd[k]=atmtd/peoplec*100; 
doseover[k]=abovemtd/peoplec*100; 
doseunder[k]=belowmtd/peoplec*100; 
dltmtd[k]=dltatmtd/dltc*100; 
dltover[k]=dltabovemtd/dltc*100; 
dltunder[k]=dltbelowmtd/dltc*100; 
 
dltoverall[k]=dltc/peoplec; 
if atmtd ne 0 then mtddltrate[k]=dltatmtd/atmtd; 
else mtddltrate[k]=0; 
mtdpop[k]=atmtd; 
totalpop[k]=peoplec; 
totaldlt[k]=dltc; 
 
end; 
avgd=sumd/10000; 
avgp=sump/10000; 
ave= mean(of dosel1-dosel10000);  
dev=STD(of dosel1-dosel10000);  
serror=STDERR(of dosel1-dosel10000); 
max= max(of dosel1-dosel10000);  
median= median(of dosel1-dosel10000);  
pctl_25=pctl(25, of dosel1-dosel10000); 
pctl_50=pctl(50, of dosel1-dosel10000); 
pctl_75=pctl(75, of dosel1-dosel10000); 
avgdosemtd=mean(of dosemtd1-dosemtd10000); 
avgdoseover=mean(of doseover1-doseover10000); 
avgdoseunder=mean(of doseunder1-doseunder10000); 
avgdltmtd=mean(of dltmtd1-dltmtd10000); 
avgdltover=mean(of dltover1-dltover10000); 
avgdltunder=mean(of dltunder1-dltunder10000); 
avgdltrate=mean(of dltoverall1-dltoverall10000); 
avgmtddltrate=mean(of mtddltrate1-mtddltrate10000); 
avgmtdpop=median(of mtdpop1-mtdpop10000); 
avgtotalpop=median(of totalpop1-totalpop10000); 
avgtotalpop1=mean(of totalpop1-totalpop10000); 
avgtotaldlt=median(of totaldlt1-totaldlt10000); 
run; 
 
/* print highest dose level reached, dose level at which the simulated 
trial finally stopped, total number of additional DLTs in the final 
dose level at which the trial stopped, median and avg number of 
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patients on trial, median number of DLTs, avg DLT rate of the trial, 
avg DLT rate at the MTD, avg percentage of patients dosed at MTD, 
under-dosed and over-dosed, avg number of patients and DLTs at each 
dose level */ 
 
proc print; 
var i gg totdlt avgtotalpop avgtotalpop1 avgtotaldlt avgdltrate 
avgmtddltrate avgdosemtd avgdoseunder avgdoseover peopledosel1-
peopledosel10 dltdosel1-dltdosel10; 
run; 
 
data simi2; 
set simi1; 
array v_[*] dosel1-dosel10000; 
array counts[20]; 
call missing (of counts[*]); 
do i = 1 to dim(v_); 
     counts[v_[i]] + 1; 
end; 
if counts1=. then counts1=0; 
if counts2=. then counts2=0; 
if counts3=. then counts3=0; 
if counts4=. then counts4=0; 
if counts5=. then counts5=0; 
if counts6=. then counts6=0; 
if counts7=. then counts7=0; 
if counts8=. then counts8=0; 
if counts9=. then counts9=0; 
if counts10=. then counts10=0; 
 
run; 
 
/* times out of 10000 that each dose level is choosen as the MTD */ 
 
proc print;  
var counts1-counts20; 
run; 
 
%mend alldesigns; 
 
%alldesigns(3+3, logistic); 
 
SAS code for starting at lower dose levels below the MTD as well as code for the 
linear dose-toxicity curves starting with different offsets: 
 
%macro alldesigns(design1, equation1); 
data simi1; 
call streaminit(1); 
 
array a{1000,6}; 
array sumi{1000}; 
array dosel[10000]; 
array dosemtd{10000}; 
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array doseover{10000}; 
array doseunder{10000}; 
array dltmtd{10000}; 
array dltover{10000}; 
array dltunder{10000}; 
array dltoverall{10000}; 
array mtddltrate{10000}; 
array mtdpop{10000}; 
array totalpop{10000}; 
array totaldlt{10000}; 
array peopledosel{20}; 
array dltdosel{20}; 
sumd=0; 
sump=0; 
 
 
/** design can be  3+3, 2+4, 4+4 a,4+4 b, 5+5 a, 5+5 b,5+5 c, 3+3+3, 
3+1+1, 10+10 a, or 20+20 a**/ 
 
length design $10; 
design="&design1"; 
 
length equation $20; 
equation="&equation1"; 
 
if design='3+3' then do; 
no1=3; 
no2=4; 
no3=6; 
o1= 1; 
o2= 3; 
o3= 1; 
o4= 6; 
o5= 1; 
o6= 6; 
end; 
if design='2+4' then do; 
no1=2; 
no2=3; 
no3=6; 
o1= 1; 
o2= 2; 
o3= 1; 
o4= 6; 
o5= 1; 
o6= 6; 
end; 
if design='4+4a' then do; 
no1=4; 
no2=5; 
no3=8; 
o1= 2; 
o2= 4; 
o3= 2; 
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o4= 8; 
o5= 2; 
o6= 8; 
end; 
if design='4+4b' then do; 
no1=4; 
no2=5; 
no3=8; 
o1= 2; 
o2= 4; 
o3= 3; 
o4= 8; 
o5= 3; 
o6= 8; 
end; 
 
if design='3+1+1' then do; 
no1=3; 
o1= 2; 
o2= 3; 
o3= 2; 
o4= 4; 
o5= 2; 
o6= 5; 
end; 
if design='3+3+3' then do; 
no1=3; 
no2=4; 
no3=6; 
o1= 1; 
o2= 3; 
o3= 2; 
o4= 6; 
o5= 2; 
o6= 9; 
end; 
if design='5+5a' then do; 
no1=5; 
no2=6; 
no3=10; 
o1= 1; 
o2= 5; 
o3= 1; 
o4= 10; 
o5= 1; 
o6= 10; 
end; 
if design='5+5b' then do; 
no1=5; 
no2=6; 
no3=10; 
o1= 2; 
o2= 5; 
o3= 2; 
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o4= 10; 
o5= 2; 
o6= 10; 
end; 
if design='5+5c' then do; 
no1=5; 
no2=6; 
no3=10; 
o1= 2; 
o2= 5; 
o3= 3; 
o4= 10; 
o5= 3; 
o6= 10; 
end; 
if design='10+10a' then do; 
no1=10; 
no2=11; 
no3=20; 
o1= 4; 
o2= 10; 
o3= 4; 
o4= 20; 
o5= 4; 
o6= 20; 
end; 
if design='20+20a' then do; 
no1=20; 
no2=21; 
no3=40; 
o1= 8; 
o2= 20; 
o3= 8; 
o4= 40; 
o5= 8; 
o6= 40; 
end; 
 
startdose = 100; 
mtddose=334; 
dltrstartdose=0.01; 
dltrmtd=0.2; 
 
/* program can handle one of 3 dose-toxicity curves */ 
if equation='linear' then do; 
 
coeff2=1/(mtddose-startdose)*(dltrmtd-dltrstartdose); 
coeff1= dltrstartdose - startdose*coeff2; 
 
end; 
 
if equation='logistic' then do; 
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coeff2=1/(mtddose-startdose)*( log(dltrmtd/(1-dltrmtd))-
log(dltrstartdose/(1-dltrstartdose)) ); 
coeff1= log(dltrstartdose/(1-dltrstartdose)) - startdose*coeff2; 
 
end; 
 
if equation='loglogistic' then do; 
 
coeff2=1/(log(mtddose)-log(startdose))*( log(dltrmtd/(1-dltrmtd))-
log(dltrstartdose/(1-dltrstartdose)) ); 
coeff1= log(dltrstartdose/(1-dltrstartdose)) - log(startdose)*coeff2; 
 
end; 
 
 
 
do k=1 to 10000; 
 
 
do i1=1 to 1000; 
do j1=1 to 6; 
a[i1,j1]=.; 
sumi[i1]=.; 
end; 
end; 
 
i=0; 
sumi[1]=0; 
peoplec=0; 
atmtd=0; 
belowmtd=0; 
abovemtd=0; 
dltc=0; 
dltatmtd=0; 
dltbelowmtd=0; 
dltabovemtd=0; 
 
dose=100; 
/** ii2 helps define how many dose levels above the lowest dose level 
the true MTD is. For our simulation study, ii2 can be 3, 2, 1 or 0 **/ 
ii2=3; 
doselevelmtd=ii2+3; 
 
do until ((sumi[i]>o1 and sumins=o2) or (sumi[i]>o3 and sumins=o4) or 
(sumi[i]>o5 and sumins=o6));  
    i = i+1; 
 sumi[i]=0; 
 sumins=0; 
 
/** You need one of the below 3 sets of numbers for the 3 linear dose 
toxicity curves with different offsets considered to examine the effect 
of the location of the starting dose relative to the true MTD. 
Otherwise comment these 3 sets of numbers. The “i”s below are such that 
we start 6 doses levels below the true MTD in each case, and will need 
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to be changed if we start 5 dose levels below the true MTD for example. 
**/ 
 
/* 
if i<=6 then dr=0.1; 
if i=7 then dr=0.2; 
if i=8 then dr=0.32; 
if i=9 then dr=0.4585988; 
if i=10 then dr=0.6429401; 
if i=11 then dr=0.8881078; 
if i>=12 then dr=1; 
*/ 
 
 
if i<=5 then dr=0.05; 
if i=6 then dr=0.1181818; 
if i=7 then dr=0.2; 
if i=8 then dr=0.2944992; 
if i=9 then dr=0.4201865; 
if i=10 then dr=0.5873463; 
if i=11 then dr=0.8096721; 
if i>=12 then dr=1; 
 
 
/* 
if i<=4 then dr=0.0; 
if i=5 then dr=0.05577262; 
if i=6 then dr=0.1226998; 
if i=7 then dr=0.2; 
if i=8 then dr=0.302812; 
if i=9 then dr=0.4395485; 
if i=10 then dr=0.6214107; 
if i=11 then dr=0.8632836; 
if i>=12 then dr=1; 
*/ 
 
/** If you are examining the effect of the location of the starting 
dose relative to the true MTD for the logistic or log-logistic dose-
toxicitiy curves, uncomment the below section **/ 
 
/* 
 
if i=ii2-2 then dose=12.5; 
if i=ii2-1 then dose=25; 
if i=ii2 then dose=50; 
if ii2=0 and i=ii2+1 then frac=1; 
if ii2>0 and i=ii2+1 then frac=2; 
if i=ii2+2 then frac=2; 
if i=ii2+3 then frac=1.67; 
if i=ii2+4 then frac=1.5; 
if i=ii2+5 then frac=1.4; 
if i>=ii2+6 then frac=1.33; 
if i>=ii2+1 then dose=dose*frac; 
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if equation='linear' then dr=min(coeff1+coeff2*dose,1); 
 
if equation='logistic' then dr=exp(coeff1+coeff2*dose)/(1+ 
exp(coeff1+coeff2*dose)); 
 
if equation='loglogistic' then dr=exp(coeff1+coeff2*log(dose))/(1+ 
exp(coeff1+coeff2*log(dose))); 
 
*/ 
 
 do j=1 to no1; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
 end; 
 
if (design='3+3' or design='2+4' or design='3+3+3' or design='5+5a') 
then do;  
if sumi[i]=1 then do; 
do j=no2 to no3; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
end; 
end; 
 
if (design='4+4a' or design='5+5b') then do;  
if (sumi[i]=1 or sumi[i]=2) then do; 
do j=no2 to no3; 
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  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
end; 
end; 
 
if (design='4+4b' or design='5+5c') then do;  
if sumi[i]=2 then do; 
do j=no2 to no3; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
end; 
end; 
 
if (design='10+10a') then do;  
if (sumi[i]=3 or sumi[i]=4) then do; 
do j=no2 to no3; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  
197 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
end; 
end; 
 
if (design='20+20a') then do;  
if (sumi[i]=7 or sumi[i]=8) then do; 
do j=no2 to no3; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
end; 
end; 
 
if design='3+3+3' then do; 
if (sumi[i]=2 and sumins=6) then do; 
do j=7 to 9; 
  a[i,j]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,j]; 
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
      if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
end; 
end; 
 
if design='3+1+1' then do; 
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if ((sumi[i]=1) or (sumi[i]=2)) then do; 
  a[i,4]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,4]; 
  sumd=sumd+a[i,4]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
 
if ((sumi[i]=2) and (sumins=4)) then do; 
  a[i,5]=rand('Bernoulli', dr); 
  sumi[i]=sumi[i]+a[i,5]; 
  sumd=sumd+a[i,5]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  sumins=sumins+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
end; 
end; 
 
 
end; 
dosel[k]=i; 
dosemtd[k]=atmtd/peoplec*100; 
doseover[k]=abovemtd/peoplec*100; 
doseunder[k]=belowmtd/peoplec*100; 
dltmtd[k]=dltatmtd/dltc*100; 
dltover[k]=dltabovemtd/dltc*100; 
dltunder[k]=dltbelowmtd/dltc*100; 
 
dltoverall[k]=dltc/peoplec; 
if atmtd ne 0 then mtddltrate[k]=dltatmtd/atmtd; 
else mtddltrate[k]=0; 
mtdpop[k]=atmtd; 
totalpop[k]=peoplec; 
totaldlt[k]=dltc; 
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end; 
avgd=sumd/10000; 
avgp=sump/10000; 
ave= mean(of dosel1-dosel10000);  
dev=STD(of dosel1-dosel10000);  
serror=STDERR(of dosel1-dosel10000); 
max= max(of dosel1-dosel10000);  
median= median(of dosel1-dosel10000);  
pctl_25=pctl(25, of dosel1-dosel10000); 
pctl_50=pctl(50, of dosel1-dosel10000); 
pctl_75=pctl(75, of dosel1-dosel10000); 
avgdosemtd=mean(of dosemtd1-dosemtd10000); 
avgdoseover=mean(of doseover1-doseover10000); 
avgdoseunder=mean(of doseunder1-doseunder10000); 
avgdltmtd=mean(of dltmtd1-dltmtd10000); 
avgdltover=mean(of dltover1-dltover10000); 
avgdltunder=mean(of dltunder1-dltunder10000); 
avgdltrate=mean(of dltoverall1-dltoverall10000); 
avgmtddltrate=mean(of mtddltrate1-mtddltrate10000); 
avgmtdpop=median(of mtdpop1-mtdpop10000); 
avgtotalpop=median(of totalpop1-totalpop10000); 
avgtotalpop1=mean(of totalpop1-totalpop10000); 
avgtotaldlt=median(of totaldlt1-totaldlt10000); 
run; 
 
/* print design, highest dose level reached/dose level at which the 
trial stops, dlt rate at the highest dose level, avg (+STD), max and 
median number of dose levels explored, median and avg number of 
patients on trial, median number of DLTs, avg DLT rate of the trial, 
avg DLT rate at the MTD, median MTD pop, avg percentage of patients 
dosed at MTD, under-dosed and over-dosed, avg number of patients and 
DLTs at each dose level */ 
 
proc print; 
var design i dr ave dev max median avgtotalpop avgtotalpop1 avgtotaldlt 
avgdltrate avgmtddltrate avgmtdpop avgdosemtd avgdoseunder avgdoseover  
peopledosel1-peopledosel10 dltdosel1-dltdosel10; 
run; 
 
data simi2; 
set simi1; 
array v_[*] dosel1-dosel10000; 
array counts[20]; 
call missing (of counts[*]); 
do i = 1 to dim(v_); 
     counts[v_[i]] + 1; 
end; 
 
run; 
 
/* times out of 10000 that the trial stops at each dose level, from 
which the percentage of times each dose level is choosen as the MTD can 
be determined - the MTD is one dose level below the dose level at which 
the trial stops */ 
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proc print;  
var counts1-counts20; 
run; 
 
%mend alldesigns; 
 
%alldesigns(3+3, logistic); 
 
 
R code for TEQR design using the R package TEQR: 
 
# logistic dose-toxicity curve 
set.seed(1111) 
OperChar<-teqrOCtox( 
sim=2000, 
firstdose=1, 
probt=c(.01,.03828,.2,.71172,.97471), 
cohortSize=3, 
MaxNoCohorts=30, 
MTDss=12, 
pTarget=.2, 
eq1=.05, 
eq2=.05, 
tootoxic=.34) 
OperChar 
 
 
R code for BOIN design using the R package BOIN: 
 
# logistic dose-toxicity curve 
get.oc(target=0.2, p.true=c(0.01, 0.03828, 0.2, 0.71172, 0.97471),startdose=1, 
ncohort=7, cohortsize=3, ntrial=2000) 
get.boundary(target=0.2, ncohort=7, cohortsize=3) 
 
 
For the mTPI design,we used the R program given in the following weblink. 
http://health.bsd.uchicago.edu/yji/software2.htm 
 
For the CRM design, we used the CRM Simulator software. 
https://biostatistics.mdanderson.org/SoftwareDownload/SingleSoftware.aspx?Soft
ware_Id=13 
 
For the EWOC design, we used the Web-EWOC software. 
https://biostatistics.csmc.edu/ewoc/ewocWeb.php 
 
/* SAS Code for finding the probability of being the highest dose level examined 
for the 3+3 design and some of its extensions (escalation-only designs) */ 
 
data a2; 
a=1; 
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b=1; 
c=1; 
d=1; 
e=1; 
f=1; 
g=1; 
h=1; 
do k=1 to 6; 
p=0.05+(k-1)*0.05; 
q=1-p; 
/* 3+3 */ 
vara = (q**3) + (3*p*(q**5)); 
varb = 1-vara; 
varc = 3*q*p**2+p**3 + 9*p**2*q**4 + 9*p**3*q**3 +3*q**2*p**4; 
a=a*vara; 
fin1=a*varb/vara; 
/* 3+3+3 */ 
vard=q**3+3*p*q**5+9*p**2*q**7; 
vare=1-vard; 
varf = 3*q*p**2+p**3 +3*q**2*p**4 + 9*p**3*q**3+ 27*p**3*q**6 + 
27*p**4*q**5 + 9*p**5*q**4; 
b=b*vard; 
fin2=b*vare/vard; 
/* 2+4 */ 
varg = (q**2) + (2*p*(q**5)); 
varh = 1-varg; 
vari = p**2 + 8*p**2*q**4+12*p**3*q**3+8*p**4*q**2+2*p**5*q; 
c=c*varg; 
fin3=c*varh/varg; 
/* 4+4 a */ 
varj=q**4+4*p*q**7+22*p**2*q**6; 
vark=1-varj; 
varl=48*p**3*q**5+52*p**4*q**4+28*p**5*q**3+6*p**6*q**2+4*p**3*q+p**4; 
d=d*varj; 
fin4=d*vark/varj; 
/* 4+4 b*/ 
varm = (q**4) + (4*p*(q**3)) + 6*p**2*q**6 + 24*p**3*q**5; 
varn = 1-varm; 
varo = 4*p**3*q+p**4+36*p**4*q**4+24*p**5*q**3+6*p**6*q**2; 
e=e*varm; 
fin5=e*varn/varm; 
/* 5+5 a */ 
varp = (q**5) + (5*p*(q**9)) + 35*p**2*q**8; 
varq = 1-varp; 
varr = 
p**5+5*p**4*q+10*p**3*q**2+100*p**3*q**7+150*p**4*q**6+125*p**5*q**5+55
*p**6*q**4+10*p**7*q**3;  
f=f*varp; 
fin6=f*varq/varp; 
/* 5+5 b */ 
vars = (q**5) + (5*p*(q**4)) + 10*p**2*q**8 + 50*p**3*q**7; 
vart = 1-vars; 
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varu = 
p**5+5*p**4*q+10*p**3*q**2+100*p**4*q**6+100*p**5*q**5+50*p**6*q**4+10*
p**7*q**3; 
g=g*vars; 
fin7=g*vart/vars; 
/* 3+1+1 */ 
varv = q**3+3*p*q**3+6*p**2*q**3; 
varw = 1-varv; 
varx=p**3+3*p**3*q+6*p**3*q**2; 
h=h*varv; 
fin8=h*varw/varv; 
output; 
end;  
 
proc print; 
var p fin1-fin8; 
title ‘Probabilities of being the highest dose level examined for 
various designs that are extensions of the 3+3 design and that consider 
only escalation’; 
run 
 
Codes for Chapter 3 
SAS code for 20+20 accelerated titration design where there is a stopping rule 
after every 6 or 8 patients are dosed: 
 
/** The upper limit for toxicity in the Bayesian decision rule for safety 
is 0.33 and the lower limit for efficacy in the Bayesian decision rule 
for efficacy is 0.5. For other thresholds, these numbers need to be 
changed in the code below. **/  
 
%macro alldesigns(design1, equation1); 
data simi1; 
call streaminit(1); 
 
array a{1000,40}; 
array aeff{1000,40};  
array asucc{1000,40};  
array sumi{1000}; 
array sumieff{1000}; 
array sumins{1000}; 
array flag{1000}; 
array flagabc{1000}; 
array flagabcd{1000}; 
array flagabcdee{1000}; 
array flagabcdff{1000}; 
array flagabcdgg{1000}; 
array flagabcdhh{1000}; 
array bayflag{1000}; 
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array pvaluea{1000}; 
array pvalueb{1000}; 
 
array dosel{10000};  
array dosemtd{10000}; 
array doseover{10000}; 
array doseunder{10000}; 
/* 
array dltmtd{11}; 
array dltover{11}; 
array dltunder{11}; 
*/ 
array dltoverall{10000}; 
array mtddltrate{10000}; 
array mtdpop{10000}; 
array totalpop{10000}; 
array totaldlt{10000}; 
array index{10000}; 
array peopledosel{10}; 
array dltdosel{10}; 
array onlyrespsdosel{10}; 
array respsnodltsdosel{10}; 
array dltratedoselevel{10}; 
array responseratedoselevel{10}; 
array utilitydltrate{10}; 
array utilityresponserate{10}; 
array utility{10}; 
array ratio{10}; 
array ratiof{10}; 
 
sumd=0; 
sump=0; 
count9=0; 
 
length design $10; 
design="&design1"; 
 
length equation $20; 
equation="&equation1"; 
 
if design='20+20' then do; 
no1=20; 
no2=21; 
no3=40; 
no4=14; 
no5=15; 
o1= 8; 
o2= 20; 
o3= 8; 
o4= 40; 
end; 
 
/** parameters used to define the dose-toxicity curve **/ 
startdose = 100; 
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mtddose=501; 
dltrstartdose=0.01; 
dltrmtd=0.2; 
doselevelmtd=4; 
 
 
if equation='linear' then do; 
 
coeff2=1/(mtddose-startdose)*(dltrmtd-dltrstartdose); 
coeff1= dltrstartdose - startdose*coeff2; 
 
end; 
 
if equation='logistic' then do; 
 
coeff2=1/(mtddose-startdose)*( log(dltrmtd/(1-dltrmtd))-
log(dltrstartdose/(1-dltrstartdose)) ); 
coeff1= log(dltrstartdose/(1-dltrstartdose)) - startdose*coeff2; 
 
end; 
 
if equation='loglogistic' then do; 
 
coeff2=1/(log(mtddose)-log(startdose))*( log(dltrmtd/(1-dltrmtd))-
log(dltrstartdose/(1-dltrstartdose)) ); 
coeff1= log(dltrstartdose/(1-dltrstartdose)) - log(startdose)*coeff2; 
 
end; 
 
 
do k=1 to 10000; 
 
 
do i1=1 to 1000; 
do j1=1 to 40; 
a[i1,j1]=.; 
aeff[i1,j1]=.;  
asucc[i1,j1]=.;  
sumi[i1]=.; 
sumieff[i1]=.;  
sumins[i1]=.; 
flag[i1]=.; 
flagabc[i1]=.; 
flagabcd[i1]=.; 
flagabcdee[i1]=.; 
flagabcdff[i1]=.; 
flagabcdgg[i1]=.; 
flagabcdgg[i1]=.; 
 
pvaluea[i1]=.; 
pvalueb[i1]=.; 
 
end; 
end; 
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i=0; 
sumi[1]=0; 
sumieff[1]=0; 
sumins[1]=0; 
peoplec=0; 
atmtd=0; 
belowmtd=0; 
abovemtd=0; 
dltc=0; 
dltatmtd=0; 
dltbelowmtd=0; 
dltabovemtd=0; 
 
 
dose=100; 
 
do until (sumi[i]>=1); 
    i = i+1; 
 sumi[i]=0; 
 sumieff[i]=0; 
 sumins[i]=0; 
 
    if i=1 then frac=1; 
    if i=2 then frac=2; 
    if i=3 then frac=1.67; 
    if i=4 then frac=1.5; 
    if i=5 then frac=1.4; 
    if i=6 then frac=1.33; 
    if i>=7 then frac=1.33; 
 
    dose=dose*frac; 
  
    if equation='linear' then dr=min(coeff1+coeff2*dose,1); 
 
    if equation='logistic' then dr=exp(coeff1+coeff2*dose)/(1+ 
exp(coeff1+coeff2*dose)); 
 
    if equation='loglogistic' then dr=exp(coeff1+coeff2*log(dose))/(1+ 
exp(coeff1+coeff2*log(dose))); 
  
/** true underlying response rates **/  
    if i=1 then dreff=0.01;  
    if i=2 then dreff=0.05; 
    if i=3 then dreff=0.15; 
    if i=4 then dreff=0.45; 
    if i=5 then dreff=0.2; 
    if i>=6 then dreff=0.05; 
 
/** correlation coefficient – correlation between true toxicity and 
efficacy rates **/ 
 r=0; 
 
    p1=dr; 
    p2=dreff; 
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/** start with 3 patients at each dose level until at least 1 DLT is 
observed **/ 
 do j=1 to 3; 
 a[i,j]=rand('Bernoulli', dr); 
 q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
 q2=(p2-q1*p1)/(1-p1); 
    if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
    else aeff[i,j]=rand("binomial",q2,1); 
    if a[i,j]=0 and aeff[i,j]=1 then asucc[i,j]=1; 
    else asucc[i,j]=0;  
 sumi[i]=sumi[i]+a[i,j]; 
 sumieff[i]=sumieff[i]+aeff[i,j];  
 sumd=sumd+a[i,j]; 
 sump=sump+1; 
 peopledosel[i]=sum(peopledosel[i],0.0001); 
 dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
 onlyrespsdosel[i]=sum(onlyrespsdosel[i],aeff[i,j]/10000); 
 respsnodltsdosel[i]=sum(respsnodltsdosel[i],asucc[i,j]/10000); 
 sumins[i]=sumins[i]+1; 
    peoplec=peoplec+1; 
 if i=doselevelmtd then atmtd=atmtd+1; 
  if i>doselevelmtd then abovemtd=abovemtd+1; 
 if i<doselevelmtd then belowmtd=belowmtd+1; 
 dltc=dltc+a[i,j]; 
 /* 
 if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
  if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
 if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
 */ 
 pvaluea[i]=cdf("beta", 0.33, 0.5+sumi[i], 0.5+sumins[i]-sumi[i]);  
 pvalueb[i]=1-cdf("beta", 0.5, 0.5+sumieff[i], 0.5+sumins[i]-
sumieff[i]);  
 end; 
 
end; 
 
/** switch to cohorts of 20 in groups of 6 or 8 patients once one or 
more DLTs are observed among 3 patients **/ 
do j=4 to 6; 
   a[i,j]=rand('Bernoulli', dr); 
   q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
   q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  if a[i,j]=0 and aeff[i,j]=1 then asucc[i,j]=1; 
  else asucc[i,j]=0;  
  sumi[i]=sumi[i]+a[i,j]; 
  sumieff[i]=sumieff[i]+aeff[i,j];  
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  onlyrespsdosel[i]=sum(onlyrespsdosel[i],aeff[i,j]/10000); 
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respsnodltsdosel[i]=sum(respsnodltsdosel[i],asucc[i,j]/10000); 
  sumins[i]=sumins[i]+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=atmtd+1; 
   if i>doselevelmtd then abovemtd=abovemtd+1; 
  if i<doselevelmtd then belowmtd=belowmtd+1; 
  dltc=dltc+a[i,j]; 
  /* 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
  */ 
  pvaluea[i]=cdf("beta", 0.33, 0.5+sumi[i], 0.5+sumins[i]-
sumi[i]);  
  pvalueb[i]=1-cdf("beta", 0.5, 0.5+sumieff[i], 
0.5+sumins[i]-sumieff[i]);  
end; 
 
if sumi[i]<4 then flagabcd[i]=1; 
else flagabcd[i]=0; 
jj3=i; 
 
/** proceed to add 8 more patients at the same dose level if there are 
less than 4 DLTs in the first 6 patients in the dose level **/ 
 
if flagabcd[jj3]=1 then do; 
 
do j=7 to 14; 
  a[i,j]=rand('Bernoulli', dr); 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  if a[i,j]=0 and aeff[i,j]=1 then asucc[i,j]=1; 
  else asucc[i,j]=0;  
  sumi[i]=sumi[i]+a[i,j]; 
  sumieff[i]=sumieff[i]+aeff[i,j];  
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  onlyrespsdosel[i]=sum(onlyrespsdosel[i],aeff[i,j]/10000); 
      
respsnodltsdosel[i]=sum(respsnodltsdosel[i],asucc[i,j]/10000); 
  sumins[i]=sumins[i]+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=atmtd+1; 
   if i>doselevelmtd then abovemtd=abovemtd+1; 
  if i<doselevelmtd then belowmtd=belowmtd+1; 
  dltc=dltc+a[i,j]; 
  /* 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
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  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
  */ 
  pvaluea[i]=cdf("beta", 0.33, 0.5+sumi[i], 0.5+sumins[i]-
sumi[i]);  
  pvalueb[i]=1-cdf("beta", 0.5, 0.5+sumieff[i], 
0.5+sumins[i]-sumieff[i]);  
end; 
 
/** proceed to add 6 more patients at the same dose level if there is 
at least one response in the first 14 patients and the number of DLTs 
is <9 or there is at least 1 DLT but less than 9 DLTs  **/ 
 
if ((0<sumi[i]<9 or (sumieff[i]>0 and 0<=sumi[i]<9))) then do; 
do j=15 to 20; 
         
  a[i,j]=rand("binomial",dr,1); 
        q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  if a[i,j]=0 and aeff[i,j]=1 then asucc[i,j]=1; 
  else asucc[i,j]=0;  
  sumi[i]=sumi[i]+a[i,j]; 
  sumieff[i]=sumieff[i]+aeff[i,j];  
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  onlyrespsdosel[i]=sum(onlyrespsdosel[i],aeff[i,j]/10000); 
     
        respsnodltsdosel[i]=sum(respsnodltsdosel[i],asucc[i,j]/10000); 
  sumins[i]=sumins[i]+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
/* 
        if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
*/ 
  pvaluea[i]=cdf("beta", 0.33, 0.5+sumi[i], 0.5+sumins[i]-
sumi[i]);  
     pvalueb[i]=1-cdf("beta", 0.5, 0.5+sumieff[i], 0.5+sumins[i]-
sumieff[i]);  
 end; 
 end; 
 
/** if number of DLTs in the first 20 patients is 7 or 8 then add 
patients in cohorts of 6 or 8 for a max of 40 patients, as long as less 
than 9 DLTs are observed **/ 
if sumi[i]=7 or sumi[i]=8 then do; 
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do j=21 to 26; 
  a[i,j]=rand('Bernoulli', dr); 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  if a[i,j]=0 and aeff[i,j]=1 then asucc[i,j]=1; 
  else asucc[i,j]=0;  
  sumi[i]=sumi[i]+a[i,j]; 
  sumieff[i]=sumieff[i]+aeff[i,j];  
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  onlyrespsdosel[i]=sum(onlyrespsdosel[i],aeff[i,j]/10000); 
 
 respsnodltsdosel[i]=sum(respsnodltsdosel[i],asucc[i,j]/10000); 
  sumins[i]=sumins[i]+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=atmtd+1; 
   if i>doselevelmtd then abovemtd=abovemtd+1; 
  if i<doselevelmtd then belowmtd=belowmtd+1; 
  dltc=dltc+a[i,j]; 
  /* 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
  */ 
  pvaluea[i]=cdf("beta", 0.33, 0.5+sumi[i], 0.5+sumins[i]-
sumi[i]);  
     pvalueb[i]=1-cdf("beta", 0.5, 0.5+sumieff[i], 0.5+sumins[i]-
sumieff[i]);  
end; 
 
if sumi[i]<9 then flagabcdee[i]=1; 
else flagabcdee[i]=0; 
jj26=i; 
 
if flagabcdee[jj26]=1 then do; 
do j=27 to 34; 
  a[i,j]=rand('Bernoulli', dr); 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  if a[i,j]=0 and aeff[i,j]=1 then asucc[i,j]=1; 
  else asucc[i,j]=0;  
  sumi[i]=sumi[i]+a[i,j]; 
  sumieff[i]=sumieff[i]+aeff[i,j];  
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  onlyrespsdosel[i]=sum(onlyrespsdosel[i],aeff[i,j]/10000); 
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 respsnodltsdosel[i]=sum(respsnodltsdosel[i],asucc[i,j]/10000); 
  sumins[i]=sumins[i]+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=atmtd+1; 
   if i>doselevelmtd then abovemtd=abovemtd+1; 
  if i<doselevelmtd then belowmtd=belowmtd+1; 
  dltc=dltc+a[i,j]; 
  /* 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
  */ 
  pvaluea[i]=cdf("beta", 0.33, 0.5+sumi[i], 0.5+sumins[i]-
sumi[i]);  
     pvalueb[i]=1-cdf("beta", 0.5, 0.5+sumieff[i], 0.5+sumins[i]-
sumieff[i]);  
end; 
 
if sumi[i]<9 then flagabcdff[i]=1; 
else flagabcdff[i]=0; 
jj35=i; 
 
if flagabcdff[jj35]=1 then do; 
do j=35 to 40; 
  a[i,j]=rand('Bernoulli', dr); 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  if a[i,j]=0 and aeff[i,j]=1 then asucc[i,j]=1; 
  else asucc[i,j]=0;  
  sumi[i]=sumi[i]+a[i,j]; 
  sumieff[i]=sumieff[i]+aeff[i,j];  
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  onlyrespsdosel[i]=sum(onlyrespsdosel[i],aeff[i,j]/10000); 
 
 respsnodltsdosel[i]=sum(respsnodltsdosel[i],asucc[i,j]/10000); 
  sumins[i]=sumins[i]+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=atmtd+1; 
   if i>doselevelmtd then abovemtd=abovemtd+1; 
  if i<doselevelmtd then belowmtd=belowmtd+1; 
  dltc=dltc+a[i,j]; 
  /* 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
  */ 
  pvaluea[i]=cdf("beta", 0.33, 0.5+sumi[i], 0.5+sumins[i]-
sumi[i]);  
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     pvalueb[i]=1-cdf("beta", 0.5, 0.5+sumieff[i], 0.5+sumins[i]-
sumieff[i]);  
end; 
end; 
 
end; 
 
end; 
 
end; 
 
if sumi[i]<=8 then flag[i]=1; 
else flag[i]=0; 
jj1=i; 
 
/** one can escalate if there are <=6 DLTs in the first 20 patients in 
a dose level, <=8 DLTs in 40 patients at a dose level or if there are 
no DLTs and no responses in the first 14 patients in a dose level **/ 
if flag[jj1]=1 and flagabcd[jj3]=1 then do; 
 
do until (sumi[i]>o1 or flagabc[jj2]=0);  
    i = i+1; 
 sumi[i]=0; 
    sumieff[i]=0;  
 sumins[i]=0; 
 
 
if i=1 then frac=1; 
if i=2 then frac=2; 
if i=3 then frac=1.67; 
if i=4 then frac=1.5; 
if i=5 then frac=1.4; 
if i=6 then frac=1.33; 
if i>=7 then frac=1.33; 
dose=dose*frac; 
 
if equation='linear' then dr=min(coeff1+coeff2*dose,1); 
 
if equation='logistic' then dr=exp(coeff1+coeff2*dose)/(1+ 
exp(coeff1+coeff2*dose)); 
 
if equation='loglogistic' then dr=exp(coeff1+coeff2*log(dose))/(1+ 
exp(coeff1+coeff2*log(dose))); 
 
if i=1 then dreff=0.01; 
if i=2 then dreff=0.05; 
if i=3 then dreff=0.15; 
if i=4 then dreff=0.45; 
if i=5 then dreff=0.2; 
if i>=6 then dreff=0.05; 
 
 
r=0; 
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p1=dr; 
p2=dreff; 
 
  do j=1 to 6; 
        a[i,j]=rand("binomial",dr,1); 
        q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  if a[i,j]=0 and aeff[i,j]=1 then asucc[i,j]=1; 
  else asucc[i,j]=0;  
  sumi[i]=sumi[i]+a[i,j]; 
  sumieff[i]=sumieff[i]+aeff[i,j];  
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  onlyrespsdosel[i]=sum(onlyrespsdosel[i],aeff[i,j]/10000); 
 
 respsnodltsdosel[i]=sum(respsnodltsdosel[i],asucc[i,j]/10000); 
  sumins[i]=sumins[i]+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
/* 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
*/ 
  pvaluea[i]=cdf("beta", 0.33, 0.5+sumi[i], 0.5+sumins[i]-
sumi[i]);  
     pvalueb[i]=1-cdf("beta", 0.5, 0.5+sumieff[i], 0.5+sumins[i]-
sumieff[i]);   
 end; 
 
    if sumi[i]<4 then flagabc[i]=1; 
    else flagabc[i]=0; 
    jj2=i; 
 
    if flagabc[jj2]=1 then do; 
 
 do j=7 to 14; 
        a[i,j]=rand("binomial",dr,1); 
        q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  if a[i,j]=0 and aeff[i,j]=1 then asucc[i,j]=1; 
  else asucc[i,j]=0;  
  sumi[i]=sumi[i]+a[i,j]; 
  sumieff[i]=sumieff[i]+aeff[i,j];  
  sumd=sumd+a[i,j]; 
  
213 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  onlyrespsdosel[i]=sum(onlyrespsdosel[i],aeff[i,j]/10000); 
 
 respsnodltsdosel[i]=sum(respsnodltsdosel[i],asucc[i,j]/10000); 
  sumins[i]=sumins[i]+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
/* 
  if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
*/ 
  pvaluea[i]=cdf("beta", 0.33, 0.5+sumi[i], 0.5+sumins[i]-
sumi[i]);  
     pvalueb[i]=1-cdf("beta", 0.5, 0.5+sumieff[i], 0.5+sumins[i]-
sumieff[i]);   
 end; 
 
 
  if ((0<sumi[i]<9 or (sumieff[i]>0 and 0<=sumi[i]<9))) then 
do; 
        do j=15 to 20; 
         
  a[i,j]=rand("binomial",dr,1); 
        q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  if a[i,j]=0 and aeff[i,j]=1 then asucc[i,j]=1; 
  else asucc[i,j]=0;  
  sumi[i]=sumi[i]+a[i,j]; 
  sumieff[i]=sumieff[i]+aeff[i,j];  
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  onlyrespsdosel[i]=sum(onlyrespsdosel[i],aeff[i,j]/10000); 
     
        respsnodltsdosel[i]=sum(respsnodltsdosel[i],asucc[i,j]/10000); 
  sumins[i]=sumins[i]+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
/* 
        if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
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*/ 
  pvaluea[i]=cdf("beta", 0.33, 0.5+sumi[i], 0.5+sumins[i]-
sumi[i]);  
     pvalueb[i]=1-cdf("beta", 0.5, 0.5+sumieff[i], 0.5+sumins[i]-
sumieff[i]);  
   end; 
   end; 
 
 
 
  if ((sumi[i]=7 or sumi[i]=8)) then do; 
 
  do j=21 to 26; 
         
  a[i,j]=rand("binomial",dr,1); 
        q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  if a[i,j]=0 and aeff[i,j]=1 then asucc[i,j]=1; 
  else asucc[i,j]=0;  
  sumi[i]=sumi[i]+a[i,j]; 
  sumieff[i]=sumieff[i]+aeff[i,j];  
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  onlyrespsdosel[i]=sum(onlyrespsdosel[i],aeff[i,j]/10000); 
 
 respsnodltsdosel[i]=sum(respsnodltsdosel[i],asucc[i,j]/10000); 
  sumins[i]=sumins[i]+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
/* 
        if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
*/ 
  pvaluea[i]=cdf("beta", 0.33, 0.5+sumi[i], 0.5+sumins[i]-
sumi[i]);  
     pvalueb[i]=1-cdf("beta", 0.5, 0.5+sumieff[i], 0.5+sumins[i]-
sumieff[i]);  
 end; 
 
 if sumi[i]<9 then flagabcdgg[i]=1; 
else flagabcdgg[i]=0; 
jj27a=i; 
 
if flagabcdgg[jj27a]=1 then do; 
 do j=27 to 34; 
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  a[i,j]=rand("binomial",dr,1); 
        q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  if a[i,j]=0 and aeff[i,j]=1 then asucc[i,j]=1; 
  else asucc[i,j]=0;  
  sumi[i]=sumi[i]+a[i,j]; 
  sumieff[i]=sumieff[i]+aeff[i,j];  
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  onlyrespsdosel[i]=sum(onlyrespsdosel[i],aeff[i,j]/10000); 
 
 respsnodltsdosel[i]=sum(respsnodltsdosel[i],asucc[i,j]/10000); 
  sumins[i]=sumins[i]+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
/* 
        if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
*/ 
  pvaluea[i]=cdf("beta", 0.33, 0.5+sumi[i], 0.5+sumins[i]-
sumi[i]);  
     pvalueb[i]=1-cdf("beta", 0.5, 0.5+sumieff[i], 0.5+sumins[i]-
sumieff[i]);  
 end; 
 
if sumi[i]<9 then flagabcdhh[i]=1; 
else flagabcdhh[i]=0; 
jj35a=i; 
 
if flagabcdhh[jj35a]=1 then do; 
 do j=35 to 40; 
         
  a[i,j]=rand("binomial",dr,1); 
        q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  if a[i,j]=0 and aeff[i,j]=1 then asucc[i,j]=1; 
  else asucc[i,j]=0;  
  sumi[i]=sumi[i]+a[i,j]; 
  sumieff[i]=sumieff[i]+aeff[i,j];  
  sumd=sumd+a[i,j]; 
  sump=sump+1; 
  peopledosel[i]=sum(peopledosel[i],0.0001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/10000); 
  onlyrespsdosel[i]=sum(onlyrespsdosel[i],aeff[i,j]/10000); 
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 respsnodltsdosel[i]=sum(respsnodltsdosel[i],asucc[i,j]/10000); 
  sumins[i]=sumins[i]+1; 
  peoplec=peoplec+1; 
  if i=doselevelmtd then atmtd=sum(atmtd,1); 
   if i>doselevelmtd then abovemtd=sum(abovemtd,1); 
  if i<doselevelmtd then belowmtd=sum(belowmtd,1); 
  dltc=dltc+a[i,j]; 
/* 
        if i=doselevelmtd then dltatmtd=dltatmtd+a[i,j]; 
   if i>doselevelmtd then dltabovemtd=dltabovemtd+a[i,j]; 
  if i<doselevelmtd then dltbelowmtd=dltbelowmtd+a[i,j]; 
*/ 
  pvaluea[i]=cdf("beta", 0.33, 0.5+sumi[i], 0.5+sumins[i]-
sumi[i]);  
     pvalueb[i]=1-cdf("beta", 0.5, 0.5+sumieff[i], 0.5+sumins[i]-
sumieff[i]);  
end; 
end; 
 
end; 
 
end; 
 
end; 
 
end; 
end; 
 
/** calculations for ratio of odds of toxicity to odds of efficacy **/ 
do i2=1 to 10; 
if sumieff[i2]*(sumins[i2]-sumi[i2]) not in (0 .) then 
ratiocalc=(sumi[i2]*(sumins[i2]-sumieff[i2]))/(sumieff[i2]*(sumins[i2]-
sumi[i2])); 
else ratiocalc=.; 
ratio[i2]=sum(ratio[i2],ratiocalc); 
if sumieff[i2]*(sumins[i2]-sumi[i2]) not in  (0 .) then ration=1; 
else ration=.; 
ratiof[i2]=sum(ratiof[i2],ration); 
end; 
 
/** calculations for satisfying the Bayesian criteria for safety and 
efficacy **/ 
do i3=1 to 10; 
if pvaluea[i3]>0.1 and pvalueb[i3]>0.1 then 
bayflag[i3]=sum(bayflag[i3],1); 
end; 
  
if (pvaluea1<=0.1 or pvalueb1<=0.1) and (pvaluea2<=0.1 or 
pvalueb2<=0.1) and (pvaluea3<=0.1 or pvalueb3<=0.1) and (pvaluea4<=0.1 
or pvalueb4<=0.1) and (pvaluea5<=0.1 or pvalueb5<=0.1) and 
(pvaluea6<=0.1 or pvalueb6<=0.1) and (pvaluea7<=0.1 or pvalueb7<=0.1) 
(pvaluea8<=0.1 or pvalueb8<=0.1) (pvaluea9<=0.1 or pvalueb9<=0.1) 
(pvaluea10<=0.1 or pvalueb10<=0.1) then bayflag[20]=sum(bayflag[20],1);   
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/** calculations for average dlt rate and response rate at each dose 
level **/ 
do i4=1 to 10; 
dltratedoselevel[i4]=sum(dltratedoselevel[i4],sumi[i4]/(sumins[i4]*1000
0)); 
responseratedoselevel[i4]=sum(responseratedoselevel[i4],sumieff[i4]/(su
mins[i4]*10000)); 
end; 
 
/** calculations for which dose level is chosen in each simulation 
based on the value of the utility function **/ 
do i5=1 to 10; 
utilitydltrate[i5]=sumi[i5]/sumins[i5]; 
utilityresponserate[i5]=sumieff[i5]/sumins[i5]; 
utility[i5]=utilityresponserate[i5]-0.1*utilitydltrate[i5]; 
end; 
 
maxutility=max(of utility[*]); 
 
Index[k]=whichN(maxutility,of utility[*]); 
 
dosel[k]=i; 
dosemtd[k]=atmtd/peoplec*100; 
doseover[k]=abovemtd/peoplec*100; 
doseunder[k]=belowmtd/peoplec*100; 
/* 
dltmtd[k]=dltatmtd/dltc*100; 
dltover[k]=dltabovemtd/dltc*100; 
dltunder[k]=dltbelowmtd/dltc*100; 
*/ 
 
dltoverall[k]=dltc/peoplec; 
if atmtd ne 0 then mtddltrate[k]=dltatmtd/atmtd; 
else mtddltrate[k]=0; 
mtdpop[k]=atmtd; 
totalpop[k]=peoplec; 
totaldlt[k]=dltc; 
if (sumins[i]=14 and sumi[i]>=9) then count9=count9+1; 
 
end; 
 
avgd=sumd/10000; 
avgp=sump/10000; 
ave= mean(of dosel1-dosel10000);  
dev=STD(of dosel1-dosel10000);  
serror=STDERR(of dosel1-dosel10000); 
max= max(of dosel1-dosel10000);  
median= median(of dosel1-dosel10000);  
pctl_25=pctl(25, of dosel1-dosel10000); 
pctl_50=pctl(50, of dosel1-dosel10000); 
pctl_75=pctl(75, of dosel1-dosel10000); 
avgdosemtd=mean(of dosemtd1-dosemtd10000); 
avgdoseover=mean(of doseover1-doseover10000); 
avgdoseunder=mean(of doseunder1-doseunder10000); 
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/* 
avgdltmtd=mean(of dltmtd1-dltmtd10); 
avgdltover=mean(of dltover1-dltover10); 
avgdltunder=mean(of dltunder1-dltunder10); 
*/ 
avgdltrate=mean(of dltoverall1-dltoverall10000); 
avgmtddltrate=mean(of mtddltrate1-mtddltrate10000); 
avgmtdpop=median(of mtdpop1-mtdpop10000); 
avgtotalpop=median(of totalpop1-totalpop10000); 
avgtotalpop1=mean(of totalpop1-totalpop10000); 
maxtotalpop=max(of totalpop1-totalpop10000); 
mintotalpop=min(of totalpop1-totalpop10000); 
avgtotaldlt=median(of totaldlt1-totaldlt10000); 
run; 
 
/** print design, highest dose level reached/dose level at which the 
trial stops, dose at highest dose level, DLT rate at the highest dose 
level, efficacy rate at the highest dose level, factor to multiply 
present dose to get the next dose level, max number of dose levels 
examined, median, mean, max and min number of patients on trial, median 
number of DLTs, average number of patients, DLTs, responders and 
responders with no DLTs at each dose level, average DLT rate and 
response rate and utility function at each dose level, divide ratio by 
ratiof to obtain the average odds ratio of toxicity to efficacy at each 
dose level  **/ 
proc print; 
var design i dose dr dreff frac max avgtotalpop avgtotalpop1 
maxtotalpop mintotalpop avgtotaldlt peopledosel1-peopledosel10 
dltdosel1-dltdosel10 onlyrespsdosel1-onlyrespsdosel10 
respsnodltsdosel1-respsnodltsdosel10 dltratedoselevel1-
dltratedoselevel10 responseratedoselevel1-responseratedoselevel10 
utility1-utility10 ratio1-ratio10 ratiof1-ratiof10; 
run; 
 
/** print for last simulation the number of DLTs at each dose level, 
number of responses at each dose level, number of patients at each dose 
level, total number of DLTs, total number of patients, p-value for 
safety decision criterion and p-value for efficacy decision criterion 
at each dose level; also print the number of times each dose level is 
chosen based on the Bayesian decision criteria **/ 
proc print data=simi1; 
var sumi1-sumi10 sumieff1-sumieff10 sumins1-sumins10 dltc peoplec 
pvaluea1-pvaluea10 pvalueb1-pvalueb10 bayflag1-bayflag10 bayflag20; 
run; 
 
 
%mend alldesigns; 
 
%alldesigns(20+20, logistic); 
 
data simi2; 
set simi1; 
array v_[*] dosel1-dosel10000; 
array counts[10]; 
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call missing (of counts[*]); 
do i = 1 to dim(v_); 
     counts[v_[i]] + 1; 
end; 
if counts1=. then counts1=0; 
if counts2=. then counts2=0; 
if counts3=. then counts3=0; 
if counts4=. then counts4=0; 
if counts5=. then counts5=0; 
if counts6=. then counts6=0; 
if counts7=. then counts7=0; 
if counts8=. then counts8=0; 
if counts9=. then counts9=0; 
if counts10=. then counts10=0; 
 
run; 
/** number of times out of 10000 that the simulated trial stops at each 
dose level **/ 
proc print;  
var counts1-counts10; 
run; 
 
data simi3; 
set simi1; 
array w_[*] index1-index10000; 
array countcounts[10]; 
call missing (of countcounts[*]); 
do i = 1 to dim(w_); 
     countcounts[w_[i]] + 1; 
end; 
 
run; 
 
/** number of times out of 10000 each dose level is choosen based on 
the utility function **/ 
proc print;  
var countcounts1-countcounts10; 
run; 
 
R code for CRM Design using the R package CRM: 
# logistic dose-toxicity curve 
prior1 <- c(0.15,0.25,0.3,0.45,0.51, 0.56) 
true1 <- c(0.01,0.02199,0.06165, 0.2,0.55412,0.8879) 
# simulations using model 2 (logistic model) 
crmsim(target=0.2,prior=prior1,true=true1,rate=0.1,cycle=21,cohort=20,nsubject=120,nsim=2000, 
model=2,a0=1,b=3,jump=FALSE,start.dose=1,seed=777) 
 
For the Eff-Tox design, we used the MD Anderson software: 
https://biostatistics.mdanderson.org/softwaredownload/SingleSoftware.as
px?Software_Id=2 
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For the OBD Isotonic design, we used the R code from Zang et al.: 
http://odin.mdacc.tmc.edu/~yyuan/Software/TargetAgent/targetAgentDF.r 
 
For the Phase 2 design calculations for sample size, we used the software EAST 
with the option “Discrete” for endpoint and “One Sample” for procedure: 
 
/** SAS code for approximate target DLT interval for the 20+20 design **/ 
proc optmodel; 
    var x >= 0 <= 1; 
   
    /* Pr[Bin(40,x)<=8]=0.5 */ 
    con Mycon1: CDF('BINOM',8,x,40) = 0.5; 
    x = 0.2; 
    print x (CDF('BINOM',8,x,40)); 
    solve; 
    print x (CDF('BINOM',8,x,40)); 
   
    drop Mycon1; 
   
    /* Pr[Bin(20,x)<=6)]=Pr(Bin(20,x)>=9] */ 
    con Mycon2: CDF('BINOM',6,x,20) = 1 - CDF('BINOM',9,x,20); 
    x = 0.35; 
    print x (CDF('BINOM',6,x,20)) (1 - CDF('BINOM',9,x,20)); 
    solve; 
    print x (CDF('BINOM',6,x,20)) (1 - CDF('BINOM',9,x,20)); 
quit; 
 
Codes for Chapter 4  
SAS code for the extended TEQR design considering efficacy and toxicity: 
/** The extended TEQR design code below works for a symmetric target 
DLT interval (symmetric about the target DLT rate pT). The code will 
need modifications for asymmetric target DLT intervals. Also, the 
upper limit for toxicity is 0.33 and the lower limit for efficacy is 0.4. 
For other thresholds, these numbers need to be changed in the isotonic 
regression parts of the code below. **/ 
 
data simi2; 
call streaminit(1); 
 
array a{10,100}; 
array aeff{10,100}; 
array sumi{1000,10}; 
array sumieff{1000,10}; 
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array sumitot{1000,10}; 
array dltr{10}; 
array effr{10}; 
array dosel{1000}; 
array totalpop{1000}; 
array dr1{10}; 
array dreff{10}; 
array peopledosel{10}; 
array dltdosel{10}; 
 
/** defining the unacceptable dlt probability, the target dlt rate, 
the equivalence range for the target DLT rate, the max sample size 
at the MTD, the cohort size and the correlation coefficient 
(correlation between the true toxicity and true efficacy rates) */ 
maxdlt=0.34; 
target=0.2; 
trange=0.05; 
maxmtdss=50; 
cohortsize=5; 
r=0; 
 
do k=1 to 1000; 
 
/* true underlying DLT and response rates */ 
dr1[1]=0.01; 
dr1[2] =0.02199; 
dr1[3]=0.06165; 
dr1[4]=0.2; 
dr1[5]=0.55412; 
dr1[6]=0.88790; 
dr1[7]=0.98936; 
dr1[8]=0.99959; 
dr1[9]=0.99999; 
dr1[10]=1; 
 
 
dreff[1]=0.1; 
dreff[2]=0.3; 
dreff[3]=0.4; 
dreff[4]=0.45; 
dreff[5]=0.55; 
dreff[6]=0.6; 
dreff[7]=0.65; 
 
 
do i1=1 to 10; 
do j1=1 to maxmtdss; 
        a[i1,j1]=.; 
        aeff[i1,j1]=.;  
  sumi[k,1]=0; 
  sumieff[k,1]=0; 
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  sumitot[k,1]=0; 
  dltr[i1]=0; 
  effr[i1]=0; 
end; 
end; 
 
 
i=2; /** start at dose level 2 to allow de-escalation **/ 
sumi[k,2]=0; 
sumieff[k,2]=0; 
sumitot[k,2]=0; 
peoplec=0; 
 
do j=1 to cohortsize; 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sumi[k,i]+a[i,j]; 
  sumitot[k,i]=sumitot[k,i]+1; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sumieff[k,i]+aeff[i,j];   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
end; 
 
/** dosing decisions of the TEQR design (escalate, stay at the same 
dose, de-escalate) performed until the maximum MTD sample size is 
reached or we need to de-escalate beyond dose level 1 **/ 
 do until ((sumsum=maxmtdss and dltrate<maxdlt) or i=0);  
 
 
    if 0<=dltr[i]<(target-trange) and dltr[i+1]<maxdlt then do; 
    i=i+1; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
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  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
    end; 
  else if 0<=dltr[i]<(target-trange) and dltr[i+1]>=maxdlt then do; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
    end; 
 
 else if (target-trange)<=dltr[i]<=(target+trange) then do; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  
224 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
    end; 
 
 else if (target+trange)<dltr[i]<=1 then do; 
    i=i-1; 
 if i > 0 then do; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
    end; 
 end; 
 
end;  
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if i ne 0 then dosel[k]=i; 
if i eq 0 then dosel[k]=20; 
 
totalpop[k]=peoplec; 
 
end; 
 
maxdose= max(of dosel1-dosel1000);  
medianpeop= median(of totalpop1-totalpop1000);  
run; 
 
/* print median number of patients on trial, avg DLT rate and 
response rate in each dose level, average number of patients and 
DLTs in each dose level */ 
proc print; 
var medianpeop dltr1-dltr10 effr1-effr10 peopledosel1-peopledosel10 
dltdosel1-dltdosel10; 
run; 
 
 
data simi3; 
set simi2 (keep=dosel1-dosel1000); 
 
array v_[*] dosel1-dosel1000; 
array counts[20]; 
call missing (of counts[*]); 
do i = 1 to dim(v_); 
     counts[v_[i]] + 1; 
end; 
 
run; 
 
/** number of times out of 1000 that each dose level is selected for 
safety before isotonic regression **/ 
proc print;  
var counts1-counts20; 
run; 
 
/* isotonic regression for observed DLT rates */ 
 
%macro doit(k1); 
 
%do jj=1  %to &k1; 
 
%global max_els2; 
 
%let onedim=Yes; *Yes/No; 
 
 
%let num1=%eval((&jj-1)*10+1); 
%let num2=%eval((&jj-1)*10+2); 
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%let num3=%eval((&jj-1)*10+3); 
%let num4=%eval((&jj-1)*10+4); 
%let num5=%eval((&jj-1)*10+5); 
%let num6=%eval((&jj-1)*10+6); 
%let num7=%eval((&jj-1)*10+7); 
%let num8=%eval((&jj-1)*10+8); 
%let num9=%eval((&jj-1)*10+9); 
%let num10=%eval((&jj-1)*10+10); 
 
 
proc iml; 
use simi2 ; 
 
read all var{sumi&num1 sumi&num2 sumi&num3 sumi&num4 sumi&num5 
sumi&num6 sumi&num7 sumi&num8 sumi&num9 sumi&num10} into x; 
 
read all var{sumitot&num1 sumitot&num2 sumitot&num3 sumitot&num4 
sumitot&num5 sumitot&num6 sumitot&num7 sumitot&num8 sumitot&num9 
sumitot&num10} into w; 
 
mi=missing(x); 
rowmi = mi[,+]; 
rowmi1=10-rowmi; 
 
call symput('rowmi2',char(rowmi1)); 
 
/* 
print mi rowmi rowmi1; 
*/ 
 
create one1 from w; 
append from w; 
create one2 from x; 
append from x; 
quit; 
run; 
 
%let max_els2=&rowmi2; *Number rows/columns; 
 
%macro assign(v,out); 
 
data &out; 
set &out; 
array cols[*] col1-col&max_els2; 
array s[*] &v.1-&v.&max_els2; 
do i=1 to &max_els2; 
%if &v=w %then %do; s[i]=max(0.0001,cols[i]); %end; 
%else %do; s[i]=cols[i]; %end; 
end; 
keep &v:; 
run; 
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%mend; 
%assign(v=w,out=one1); 
%assign(v=x,out=one2); 
 
data one; 
merge one1 one2; 
array ys[*] y1-y&max_els2; 
array ws[*] w1-w&max_els2; 
array xs[*] x1-x&max_els2; 
array zs[*] z1-z&max_els2; 
array ss[*] s1-s&max_els2; 
do i=1 to &max_els2; 
if ws[i]>0 then ys[i]=xs[i]/ws[i]; 
else ys[i]=0; 
zs[i]=ys[i]; 
ss[i]=0; 
end; 
drop i x:; 
run; 
 
proc datasets; 
delete one1 one2; 
run; 
 
/* 
proc print n width=min; 
title 'orig'; 
var w1-w&max_els2 y1-y&max_els2; 
run; 
*/ 
 
%let flag=0; 
%let n=0; 
%do %until(&flag=1 or (&onedim=Yes and &n=1)); 
%let n=%eval(&n+1); 
 
%macro rename(v,out); 
 
data &out; 
retain &v.1-&v.&max_els2; 
keep &v.1-&v.&max_els2; 
set one; 
run; 
 
%mend; 
%rename(v=y,out=y); 
%rename(v=w,out=w); 
%rename(v=z,out=z); 
%rename(v=s,out=s); 
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%if &onedim^=Yes %then %do; 
%if &n^=1 %then %do; 
proc iml;   
use y; read all into one1; 
use w; read all into one2; 
use z; read all into one3; 
use s; read all into one4; 
new=T(one1); 
new2=T(one2); 
new3=T(one3); 
new4=T(one4); 
create one1 from new; 
append from new; 
create one2 from new2; 
append from new2; 
create one3 from new3; 
append from new3; 
create one4 from new4; 
append from new4; 
quit; 
run; 
 
%assign(v=y,out=one1); 
%assign(v=w,out=one2); 
%assign(v=z,out=one3); 
%assign(v=s,out=one4); 
 
data one; 
merge one1 one2 one3 one4; 
run; 
 
proc datasets; 
delete one1 one2 one3 one4 y w z s; 
run; 
%end; 
%end; 
 
data one; 
set one; 
 
%macro pav(max_els=,array=,weights=); 
 
array _yo_[&max_els] yo1-yo&max_els; 
array _w_[&max_els] w1-w&max_els; 
array _y_[&max_els] y1-y&max_els; 
array _z_[&max_els] z1-z&max_els; 
array _s_[&max_els] s1-s&max_els; 
 
do i=1 to &max_els; 
_yo_[i]=_y_[i]; 
end; 
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%if &n=2 %then %do; 
do i=1 to &max_els; 
_y_[i]=_z_[i]; 
end; 
%end; 
%else %if &n>=3 %then %do; 
do i=1 to &max_els; 
*_y_[i]=max(0,_z_[i]+_s_[i]); 
_y_[i]=_z_[i]+_s_[i]; 
end; 
%end; 
 
%global index ; 
%if %quote(&index)= 
%then 
%let index=1 ; 
%else 
   %let index=%eval(&index+1) ; 
%let pooled = _pool&index._ ; 
%let parray = _parr&index._ ; 
%let pwghts = _pwgt&index._ ; 
 
array &pooled {&max_els} _TEMPORARY_ ; 
array &parray {&max_els} _TEMPORARY_ ; 
array &pwghts {&max_els} _TEMPORARY_ ; 
 
if dim(&array) = 1 then Go to epav&index ; 
 
do _pav_j_ = 1 to dim(&array) ; 
&pooled(_pav_j_) = 0 ; 
&parray(_pav_j_) = 0 ; 
&pwghts(_pav_j_) = 0 ; 
end ; 
 
&parray(1) = &array(1) ; 
&pwghts(1) = &weights(1) ; 
_pav_j_ = 1 ; 
 
do _pav_i_ = 2 to dim(&array) ; 
 
  /* if ajacent violated, then pool */ 
  if (&parray(_pav_j_) > &array(_pav_i_)) then do ; 
     _plwght_ = &pwghts(_pav_j_) + &weights(_pav_i_) ; 
    _plval_ = ((&parray(_pav_j_)*&pwghts(_pav_j_)) + 
             (&array(_pav_i_)*&weights(_pav_i_))) / _plwght_ ; 
 
    &pooled(_pav_i_) = 1 ; 
    flag=0; *added; 
    if _pav_j_ > 1 then do ; 
       _pav_j_ = _pav_j_ - 1 ; 
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       _pav_jj_ = _pav_i_ ; 
       do while (flag=0 & ( &parray(_pav_j_)>_plval_) & (_pav_i_ >= 
1)); *added flag=0; 
       put &parray(_pav_j_)= _pav_j_= _plval_=; 
         _tplval_ = _plval_ ; 
         _tplwgt_ = _plwght_ ; /* tplwgt misspelled */ 
          do until (not &pooled(_pav_jj_)) ; 
              _pav_jj_ = _pav_jj_ - 1 ; 
           put _pav_jj_= &pooled(_pav_jj_)=; 
              end ; /* do until */ 
 
          _plwght_ = &pwghts(_pav_j_) + _tplwgt_ ; 
          _plval_  = ((&parray(_pav_j_) * &pwghts(_pav_j_)) + 
                      (_tplval_*_tplwgt_)) / _plwght_ ;  
         &pooled(_pav_jj_) = 1 ; 
         _pav_j_ = _pav_j_ -1 ; 
         if _pav_j_=0 then do; flag=1; _pav_j_=1; end; *added; 
         end ; /* do while */ 
      _pav_j_ = _pav_j_ + 1 ; 
      end ; /* if _pav_j_ > 1 */ 
      if flag=1 then do; *added; 
         _pav_j_=_pav_j_-1; *added; 
         do i=1 to _pav_i_;  *added*; 
         &parray(i) = _plval_ ; *added; 
         &pwghts(i) = _plwght_ ; *added; 
         end;  *added*; 
         end;  *added*; 
     else do; *added; 
     &parray(_pav_j_) = _plval_ ; 
     &pwghts(_pav_j_) = _plwght_ ; 
     end; *added; 
     end ; /* if (&parray... */ 
 
     else do ; 
         _pav_j_ = _pav_j_ + 1 ; 
          &parray(_pav_j_) = &array(_pav_i_) ; 
          &pwghts(_pav_j_) = &weights(_pav_i_) ; 
          end ; 
     end ; /* _pav_i_=2 to dim(array) */ 
 
  &array(1) = &parray(1) ; 
 _pav_j_=1 ; 
 _pav_jj_=1 ; /*left off underscore*/ 
 
 /* put the pooled data back into the original array */ 
 do _pav_j_ = 2 to dim(&array) ; 
   if ^&pooled(_pav_j_) then _pav_jj_ = _pav_jj_ + 1 ; 
   &array(_pav_j_) = &parray(_pav_jj_) ; 
 end ; 
 
 Epav&index: 
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 drop _pav_j_ _pav_i_ _pav_jj_ _plval_ _plwght_ _tplval_ _tplwgt_ ; 
 
          ok=0; 
          do i=1 to &max_els; 
          %if &n=1 %then %do;  
          _s_[i]=_y_[i]-_z_[i]; %end; 
          %else %if &n>=2 %then %do;  
          _s_[i]=_y_[i]-_z_[i]-_s_[i]; %end; 
          if abs(_yo_[i]-_y_[i])>.0001 then ok=ok+1; 
          end; 
    run; 
 
    %mend; 
 
%pav(max_els=&max_els2,array=_y_,weights=_w_); 
 
data one; 
set one; 
index2=1; 
run; 
 
data one; 
set one end=lastrec; 
by index2; 
retain ok2; 
if first.index2 then ok2=ok; 
else ok2=ok2+ok; 
if lastrec and ((mod(&n,2)^=0 and ok2=0) or &n=199) then call 
symput('flag','1');  
*if lastrec and (&n=51) then call symput('flag','1');  
 
/** highest dose level with DLT rate <=0.33 after isotonic 
regression **/ 
if y1>0.33 then mtdiso=0; 
if .<y1<=0.33 then mtdiso=1; 
if .<y2<=0.33 then mtdiso=2; 
if .<y3<=0.33 then mtdiso=3; 
if .<y4<=0.33 then mtdiso=4; 
if .<y5<=0.33 then mtdiso=5; 
if .<y6<=0.33 then mtdiso=6; 
if .<y7<=0.33 then mtdiso=7; 
if .<y8<=0.33 then mtdiso=8; 
if .<y9<=0.33 then mtdiso=9; 
if .<y10<=0.33 then mtdiso=10; 
 
drop i index2 ok:; 
run; 
 
/* 
proc print; var  w1-w&max_els2 y1-y&max_els2; title "Iter &n After 
Iso"; run; 
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*/ 
 
data finalmtdiso&jj; 
set one; 
keep mtdiso; 
run; 
 
%end; 
 
%end; 
%mend; 
 
 
%doit(1000); 
 
data finaliso; 
set finalmtdiso1 - finalmtdiso1000; 
run; 
 
/** number of times out of 1000 that each dose level is selected for 
safety after isotonic regression (highest dose level at which the 
smoothed DLT rate is <=0.33) **/ 
proc freq; 
tables mtdiso; 
run; 
 
***********; 
 
/* isotonic regression for observed response rates */ 
 
%macro doiteff(k1); 
 
%do jj=1  %to &k1; 
 
%global max_els2; 
 
%let onedim=Yes; *Yes/No; 
 
 
%let num1=%eval((&jj-1)*10+1); 
%let num2=%eval((&jj-1)*10+2); 
%let num3=%eval((&jj-1)*10+3); 
%let num4=%eval((&jj-1)*10+4); 
%let num5=%eval((&jj-1)*10+5); 
%let num6=%eval((&jj-1)*10+6); 
%let num7=%eval((&jj-1)*10+7); 
%let num8=%eval((&jj-1)*10+8); 
%let num9=%eval((&jj-1)*10+9); 
%let num10=%eval((&jj-1)*10+10); 
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proc iml; 
use simi2 ; 
 
read all var{sumieff&num1 sumieff&num2 sumieff&num3 sumieff&num4 
sumieff&num5 sumieff&num6 sumieff&num7 sumieff&num8 sumieff&num9 
sumieff&num10} into x; 
 
read all var{sumitot&num1 sumitot&num2 sumitot&num3 sumitot&num4 
sumitot&num5 sumitot&num6 sumitot&num7 sumitot&num8 sumitot&num9 
sumitot&num10} into w; 
 
mi=missing(x); 
rowmi = mi[,+]; 
rowmi1=10-rowmi; 
 
call symput('rowmi2',char(rowmi1)); 
 
/* 
print mi rowmi rowmi1; 
*/ 
 
create one1 from w; 
append from w; 
create one2 from x; 
append from x; 
quit; 
run; 
 
%let max_els2=&rowmi2; *Number rows/columns; 
 
%macro assign(v,out); 
 
data &out; 
set &out; 
array cols[*] col1-col&max_els2; 
array s[*] &v.1-&v.&max_els2; 
do i=1 to &max_els2; 
%if &v=w %then %do; s[i]=max(0.0001,cols[i]); %end; 
%else %do; s[i]=cols[i]; %end; 
end; 
keep &v:; 
run; 
 
%mend; 
%assign(v=w,out=one1); 
%assign(v=x,out=one2); 
 
data one; 
merge one1 one2; 
array ys[*] y1-y&max_els2; 
array ws[*] w1-w&max_els2; 
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array xs[*] x1-x&max_els2; 
array zs[*] z1-z&max_els2; 
array ss[*] s1-s&max_els2; 
do i=1 to &max_els2; 
if ws[i]>0 then ys[i]=xs[i]/ws[i]; 
else ys[i]=0; 
zs[i]=ys[i]; 
ss[i]=0; 
end; 
drop i x:; 
run; 
 
proc datasets; 
delete one1 one2; 
run; 
 
/* 
proc print n width=min; 
title 'orig'; 
var w1-w&max_els2 y1-y&max_els2; 
run; 
*/ 
 
%let flag=0; 
%let n=0; 
%do %until(&flag=1 or (&onedim=Yes and &n=1)); 
%let n=%eval(&n+1); 
 
%macro rename(v,out); 
 
data &out; 
retain &v.1-&v.&max_els2; 
keep &v.1-&v.&max_els2; 
set one; 
run; 
 
%mend; 
%rename(v=y,out=y); 
%rename(v=w,out=w); 
%rename(v=z,out=z); 
%rename(v=s,out=s); 
 
%if &onedim^=Yes %then %do; 
%if &n^=1 %then %do; 
proc iml;   
use y; read all into one1; 
use w; read all into one2; 
use z; read all into one3; 
use s; read all into one4; 
new=T(one1); 
new2=T(one2); 
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new3=T(one3); 
new4=T(one4); 
create one1 from new; 
append from new; 
create one2 from new2; 
append from new2; 
create one3 from new3; 
append from new3; 
create one4 from new4; 
append from new4; 
quit; 
run; 
 
%assign(v=y,out=one1); 
%assign(v=w,out=one2); 
%assign(v=z,out=one3); 
%assign(v=s,out=one4); 
 
data one; 
merge one1 one2 one3 one4; 
run; 
 
proc datasets; 
delete one1 one2 one3 one4 y w z s; 
run; 
%end; 
%end; 
 
data one; 
set one; 
 
%macro pav(max_els=,array=,weights=); 
 
array _yo_[&max_els] yo1-yo&max_els; 
array _w_[&max_els] w1-w&max_els; 
array _y_[&max_els] y1-y&max_els; 
array _z_[&max_els] z1-z&max_els; 
array _s_[&max_els] s1-s&max_els; 
 
do i=1 to &max_els; 
_yo_[i]=_y_[i]; 
end; 
 
%if &n=2 %then %do; 
do i=1 to &max_els; 
_y_[i]=_z_[i]; 
end; 
%end; 
%else %if &n>=3 %then %do; 
do i=1 to &max_els; 
*_y_[i]=max(0,_z_[i]+_s_[i]); 
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_y_[i]=_z_[i]+_s_[i]; 
end; 
%end; 
 
%global index ; 
%if %quote(&index)= 
%then 
%let index=1 ; 
%else 
   %let index=%eval(&index+1) ; 
%let pooled = _pool&index._ ; 
%let parray = _parr&index._ ; 
%let pwghts = _pwgt&index._ ; 
 
array &pooled {&max_els} _TEMPORARY_ ; 
array &parray {&max_els} _TEMPORARY_ ; 
array &pwghts {&max_els} _TEMPORARY_ ; 
 
if dim(&array) = 1 then Go to epav&index ; 
 
do _pav_j_ = 1 to dim(&array) ; 
&pooled(_pav_j_) = 0 ; 
&parray(_pav_j_) = 0 ; 
&pwghts(_pav_j_) = 0 ; 
end ; 
 
&parray(1) = &array(1) ; 
&pwghts(1) = &weights(1) ; 
_pav_j_ = 1 ; 
 
do _pav_i_ = 2 to dim(&array) ; 
 
  /* if ajacent violated, then pool */ 
  if (&parray(_pav_j_) > &array(_pav_i_)) then do ; 
     _plwght_ = &pwghts(_pav_j_) + &weights(_pav_i_) ; 
    _plval_ = ((&parray(_pav_j_)*&pwghts(_pav_j_)) + 
             (&array(_pav_i_)*&weights(_pav_i_))) / _plwght_ ; 
 
    &pooled(_pav_i_) = 1 ; 
    flag=0; *added; 
    if _pav_j_ > 1 then do ; 
       _pav_j_ = _pav_j_ - 1 ; 
       _pav_jj_ = _pav_i_ ; 
       do while (flag=0 & ( &parray(_pav_j_)>_plval_) & (_pav_i_ >= 
1)); *added flag=0; 
       put &parray(_pav_j_)= _pav_j_= _plval_=; 
         _tplval_ = _plval_ ; 
         _tplwgt_ = _plwght_ ; /* tplwgt misspelled */ 
          do until (not &pooled(_pav_jj_)) ; 
              _pav_jj_ = _pav_jj_ - 1 ; 
           put _pav_jj_= &pooled(_pav_jj_)=; 
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              end ; /* do until */ 
 
          _plwght_ = &pwghts(_pav_j_) + _tplwgt_ ; 
          _plval_  = ((&parray(_pav_j_) * &pwghts(_pav_j_)) + 
                      (_tplval_*_tplwgt_)) / _plwght_ ;  
         &pooled(_pav_jj_) = 1 ; 
         _pav_j_ = _pav_j_ -1 ; 
         if _pav_j_=0 then do; flag=1; _pav_j_=1; end; *added; 
         end ; /* do while */ 
      _pav_j_ = _pav_j_ + 1 ; 
      end ; /* if _pav_j_ > 1 */ 
      if flag=1 then do; *added; 
         _pav_j_=_pav_j_-1; *added; 
         do i=1 to _pav_i_;  *added*; 
         &parray(i) = _plval_ ; *added; 
         &pwghts(i) = _plwght_ ; *added; 
         end;  *added*; 
         end;  *added*; 
     else do; *added; 
     &parray(_pav_j_) = _plval_ ; 
     &pwghts(_pav_j_) = _plwght_ ; 
     end; *added; 
     end ; /* if (&parray... */ 
 
     else do ; 
         _pav_j_ = _pav_j_ + 1 ; 
          &parray(_pav_j_) = &array(_pav_i_) ; 
          &pwghts(_pav_j_) = &weights(_pav_i_) ; 
          end ; 
     end ; /* _pav_i_=2 to dim(array) */ 
 
  &array(1) = &parray(1) ; 
 _pav_j_=1 ; 
 _pav_jj_=1 ; /*left off underscore*/ 
 
 /* put the pooled data back into the original array */ 
 do _pav_j_ = 2 to dim(&array) ; 
   if ^&pooled(_pav_j_) then _pav_jj_ = _pav_jj_ + 1 ; 
   &array(_pav_j_) = &parray(_pav_jj_) ; 
 end ; 
 
 Epav&index: 
 drop _pav_j_ _pav_i_ _pav_jj_ _plval_ _plwght_ _tplval_ _tplwgt_ ; 
 
          ok=0; 
          do i=1 to &max_els; 
          %if &n=1 %then %do;  
          _s_[i]=_y_[i]-_z_[i]; %end; 
          %else %if &n>=2 %then %do;  
          _s_[i]=_y_[i]-_z_[i]-_s_[i]; %end; 
          if abs(_yo_[i]-_y_[i])>.0001 then ok=ok+1; 
  
238 
          end; 
    run; 
 
    %mend; 
 
%pav(max_els=&max_els2,array=_y_,weights=_w_); 
 
data one; 
set one; 
index2=1; 
run; 
 
data one; 
set one end=lastrec; 
by index2; 
retain ok2; 
if first.index2 then ok2=ok; 
else ok2=ok2+ok; 
if lastrec and ((mod(&n,2)^=0 and ok2=0) or &n=199) then call 
symput('flag','1');  
*if lastrec and (&n=51) then call symput('flag','1');  
 
/** lowest dose level with response rate >=0.4 after isotonic 
regression **/ 
effiso=0; 
if y1>=0.4 then effiso=1; 
else if y2>=0.4 then effiso=2; 
else if y3>=0.4 then effiso=3; 
else if y4>=0.4 then effiso=4; 
else if y5>=0.4 then effiso=5; 
else if y6>=0.4 then effiso=6; 
else if y7>=0.4 then effiso=7; 
else if y8>=0.4 then effiso=8; 
else if y9>=0.4 then effiso=9; 
else if y10>=0.4 then effiso=10; 
 
drop i index2 ok:; 
run; 
 
/* 
proc print; var  w1-w&max_els2 y1-y&max_els2; title "Iter &n After 
Iso"; run; 
*/ 
 
data finaleffiso&jj; 
set one; 
keep effiso; 
run; 
 
%end; 
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%end; 
%mend; 
 
%doiteff(1000); 
 
data finaliso1; 
set finaleffiso1 - finaleffiso1000; 
run; 
 
/** number of times out of 1000 that each dose level is selected for 
efficacy after isotonic regression (lowest dose level at which the 
smoothed response rate is >=0.4) **/ 
proc freq; 
tables effiso; 
run; 
 
*****************; 
/** code for number of times out of 1000 that each dose is selected as 
optimal dose when the dlt rates are monotonically increasing and the 
response rates are monotonically increasing or monotonically non-
decreasing **/ 
 
data finaliso111; 
set finaliso; 
retain a; 
a=sum(a,1); 
run; 
 
data finaliso112; 
set finaliso1; 
retain a; 
a=sum(a,1); 
run; 
 
data teqrisoiso; 
merge finaliso111 finaliso112; 
by a; 
if effiso ne 0 and effiso<=mtdiso then optimal=mtdiso; 
else optimal=0; 
run; 
 
proc freq; 
tables optimal; 
run; 
 
 
 
SAS code for the extended mTPI design considering efficacy and toxicity: 
/** The extended mTPI design code below works for a symmetric target 
DLT interval (symmetric about the target DLT rate pT). The code will 
need modifications for asymmetric target DLT intervals. Also, the 
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upper limit for toxicity is 0.33 and the lower limit for efficacy is 0.4. 
For other thresholds, these numbers need to be changed in the isotonic 
regression parts of the code below. **/ 
 
data simi2; 
call streaminit(1); 
 
array a{10,100}; 
array aeff{10,100}; 
array sumi{1000,10}; 
array sumieff{1000,10}; 
array sumitot{1000,10}; 
array dltr{10}; 
array effr{10}; 
array calc1{10}; 
array calc2{10}; 
array calc3{10}; 
array calc4{10}; 
array dosel{1000}; 
array totalpop{1000}; 
array dr1{10}; 
array dreff{10}; 
array peopledosel{10}; 
array dltdosel{10}; 
 
/** defining the target dlt rate, the equivalence range for the 
target DLT rate, the max sample size, the cohort size and the 
correlation coefficient (correlation between the true toxicity and 
true efficacy rates) */ 
 
target=0.2; 
trange=0.05; 
maxss=50; 
cohortsize=5; 
r=0; 
 
do k=1 to 1000; 
 
/** true underlying DLT and response rates **/ 
dr1[1]=0.01; 
dr1[2] =0.02199; 
dr1[3]=0.06165; 
dr1[4]=0.2; 
dr1[5]=0.55412; 
dr1[6]=0.88790; 
dr1[7]=0.98936; 
dr1[8]=0.99959; 
dr1[9]=0.99999; 
dr1[10]=1; 
 
dreff[1]=0.1; 
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dreff[2]=0.3; 
dreff[3]=0.4; 
dreff[4]=0.45; 
dreff[5]=0.55; 
dreff[6]=0.6; 
dreff[7]=0.65; 
 
 
do i1=1 to 10; 
do j1=1 to maxss; 
        a[i1,j1]=.; 
        aeff[i1,j1]=.;  
  sumi[k,1]=0; 
  sumieff[k,1]=0; 
  sumitot[k,1]=0; 
  dltr[i1]=0; 
  effr[i1]=0; 
  calc1[i1]=0; 
  calc2[i1]=0; 
  calc3[i1]=0; 
  calc4[i1]=0; 
end; 
end; 
 
 
i=2; /** start at dose level 2 to allow de-escalation **/ 
sumi[k,2]=0; 
sumieff[k,2]=0; 
sumitot[k,2]=0; 
peoplec=0; 
 
do j=1 to cohortsize; 
  if ranuni(1)<dr1[i] then a[i,j]=1; else a[i,j]=0; 
/*a[i,j]=rand('Bernoulli', dr1[i]);*/ 
  sumi[k,i]=sumi[k,i]+a[i,j]; 
  sumitot[k,i]=sumitot[k,i]+1; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sumieff[k,i]+aeff[i,j];   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
 
  calc1[i]= (1-cdf("beta", target+trange, sumi[k,i]+1, 
sumitot[k,i]-sumi[k,i]+1))/(1-target-trange); 
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  calc2[i]=  (cdf("beta", target+trange, sumi[k,i]+1, 
sumitot[k,i]-sumi[k,i]+1) - cdf("beta", target-trange, sumi[k,i]+1, 
sumitot[k,i]-sumi[k,i]+1))/(trange+trange); 
  calc3[i]= (cdf("beta", target-trange, sumi[k,i]+1, 
sumitot[k,i]-sumi[k,i]+1)/(target-trange)); 
  calc4[i]= 1-cdf("beta", target, sumi[k,i]+1, 
sumitot[k,i]-sumi[k,i]+1); 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
end; 
 
 
/** dosing decisions of the mTPI design (escalate, stay at the same 
dose, de-escalate) performed until the maximum sample size is 
reached or we need to de-escalate beyond dose level 1 **/ 
 do until ((peoplec=maxss) or i=0);  
 
 
    if calc3[i]>=calc2[i] and calc3[i]>calc1[i] and calc4[i+1]<=0.95 
then do; 
    i=i+1; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  if ranuni(1)<dr1[i] then a[i,j]=1; else a[i,j]=0; 
/*a[i,j]=rand('Bernoulli', dr1[i]);*/ 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  calc1[i]= (1-cdf("beta", target+trange, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1))/(1-target-trange); 
  calc2[i]=  (cdf("beta", target+trange, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1) - cdf("beta", target-trange, 
sum(sumi[k,i],1), sum(sumitot[k,i],-sumi[k,i])+1))/(trange+trange); 
  calc3[i]= (cdf("beta", target-trange, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1)/(target-trange)); 
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  calc4[i]= 1-cdf("beta", target, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1); 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
    end; 
 
  else if calc3[i]>=calc2[i] and calc3[i]>calc1[i] and 
calc4[i+1]>0.95 then do; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  if ranuni(1)<dr1[i] then a[i,j]=1; else a[i,j]=0; 
/*a[i,j]=rand('Bernoulli', dr1[i]);*/ 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  calc1[i]= (1-cdf("beta", target+trange, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1))/(1-target-trange); 
  calc2[i]=  (cdf("beta", target+trange, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1) - cdf("beta", target-trange, 
sum(sumi[k,i],1), sum(sumitot[k,i],-sumi[k,i])+1))/(trange+trange); 
  calc3[i]= (cdf("beta", target-trange, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1)/(target-trange)); 
  calc4[i]= 1-cdf("beta", target, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1); 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
    end; 
 
 else if calc2[i]>=calc1[i] and calc2[i]>calc3[i] then do; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
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  if ranuni(1)<dr1[i] then a[i,j]=1; else a[i,j]=0; 
/*a[i,j]=rand('Bernoulli', dr1[i]);*/ 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
        calc1[i]= (1-cdf("beta", target+trange, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1))/(1-target-trange); 
  calc2[i]=  (cdf("beta", target+trange, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1) - cdf("beta", target-trange, 
sum(sumi[k,i],1), sum(sumitot[k,i],-sumi[k,i])+1))/(trange+trange); 
  calc3[i]= (cdf("beta", target-trange, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1)/(target-trange)); 
  calc4[i]= 1-cdf("beta", target, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1); 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
    end; 
 
 else if calc1[i]>calc2[i] and calc1[i]>calc3[i] then do; 
    i=i-1; 
 if i > 0 then do; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  if ranuni(1)<dr1[i] then a[i,j]=1; else a[i,j]=0; 
/*a[i,j]=rand('Bernoulli', dr1[i]);*/ 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
  
245 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  calc1[i]= (1-cdf("beta", target+trange, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1))/(1-target-trange); 
  calc2[i]=  (cdf("beta", target+trange, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1) - cdf("beta", target-trange, 
sum(sumi[k,i],1), sum(sumitot[k,i],-sumi[k,i])+1))/(trange+trange); 
  calc3[i]= (cdf("beta", target-trange, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1)/(target-trange)); 
  calc4[i]= 1-cdf("beta", target, sum(sumi[k,i],1), 
sum(sumitot[k,i],-sumi[k,i])+1); 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
    end; 
 end; 
 
end;  
 
if i eq 0 then dosel[k]=20; 
if i ne 0 then dosel[k]=i; 
 
totalpop[k]=peoplec; 
 
end; 
 
maxdose= max(of dosel1-dosel1000);  
medianpeop= median(of totalpop1-totalpop1000);  
run; 
 
/* print median number of patients on trial, avg DLT rate and 
response rate in each dose level, average number of patients and 
DLTs in each dose level */ 
proc print; 
var medianpeop  dltr1-dltr10 effr1-effr10 peopledosel1-peopledosel10 
dltdosel1-dltdosel10; 
run; 
 
data simi3; 
set simi2 (keep=dosel1-dosel1000); 
 
array v_[*] dosel1-dosel1000; 
array counts[20]; 
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call missing (of counts[*]); 
do i = 1 to dim(v_); 
     counts[v_[i]] + 1; 
end; 
 
run; 
 
/** number of times out of 1000 that each dose level is selected for 
safety before isotonic regression **/ 
 
proc print;  
var counts1-counts20; 
run; 
 
/* isotonic regression for observed DLT rates */ 
 
 
%macro doit(k1); 
 
%do jj=1  %to &k1; 
 
%global max_els2; 
 
%let onedim=Yes; *Yes/No; 
 
 
%let num1=%eval((&jj-1)*10+1); 
%let num2=%eval((&jj-1)*10+2); 
%let num3=%eval((&jj-1)*10+3); 
%let num4=%eval((&jj-1)*10+4); 
%let num5=%eval((&jj-1)*10+5); 
%let num6=%eval((&jj-1)*10+6); 
%let num7=%eval((&jj-1)*10+7); 
%let num8=%eval((&jj-1)*10+8); 
%let num9=%eval((&jj-1)*10+9); 
%let num10=%eval((&jj-1)*10+10); 
 
 
proc iml; 
use simi2 ; 
 
read all var{sumi&num1 sumi&num2 sumi&num3 sumi&num4 sumi&num5 
sumi&num6 sumi&num7 sumi&num8 sumi&num9 sumi&num10} into x; 
 
read all var{sumitot&num1 sumitot&num2 sumitot&num3 sumitot&num4 
sumitot&num5 sumitot&num6 sumitot&num7 sumitot&num8 sumitot&num9 
sumitot&num10} into w; 
 
mi=missing(x); 
rowmi = mi[,+]; 
rowmi1=10-rowmi; 
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call symput('rowmi2',char(rowmi1)); 
 
/* 
print mi rowmi rowmi1; 
*/ 
 
create one1 from w; 
append from w; 
create one2 from x; 
append from x; 
quit; 
run; 
 
%let max_els2=&rowmi2; *Number rows/columns; 
 
%macro assign(v,out); 
 
data &out; 
set &out; 
array cols[*] col1-col&max_els2; 
array s[*] &v.1-&v.&max_els2; 
do i=1 to &max_els2; 
%if &v=w %then %do; s[i]=max(0.0001,cols[i]); %end; 
%else %do; s[i]=cols[i]; %end; 
end; 
keep &v:; 
run; 
 
%mend; 
%assign(v=w,out=one1); 
%assign(v=x,out=one2); 
 
data one; 
merge one1 one2; 
array ys[*] y1-y&max_els2; 
array ws[*] w1-w&max_els2; 
array xs[*] x1-x&max_els2; 
array zs[*] z1-z&max_els2; 
array ss[*] s1-s&max_els2; 
do i=1 to &max_els2; 
if ws[i]>0 then ys[i]=xs[i]/ws[i]; 
else ys[i]=0; 
zs[i]=ys[i]; 
ss[i]=0; 
end; 
drop i x:; 
run; 
 
proc datasets; 
delete one1 one2; 
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run; 
 
/* 
proc print n width=min; 
title 'orig'; 
var w1-w&max_els2 y1-y&max_els2; 
run; 
*/ 
 
%let flag=0; 
%let n=0; 
%do %until(&flag=1 or (&onedim=Yes and &n=1)); 
%let n=%eval(&n+1); 
 
%macro rename(v,out); 
 
data &out; 
retain &v.1-&v.&max_els2; 
keep &v.1-&v.&max_els2; 
set one; 
run; 
 
%mend; 
%rename(v=y,out=y); 
%rename(v=w,out=w); 
%rename(v=z,out=z); 
%rename(v=s,out=s); 
 
%if &onedim^=Yes %then %do; 
%if &n^=1 %then %do; 
proc iml;   
use y; read all into one1; 
use w; read all into one2; 
use z; read all into one3; 
use s; read all into one4; 
new=T(one1); 
new2=T(one2); 
new3=T(one3); 
new4=T(one4); 
create one1 from new; 
append from new; 
create one2 from new2; 
append from new2; 
create one3 from new3; 
append from new3; 
create one4 from new4; 
append from new4; 
quit; 
run; 
 
%assign(v=y,out=one1); 
  
249 
%assign(v=w,out=one2); 
%assign(v=z,out=one3); 
%assign(v=s,out=one4); 
 
data one; 
merge one1 one2 one3 one4; 
run; 
 
proc datasets; 
delete one1 one2 one3 one4 y w z s; 
run; 
%end; 
%end; 
 
data one; 
set one; 
 
%macro pav(max_els=,array=,weights=); 
 
array _yo_[&max_els] yo1-yo&max_els; 
array _w_[&max_els] w1-w&max_els; 
array _y_[&max_els] y1-y&max_els; 
array _z_[&max_els] z1-z&max_els; 
array _s_[&max_els] s1-s&max_els; 
 
do i=1 to &max_els; 
_yo_[i]=_y_[i]; 
end; 
 
%if &n=2 %then %do; 
do i=1 to &max_els; 
_y_[i]=_z_[i]; 
end; 
%end; 
%else %if &n>=3 %then %do; 
do i=1 to &max_els; 
*_y_[i]=max(0,_z_[i]+_s_[i]); 
_y_[i]=_z_[i]+_s_[i]; 
end; 
%end; 
 
%global index ; 
%if %quote(&index)= 
%then 
%let index=1 ; 
%else 
   %let index=%eval(&index+1) ; 
%let pooled = _pool&index._ ; 
%let parray = _parr&index._ ; 
%let pwghts = _pwgt&index._ ; 
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array &pooled {&max_els} _TEMPORARY_ ; 
array &parray {&max_els} _TEMPORARY_ ; 
array &pwghts {&max_els} _TEMPORARY_ ; 
 
if dim(&array) = 1 then Go to epav&index ; 
 
do _pav_j_ = 1 to dim(&array) ; 
&pooled(_pav_j_) = 0 ; 
&parray(_pav_j_) = 0 ; 
&pwghts(_pav_j_) = 0 ; 
end ; 
 
&parray(1) = &array(1) ; 
&pwghts(1) = &weights(1) ; 
_pav_j_ = 1 ; 
 
do _pav_i_ = 2 to dim(&array) ; 
 
  /* if ajacent violated, then pool */ 
  if (&parray(_pav_j_) > &array(_pav_i_)) then do ; 
     _plwght_ = &pwghts(_pav_j_) + &weights(_pav_i_) ; 
    _plval_ = ((&parray(_pav_j_)*&pwghts(_pav_j_)) + 
             (&array(_pav_i_)*&weights(_pav_i_))) / _plwght_ ; 
 
    &pooled(_pav_i_) = 1 ; 
    flag=0; *added; 
    if _pav_j_ > 1 then do ; 
       _pav_j_ = _pav_j_ - 1 ; 
       _pav_jj_ = _pav_i_ ; 
       do while (flag=0 & ( &parray(_pav_j_)>_plval_) & (_pav_i_ >= 
1)); *added flag=0; 
       put &parray(_pav_j_)= _pav_j_= _plval_=; 
         _tplval_ = _plval_ ; 
         _tplwgt_ = _plwght_ ; /* tplwgt misspelled */ 
          do until (not &pooled(_pav_jj_)) ; 
              _pav_jj_ = _pav_jj_ - 1 ; 
           put _pav_jj_= &pooled(_pav_jj_)=; 
              end ; /* do until */ 
 
          _plwght_ = &pwghts(_pav_j_) + _tplwgt_ ; 
          _plval_  = ((&parray(_pav_j_) * &pwghts(_pav_j_)) + 
                      (_tplval_*_tplwgt_)) / _plwght_ ;  
         &pooled(_pav_jj_) = 1 ; 
         _pav_j_ = _pav_j_ -1 ; 
         if _pav_j_=0 then do; flag=1; _pav_j_=1; end; *added; 
         end ; /* do while */ 
      _pav_j_ = _pav_j_ + 1 ; 
      end ; /* if _pav_j_ > 1 */ 
      if flag=1 then do; *added; 
         _pav_j_=_pav_j_-1; *added; 
         do i=1 to _pav_i_;  *added*; 
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         &parray(i) = _plval_ ; *added; 
         &pwghts(i) = _plwght_ ; *added; 
         end;  *added*; 
         end;  *added*; 
     else do; *added; 
     &parray(_pav_j_) = _plval_ ; 
     &pwghts(_pav_j_) = _plwght_ ; 
     end; *added; 
     end ; /* if (&parray... */ 
 
     else do ; 
         _pav_j_ = _pav_j_ + 1 ; 
          &parray(_pav_j_) = &array(_pav_i_) ; 
          &pwghts(_pav_j_) = &weights(_pav_i_) ; 
          end ; 
     end ; /* _pav_i_=2 to dim(array) */ 
 
  &array(1) = &parray(1) ; 
 _pav_j_=1 ; 
 _pav_jj_=1 ; /*left off underscore*/ 
 
 /* put the pooled data back into the original array */ 
 do _pav_j_ = 2 to dim(&array) ; 
   if ^&pooled(_pav_j_) then _pav_jj_ = _pav_jj_ + 1 ; 
   &array(_pav_j_) = &parray(_pav_jj_) ; 
 end ; 
 
 Epav&index: 
 drop _pav_j_ _pav_i_ _pav_jj_ _plval_ _plwght_ _tplval_ _tplwgt_ ; 
 
          ok=0; 
          do i=1 to &max_els; 
          %if &n=1 %then %do;  
          _s_[i]=_y_[i]-_z_[i]; %end; 
          %else %if &n>=2 %then %do;  
          _s_[i]=_y_[i]-_z_[i]-_s_[i]; %end; 
          if abs(_yo_[i]-_y_[i])>.0001 then ok=ok+1; 
          end; 
    run; 
 
    %mend; 
 
%pav(max_els=&max_els2,array=_y_,weights=_w_); 
 
data one; 
set one; 
index2=1; 
run; 
 
data one; 
set one end=lastrec; 
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by index2; 
retain ok2; 
if first.index2 then ok2=ok; 
else ok2=ok2+ok; 
if lastrec and ((mod(&n,2)^=0 and ok2=0) or &n=199) then call 
symput('flag','1');  
*if lastrec and (&n=51) then call symput('flag','1');  
 
/** highest dose level with DLT rate <=0.33 after isotonic 
regression **/ 
if y1>0.33 then mtdiso=0; 
if .<y1<=0.33 then mtdiso=1; 
if .<y2<=0.33 then mtdiso=2; 
if .<y3<=0.33 then mtdiso=3; 
if .<y4<=0.33 then mtdiso=4; 
if .<y5<=0.33 then mtdiso=5; 
if .<y6<=0.33 then mtdiso=6; 
if .<y7<=0.33 then mtdiso=7; 
if .<y8<=0.33 then mtdiso=8; 
if .<y9<=0.33 then mtdiso=9; 
if .<y10<=0.33 then mtdiso=10; 
 
drop i index2 ok:; 
run; 
 
/* 
proc print; var  w1-w&max_els2 y1-y&max_els2; title "Iter &n After 
Iso"; run; 
*/ 
 
data finalmtdiso&jj; 
set one; 
keep mtdiso; 
run; 
 
%end; 
 
%end; 
%mend; 
 
 
%doit(1000); 
 
data finaliso; 
set finalmtdiso1 - finalmtdiso1000; 
run; 
 
/** number of times out of 1000 that each dose level is selected for 
safety after isotonic regression (highest dose level at which the 
smoothed DLT rate is <=0.33) **/ 
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proc freq; 
tables mtdiso; 
run; 
 
***********; 
/* isotonic regression for observed response rates */ 
 
%macro doiteff(k1); 
 
%do jj=1  %to &k1; 
 
%global max_els2; 
 
%let onedim=Yes; *Yes/No; 
 
 
%let num1=%eval((&jj-1)*10+1); 
%let num2=%eval((&jj-1)*10+2); 
%let num3=%eval((&jj-1)*10+3); 
%let num4=%eval((&jj-1)*10+4); 
%let num5=%eval((&jj-1)*10+5); 
%let num6=%eval((&jj-1)*10+6); 
%let num7=%eval((&jj-1)*10+7); 
%let num8=%eval((&jj-1)*10+8); 
%let num9=%eval((&jj-1)*10+9); 
%let num10=%eval((&jj-1)*10+10); 
 
 
proc iml; 
use simi2 ; 
 
read all var{sumieff&num1 sumieff&num2 sumieff&num3 sumieff&num4 
sumieff&num5 sumieff&num6 sumieff&num7 sumieff&num8 sumieff&num9 
sumieff&num10} into x; 
 
read all var{sumitot&num1 sumitot&num2 sumitot&num3 sumitot&num4 
sumitot&num5 sumitot&num6 sumitot&num7 sumitot&num8 sumitot&num9 
sumitot&num10} into w; 
 
mi=missing(x); 
rowmi = mi[,+]; 
rowmi1=10-rowmi; 
 
call symput('rowmi2',char(rowmi1)); 
 
/* 
print mi rowmi rowmi1; 
*/ 
 
create one1 from w; 
append from w; 
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create one2 from x; 
append from x; 
quit; 
run; 
 
%let max_els2=&rowmi2; *Number rows/columns; 
 
%macro assign(v,out); 
 
data &out; 
set &out; 
array cols[*] col1-col&max_els2; 
array s[*] &v.1-&v.&max_els2; 
do i=1 to &max_els2; 
%if &v=w %then %do; s[i]=max(0.0001,cols[i]); %end; 
%else %do; s[i]=cols[i]; %end; 
end; 
keep &v:; 
run; 
 
%mend; 
%assign(v=w,out=one1); 
%assign(v=x,out=one2); 
 
data one; 
merge one1 one2; 
array ys[*] y1-y&max_els2; 
array ws[*] w1-w&max_els2; 
array xs[*] x1-x&max_els2; 
array zs[*] z1-z&max_els2; 
array ss[*] s1-s&max_els2; 
do i=1 to &max_els2; 
if ws[i]>0 then ys[i]=xs[i]/ws[i]; 
else ys[i]=0; 
zs[i]=ys[i]; 
ss[i]=0; 
end; 
drop i x:; 
run; 
 
proc datasets; 
delete one1 one2; 
run; 
 
/* 
proc print n width=min; 
title 'orig'; 
var w1-w&max_els2 y1-y&max_els2; 
run; 
*/ 
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%let flag=0; 
%let n=0; 
%do %until(&flag=1 or (&onedim=Yes and &n=1)); 
%let n=%eval(&n+1); 
 
%macro rename(v,out); 
 
data &out; 
retain &v.1-&v.&max_els2; 
keep &v.1-&v.&max_els2; 
set one; 
run; 
 
%mend; 
%rename(v=y,out=y); 
%rename(v=w,out=w); 
%rename(v=z,out=z); 
%rename(v=s,out=s); 
 
%if &onedim^=Yes %then %do; 
%if &n^=1 %then %do; 
proc iml;   
use y; read all into one1; 
use w; read all into one2; 
use z; read all into one3; 
use s; read all into one4; 
new=T(one1); 
new2=T(one2); 
new3=T(one3); 
new4=T(one4); 
create one1 from new; 
append from new; 
create one2 from new2; 
append from new2; 
create one3 from new3; 
append from new3; 
create one4 from new4; 
append from new4; 
quit; 
run; 
 
%assign(v=y,out=one1); 
%assign(v=w,out=one2); 
%assign(v=z,out=one3); 
%assign(v=s,out=one4); 
 
data one; 
merge one1 one2 one3 one4; 
run; 
 
proc datasets; 
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delete one1 one2 one3 one4 y w z s; 
run; 
%end; 
%end; 
 
data one; 
set one; 
 
%macro pav(max_els=,array=,weights=); 
 
array _yo_[&max_els] yo1-yo&max_els; 
array _w_[&max_els] w1-w&max_els; 
array _y_[&max_els] y1-y&max_els; 
array _z_[&max_els] z1-z&max_els; 
array _s_[&max_els] s1-s&max_els; 
 
do i=1 to &max_els; 
_yo_[i]=_y_[i]; 
end; 
 
%if &n=2 %then %do; 
do i=1 to &max_els; 
_y_[i]=_z_[i]; 
end; 
%end; 
%else %if &n>=3 %then %do; 
do i=1 to &max_els; 
*_y_[i]=max(0,_z_[i]+_s_[i]); 
_y_[i]=_z_[i]+_s_[i]; 
end; 
%end; 
 
%global index ; 
%if %quote(&index)= 
%then 
%let index=1 ; 
%else 
   %let index=%eval(&index+1) ; 
%let pooled = _pool&index._ ; 
%let parray = _parr&index._ ; 
%let pwghts = _pwgt&index._ ; 
 
array &pooled {&max_els} _TEMPORARY_ ; 
array &parray {&max_els} _TEMPORARY_ ; 
array &pwghts {&max_els} _TEMPORARY_ ; 
 
if dim(&array) = 1 then Go to epav&index ; 
 
do _pav_j_ = 1 to dim(&array) ; 
&pooled(_pav_j_) = 0 ; 
&parray(_pav_j_) = 0 ; 
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&pwghts(_pav_j_) = 0 ; 
end ; 
 
&parray(1) = &array(1) ; 
&pwghts(1) = &weights(1) ; 
_pav_j_ = 1 ; 
 
do _pav_i_ = 2 to dim(&array) ; 
 
  /* if ajacent violated, then pool */ 
  if (&parray(_pav_j_) > &array(_pav_i_)) then do ; 
     _plwght_ = &pwghts(_pav_j_) + &weights(_pav_i_) ; 
    _plval_ = ((&parray(_pav_j_)*&pwghts(_pav_j_)) + 
             (&array(_pav_i_)*&weights(_pav_i_))) / _plwght_ ; 
 
    &pooled(_pav_i_) = 1 ; 
    flag=0; *added; 
    if _pav_j_ > 1 then do ; 
       _pav_j_ = _pav_j_ - 1 ; 
       _pav_jj_ = _pav_i_ ; 
       do while (flag=0 & ( &parray(_pav_j_)>_plval_) & (_pav_i_ >= 
1)); *added flag=0; 
       put &parray(_pav_j_)= _pav_j_= _plval_=; 
         _tplval_ = _plval_ ; 
         _tplwgt_ = _plwght_ ; /* tplwgt misspelled */ 
          do until (not &pooled(_pav_jj_)) ; 
              _pav_jj_ = _pav_jj_ - 1 ; 
           put _pav_jj_= &pooled(_pav_jj_)=; 
              end ; /* do until */ 
 
          _plwght_ = &pwghts(_pav_j_) + _tplwgt_ ; 
          _plval_  = ((&parray(_pav_j_) * &pwghts(_pav_j_)) + 
                      (_tplval_*_tplwgt_)) / _plwght_ ;  
         &pooled(_pav_jj_) = 1 ; 
         _pav_j_ = _pav_j_ -1 ; 
         if _pav_j_=0 then do; flag=1; _pav_j_=1; end; *added; 
         end ; /* do while */ 
      _pav_j_ = _pav_j_ + 1 ; 
      end ; /* if _pav_j_ > 1 */ 
      if flag=1 then do; *added; 
         _pav_j_=_pav_j_-1; *added; 
         do i=1 to _pav_i_;  *added*; 
         &parray(i) = _plval_ ; *added; 
         &pwghts(i) = _plwght_ ; *added; 
         end;  *added*; 
         end;  *added*; 
     else do; *added; 
     &parray(_pav_j_) = _plval_ ; 
     &pwghts(_pav_j_) = _plwght_ ; 
     end; *added; 
     end ; /* if (&parray... */ 
  
258 
 
     else do ; 
         _pav_j_ = _pav_j_ + 1 ; 
          &parray(_pav_j_) = &array(_pav_i_) ; 
          &pwghts(_pav_j_) = &weights(_pav_i_) ; 
          end ; 
     end ; /* _pav_i_=2 to dim(array) */ 
 
  &array(1) = &parray(1) ; 
 _pav_j_=1 ; 
 _pav_jj_=1 ; /*left off underscore*/ 
 
 /* put the pooled data back into the original array */ 
 do _pav_j_ = 2 to dim(&array) ; 
   if ^&pooled(_pav_j_) then _pav_jj_ = _pav_jj_ + 1 ; 
   &array(_pav_j_) = &parray(_pav_jj_) ; 
 end ; 
 
 Epav&index: 
 drop _pav_j_ _pav_i_ _pav_jj_ _plval_ _plwght_ _tplval_ _tplwgt_ ; 
 
          ok=0; 
          do i=1 to &max_els; 
          %if &n=1 %then %do;  
          _s_[i]=_y_[i]-_z_[i]; %end; 
          %else %if &n>=2 %then %do;  
          _s_[i]=_y_[i]-_z_[i]-_s_[i]; %end; 
          if abs(_yo_[i]-_y_[i])>.0001 then ok=ok+1; 
          end; 
    run; 
 
    %mend; 
 
%pav(max_els=&max_els2,array=_y_,weights=_w_); 
 
data one; 
set one; 
index2=1; 
run; 
 
data one; 
set one end=lastrec; 
by index2; 
retain ok2; 
if first.index2 then ok2=ok; 
else ok2=ok2+ok; 
if lastrec and ((mod(&n,2)^=0 and ok2=0) or &n=199) then call 
symput('flag','1');  
*if lastrec and (&n=51) then call symput('flag','1');  
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/** lowest dose level with response rate >=0.4 after isotonic 
regression **/ 
effiso=0; 
if y1>=0.4 then effiso=1; 
else if y2>=0.4 then effiso=2; 
else if y3>=0.4 then effiso=3; 
else if y4>=0.4 then effiso=4; 
else if y5>=0.4 then effiso=5; 
else if y6>=0.4 then effiso=6; 
else if y7>=0.4 then effiso=7; 
else if y8>=0.4 then effiso=8; 
else if y9>=0.4 then effiso=9; 
else if y10>=0.4 then effiso=10; 
 
drop i index2 ok:; 
run; 
 
/* 
proc print; var  w1-w&max_els2 y1-y&max_els2; title "Iter &n After 
Iso"; run; 
*/ 
 
data finaleffiso&jj; 
set one; 
keep effiso; 
run; 
 
%end; 
 
%end; 
%mend; 
 
 
%doiteff(1000); 
 
data finaliso1; 
set finaleffiso1 - finaleffiso1000; 
run; 
 
/** number of times out of 1000 that each dose level is selected for 
efficacy after isotonic regression (lowest dose level at which the 
smoothed response rate is >=0.4) **/ 
proc freq; 
tables effiso; 
run; 
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SAS code for the extended TEQR design for isotonic regression on the difference 
in observed response rates between adjacent dose levels from each simulation 
(used in determining the optimal dose for efficacy and safety for an umbrella-
shaped dose-response curve): 
data simi2 aa4; 
call streaminit(1); 
 
array a{10,100}; 
array aeff{10,100}; 
array sumi{1000,10}; 
array sumieff{1000,10}; 
array sumitot{1000,10}; 
array dltr{10}; 
array effr{10}; 
array dosel{1000}; 
array totalpop{1000}; 
array dr1{10}; 
array dreff{10}; 
array peopledosel{10}; 
array dltdosel{10}; 
 
maxdlt=0.34; 
target=0.2; 
trange=0.05; 
maxmtdss=50; 
cohortsize=5; 
 
er=0.6; 
r=0; 
flagytox=0; 
flagyeff=0; 
flagyboth=0; 
 
do k=1 to 1000; 
 
/** True toxicity rates and true response rates at each dose **/ 
dr1[1]=0.01; 
dr1[2] =0.02199; 
dr1[3]=0.06165; 
dr1[4]=0.2; 
dr1[5]=0.55412; 
dr1[6]=0.88790; 
dr1[7]=0.98936; 
dr1[8]=0.99959; 
dr1[9]=0.99999; 
dr1[10]=1; 
 
dreff[1]=0.1; 
dreff[2]=0.3; 
dreff[3]=0.4; 
dreff[4]=0.45; 
dreff[5]=0.55; 
dreff[6]=0.6; 
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dreff[7]=0.65; 
 
 
do i1=1 to 10; 
do j1=1 to maxmtdss; 
        a[i1,j1]=.; 
        aeff[i1,j1]=.;  
  sumi[k,1]=0; 
  sumieff[k,1]=0; 
  sumitot[k,1]=0; 
  dltr[i1]=.; 
  effr[i1]=.; 
  dltr[1]=0; 
  effr[1]=0; 
end; 
end; 
 
 
i=2; /** start at dose level 2 to allow de-escalation **/ 
sumi[k,2]=0; 
sumieff[k,2]=0; 
sumitot[k,2]=0; 
peoplec=0; 
 
do j=1 to cohortsize; 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sumi[k,i]+a[i,j]; 
  sumitot[k,i]=sumitot[k,i]+1; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sumieff[k,i]+aeff[i,j];   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
end; 
 
/** dosing decisions of the TEQR design (escalate, stay at the same 
dose, de-escalate) performed until the maximum MTD sample size is 
reached or we need to de-escalate beyond dose level 1 **/ 
 
 do until ((sumsum=maxmtdss and dltrate<maxdlt) or i=0 /* or 
effrate>=er*/);  
 
 
  
262 
    if 0<=dltr[i]<(target-trange) and dltr[i+1]<maxdlt then do; 
    i=i+1; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
    end; 
  else if 0<=dltr[i]<(target-trange) and dltr[i+1]>=maxdlt then do; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
    end; 
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 else if (target-trange)<=dltr[i]<=(target+trange) then do; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
    end; 
 
 else if (target+trange)<dltr[i]<=1 then do; 
    i=i-1; 
 if i > 0 then do; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
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    end; 
 end; 
 
end;  
 
if i ne 0 then dosel[k]=i; 
if i eq 0 then dosel[k]=20; 
 
totalpop[k]=peoplec; 
if k>=1 then output aa4; 
end; 
 
maxdose= max(of dosel1-dosel1000);  
medianpeop= median(of totalpop1-totalpop1000);  
run; 
 
 
data aa5; 
set aa4; 
keep effr1-effr10; 
run; 
 
data aa6; 
set aa5; 
if effr1=effr2 then effr2=effr2+0.001; 
if effr1=effr3 then effr3=effr3+0.001; 
if effr1=effr4 then effr4=effr4+0.001; 
if effr1=effr5 then effr5=effr5+0.001; 
if effr1=effr6 then effr6=effr6+0.001; 
if effr2=effr3 then effr3=effr3+0.001; 
if effr2=effr4 then effr4=effr4+0.001; 
if effr2=effr5 then effr5=effr5+0.001; 
if effr2=effr6 then effr6=effr6+0.001; 
if effr3=effr4 then effr4=effr4+0.001; 
if effr3=effr5 then effr5=effr5+0.001; 
if effr3=effr6 then effr6=effr6+0.001; 
if effr4=effr5 then effr5=effr5+0.001; 
if effr4=effr6 then effr6=effr6+0.001; 
if effr5=effr6 then effr6=effr6+0.001; 
 
run; 
 
/** dataset with difference in observed response rates between adjacent 
dose levels **/ 
data aa7; 
set aa5; 
effra1=effr1-effr2; 
effra2=effr2-effr3; 
effra3=effr3-effr4; 
effra4=effr4-effr5; 
effra5=effr5-effr6; 
effra6=effr6-effr7; 
effra7=effr7-effr8; 
effra8=effr8-effr9; 
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effra9=effr9-effr10; 
run; 
 
data aa9; 
set aa7; 
if effra1 ne . then weight1=1; 
if effra2 ne . then weight2=1; 
if effra3 ne . then weight3=1; 
if effra4 ne . then weight4=1; 
if effra5 ne . then weight5=1; 
if effra6 ne . then weight6=1; 
if effra7 ne . then weight7=1; 
if effra8 ne . then weight8=1; 
if effra9 ne . then weight9=1; 
run; 
  
 
/** Data sets with difference in observed response rates between 
adjacent dose levels from each simulation to be used in the isotonic 
regression macro **/ 
%macro multids;                     
 
  %do I = 1 %to 1000;          
 
     data Data&I;                   
 
       set aa9 (keep=effra1-effra9 weight1-weight9);                    
 
       if _N_=&I then output;         
 
     run;                           
 
     %end;                            
 
%mend;                           
 
  
 
%multids; 
 
/** isotonic regression on the differences in observed response rates 
between adjacent dose levels **/ 
 
%macro doiteff(k1); 
 
%do jj=1  %to &k1; 
 
%global max_els2; 
 
%let onedim=Yes; *Yes/No; 
 
proc iml; 
use data&jj ; 
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read all var{effra1 effra2 effra3 effra4 effra5 effra6 effra7 effra8 
effra9} into x; 
 
read all var{weight1 weight2 weight3 weight4 weight5 weight6 weight7 
weight8 weight9} into w; 
 
mi=missing(x); 
rowmi = mi[,+]; 
rowmi1=9-rowmi; 
 
call symput('rowmi2',char(rowmi1)); 
 
/* 
print mi rowmi rowmi1; 
*/ 
 
create one1 from w; 
append from w; 
create one2 from x; 
append from x; 
quit; 
run; 
 
%let max_els2=&rowmi2; *Number rows/columns; 
 
%macro assign(v,out); 
 
data &out; 
set &out; 
array cols[*] col1-col&max_els2; 
array s[*] &v.1-&v.&max_els2; 
do i=1 to &max_els2; 
%if &v=w %then %do; s[i]=max(0.0001,cols[i]); %end; 
%else %do; s[i]=cols[i]; %end; 
end; 
keep &v:; 
run; 
 
%mend; 
%assign(v=w,out=one1); 
%assign(v=x,out=one2); 
 
data one; 
merge one1 one2; 
array ys[*] y1-y&max_els2; 
array ws[*] w1-w&max_els2; 
array xs[*] x1-x&max_els2; 
array zs[*] z1-z&max_els2; 
array ss[*] s1-s&max_els2; 
do i=1 to &max_els2; 
if ws[i]>0 then ys[i]=xs[i]/ws[i]; 
else ys[i]=0; 
zs[i]=ys[i]; 
ss[i]=0; 
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end; 
drop i x:; 
run; 
 
proc datasets; 
delete one1 one2; 
run; 
 
/* 
proc print n width=min; 
title 'orig'; 
var w1-w&max_els2 y1-y&max_els2; 
run; 
*/ 
 
%let flag=0; 
%let n=0; 
%do %until(&flag=1 or (&onedim=Yes and &n=1)); 
%let n=%eval(&n+1); 
 
%macro rename(v,out); 
 
data &out; 
retain &v.1-&v.&max_els2; 
keep &v.1-&v.&max_els2; 
set one; 
run; 
 
%mend; 
%rename(v=y,out=y); 
%rename(v=w,out=w); 
%rename(v=z,out=z); 
%rename(v=s,out=s); 
 
%if &onedim^=Yes %then %do; 
%if &n^=1 %then %do; 
proc iml;   
use y; read all into one1; 
use w; read all into one2; 
use z; read all into one3; 
use s; read all into one4; 
new=T(one1); 
new2=T(one2); 
new3=T(one3); 
new4=T(one4); 
create one1 from new; 
append from new; 
create one2 from new2; 
append from new2; 
create one3 from new3; 
append from new3; 
create one4 from new4; 
append from new4; 
quit; 
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run; 
 
%assign(v=y,out=one1); 
%assign(v=w,out=one2); 
%assign(v=z,out=one3); 
%assign(v=s,out=one4); 
 
data one; 
merge one1 one2 one3 one4; 
run; 
 
proc datasets; 
delete one1 one2 one3 one4 y w z s; 
run; 
%end; 
%end; 
 
data one; 
set one; 
 
%macro pav(max_els=,array=,weights=); 
 
array _yo_[&max_els] yo1-yo&max_els; 
array _w_[&max_els] w1-w&max_els; 
array _y_[&max_els] y1-y&max_els; 
array _z_[&max_els] z1-z&max_els; 
array _s_[&max_els] s1-s&max_els; 
 
do i=1 to &max_els; 
_yo_[i]=_y_[i]; 
end; 
 
%if &n=2 %then %do; 
do i=1 to &max_els; 
_y_[i]=_z_[i]; 
end; 
%end; 
%else %if &n>=3 %then %do; 
do i=1 to &max_els; 
*_y_[i]=max(0,_z_[i]+_s_[i]); 
_y_[i]=_z_[i]+_s_[i]; 
end; 
%end; 
 
%global index ; 
%if %quote(&index)= 
%then 
%let index=1 ; 
%else 
   %let index=%eval(&index+1) ; 
%let pooled = _pool&index._ ; 
%let parray = _parr&index._ ; 
%let pwghts = _pwgt&index._ ; 
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array &pooled {&max_els} _TEMPORARY_ ; 
array &parray {&max_els} _TEMPORARY_ ; 
array &pwghts {&max_els} _TEMPORARY_ ; 
 
if dim(&array) = 1 then Go to epav&index ; 
 
do _pav_j_ = 1 to dim(&array) ; 
&pooled(_pav_j_) = 0 ; 
&parray(_pav_j_) = 0 ; 
&pwghts(_pav_j_) = 0 ; 
end ; 
 
&parray(1) = &array(1) ; 
&pwghts(1) = &weights(1) ; 
_pav_j_ = 1 ; 
 
do _pav_i_ = 2 to dim(&array) ; 
 
  /* if ajacent violated, then pool */ 
  if (&parray(_pav_j_) > &array(_pav_i_)) then do ; 
     _plwght_ = &pwghts(_pav_j_) + &weights(_pav_i_) ; 
    _plval_ = ((&parray(_pav_j_)*&pwghts(_pav_j_)) + 
             (&array(_pav_i_)*&weights(_pav_i_))) / _plwght_ ; 
 
    &pooled(_pav_i_) = 1 ; 
    flag=0; *added; 
    if _pav_j_ > 1 then do ; 
       _pav_j_ = _pav_j_ - 1 ; 
       _pav_jj_ = _pav_i_ ; 
       do while (flag=0 & ( &parray(_pav_j_)>_plval_) & (_pav_i_ >= 
1)); *added flag=0; 
       put &parray(_pav_j_)= _pav_j_= _plval_=; 
         _tplval_ = _plval_ ; 
         _tplwgt_ = _plwght_ ; /* tplwgt misspelled */ 
          do until (not &pooled(_pav_jj_)) ; 
              _pav_jj_ = _pav_jj_ - 1 ; 
           put _pav_jj_= &pooled(_pav_jj_)=; 
              end ; /* do until */ 
 
          _plwght_ = &pwghts(_pav_j_) + _tplwgt_ ; 
          _plval_  = ((&parray(_pav_j_) * &pwghts(_pav_j_)) + 
                      (_tplval_*_tplwgt_)) / _plwght_ ;  
         &pooled(_pav_jj_) = 1 ; 
         _pav_j_ = _pav_j_ -1 ; 
         if _pav_j_=0 then do; flag=1; _pav_j_=1; end; *added; 
         end ; /* do while */ 
      _pav_j_ = _pav_j_ + 1 ; 
      end ; /* if _pav_j_ > 1 */ 
      if flag=1 then do; *added; 
         _pav_j_=_pav_j_-1; *added; 
         do i=1 to _pav_i_;  *added*; 
         &parray(i) = _plval_ ; *added; 
         &pwghts(i) = _plwght_ ; *added; 
         end;  *added*; 
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         end;  *added*; 
     else do; *added; 
     &parray(_pav_j_) = _plval_ ; 
     &pwghts(_pav_j_) = _plwght_ ; 
     end; *added; 
     end ; /* if (&parray... */ 
 
     else do ; 
         _pav_j_ = _pav_j_ + 1 ; 
          &parray(_pav_j_) = &array(_pav_i_) ; 
          &pwghts(_pav_j_) = &weights(_pav_i_) ; 
          end ; 
     end ; /* _pav_i_=2 to dim(array) */ 
 
  &array(1) = &parray(1) ; 
 _pav_j_=1 ; 
 _pav_jj_=1 ; /*left off underscore*/ 
 
 /* put the pooled data back into the original array */ 
 do _pav_j_ = 2 to dim(&array) ; 
   if ^&pooled(_pav_j_) then _pav_jj_ = _pav_jj_ + 1 ; 
   &array(_pav_j_) = &parray(_pav_jj_) ; 
 end ; 
 
 Epav&index: 
 drop _pav_j_ _pav_i_ _pav_jj_ _plval_ _plwght_ _tplval_ _tplwgt_ ; 
 
          ok=0; 
          do i=1 to &max_els; 
          %if &n=1 %then %do;  
          _s_[i]=_y_[i]-_z_[i]; %end; 
          %else %if &n>=2 %then %do;  
          _s_[i]=_y_[i]-_z_[i]-_s_[i]; %end; 
          if abs(_yo_[i]-_y_[i])>.0001 then ok=ok+1; 
          end; 
    run; 
 
    %mend; 
 
%pav(max_els=&max_els2,array=_y_,weights=_w_); 
 
data one; 
set one; 
index2=1; 
run; 
 
data one; 
set one end=lastrec; 
by index2; 
retain ok2; 
if first.index2 then ok2=ok; 
else ok2=ok2+ok; 
if lastrec and ((mod(&n,2)^=0 and ok2=0) or &n=199) then call 
symput('flag','1');  
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*if lastrec and (&n=51) then call symput('flag','1');  
 
effiso=0; 
if y1>=0 then effiso=1; 
if y2=0 then effiso=2; 
if y3=0 then effiso=3; 
if y4=0 then effiso=4; 
if y5=0 then effiso=5; 
if y6=0 then effiso=6; 
 
if y1<0 and y2>0 and abs(y1)<=abs(y2) then effiso=1; 
if y1<0 and y2>0 and abs(y1)>abs(y2) then effiso=2; 
 
if y2<0 and y3>0 and abs(y2)<=abs(y3) then effiso=2; 
if y2<0 and y3>0 and abs(y2)>abs(y3) then effiso=3; 
 
if y3<0 and y4>0 and abs(y3)<=abs(y4) then effiso=3; 
if y3<0 and y4>0 and abs(y3)>abs(y4) then effiso=4; 
 
if y4<0 and y5>0 and abs(y4)<=abs(y5) then effiso=4; 
if y4<0 and y5>0 and abs(y4)>abs(y5) then effiso=5; 
 
if y5<0 and y6>0 and abs(y5)<=abs(y6) then effiso=5; 
if y5<0 and y6>0 and abs(y5)>abs(y6) then effiso=6; 
 
if .<y1<0 and y2 eq .  then effiso=1; 
if .<y2<0 and y3 eq .  then effiso=2; 
if .<y3<0 and y4 eq .  then effiso=3; 
if .<y4<0 and y5 eq .  then effiso=4; 
if .<y5<0 and y6 eq .  then effiso=5; 
if .<y6<0 and y7 eq .  then effiso=6; 
drop i index2 ok:; 
run; 
 
/* 
proc print; var  w1-w&max_els2 y1-y&max_els2; title "Iter &n After 
Iso"; run; 
*/ 
 
data finaleffiso&jj; 
set one; 
run; 
 
%end; 
 
%end; 
%mend; 
 
 
%doiteff(1000); 
 
data finaliso1; 
set finaleffiso1 - finaleffiso1000; 
if effiso=1 and y1=0 then peak=2; 
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if effiso=1 and y1>0 then peak=1; 
if effiso=1 and y1<0 and y2 ne . then peak=2; 
if effiso=1 and y1<0 and y2 eq . then peak=0; 
if effiso=2 and y2=0 then peak=3; 
if effiso=2 and y2>0 then peak=2; 
if effiso=2 and y2<0 and y3 ne . then peak=3; 
if effiso=2 and y2<0 and y3 eq . then peak=0; 
if effiso=3 and y3=0 then peak=4; 
if effiso=3 and y3>0 then peak=3; 
if effiso=3 and y3<0 and y4 ne . then peak=4; 
if effiso=3 and y3<0 and y4 eq . then peak=0; 
if effiso=4 and y4=0 then peak=5; 
if effiso=4 and y4>0 then peak=4; 
if effiso=4 and y4<0 and y5 ne . then peak=5; 
if effiso=4 and y4<0 and y5 eq . then peak=0; 
if effiso=5 and y5=0 then peak=6; 
if effiso=5 and y5>0 then peak=5; 
if effiso=5 and y5<0 and y6 ne . then peak=6; 
if effiso=5 and y5<0 and y6 eq . then peak=0; 
 
 
 
keep y1-y9 yo1-yo9 peak effiso; 
run; 
 
proc print data=finaliso1; 
var y1-y5 yo1-yo5 effiso peak; 
run; 
 
 
/** Number of times out of 1000 simulations that each dose level is 
choosen as the peak **/ 
proc freq; 
tables peak; 
run; 
 
/** Code for finding the optimal dose for an umbrella shaped dose-
response curve **/ 
 
data finaliso1; 
set finaliso1; 
retain id; 
id = sum(id, 1); 
run; 
 
/** Data set with the dose level that is selected as the highest dose 
that is safe after isotonic regression – can be obtained from the first 
TEQR program in “Codes for Chapter 4”. **/ 
 
PROC IMPORT OUT= WORK.mtdiso  
            DATAFILE= "D:\Documents and 
Settings\rananthakrishnan\Deskto 
p\mtdiso.xls"  
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            DBMS=EXCEL REPLACE; 
     RANGE="mtdiso";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 
     SCANTIME=YES; 
RUN; 
 
data aa5; 
set aa5; 
retain id; 
id=sum(id, 1); 
run; 
 
data mtdiso; 
set mtdiso; 
retain id; 
id=sum(id, 1); 
run; 
 
data finaliso2; 
merge finaliso1 mtdiso aa5; 
by id; 
if peak=0 then optimal=0; 
 
if peak=6 and effr6>=0.4 and mtdiso>=6 then optimal=6; 
if peak=6 and effr6<0.4 and mtdiso>=6 then optimal=0; 
if peak=6 and mtdiso=5 and effr5>=0.4 then optimal=5; 
if peak=6 and mtdiso=5 and effr5<0.4 then optimal=0; 
if peak=6 and mtdiso=4 and effr4>=0.4 then optimal=4; 
if peak=6 and mtdiso=4 and effr4<0.4 then optimal=0; 
if peak=6 and mtdiso=3 and effr3>=0.4 then optimal=3; 
if peak=6 and mtdiso=3 and effr3<0.4 then optimal=0; 
if peak=6 and mtdiso=2 and effr2>=0.4 then optimal=2; 
if peak=6 and mtdiso=2 and effr2<0.4 then optimal=0; 
if peak=6 and mtdiso=1 and effr1>=0.4 then optimal=1; 
if peak=6 and mtdiso=1 and effr1<0.4 then optimal=0; 
 
if peak=5 and effr5>=0.4 and mtdiso>=5 then optimal=5; 
if peak=5 and effr5<0.4 and mtdiso>=5 then optimal=0; 
if peak=5 and mtdiso=4 and effr4>=0.4 then optimal=4; 
if peak=5 and mtdiso=4 and effr4<0.4 then optimal=0; 
if peak=5 and mtdiso=3 and effr3>=0.4 then optimal=3; 
if peak=5 and mtdiso=3 and effr3<0.4 then optimal=0; 
if peak=5 and mtdiso=2 and effr2>=0.4 then optimal=2; 
if peak=5 and mtdiso=2 and effr2<0.4 then optimal=0; 
if peak=5 and mtdiso=1 and effr1>=0.4 then optimal=1; 
if peak=5 and mtdiso=1 and effr1<0.4 then optimal=0; 
 
if peak=4 and effr4>=0.4 and mtdiso>=4 then optimal=4; 
if peak=4 and effr4<0.4 and mtdiso>=4 then optimal=0; 
if peak=4 and mtdiso=3 and effr3>=0.4 then optimal=3; 
if peak=4 and mtdiso=3 and effr3<0.4 then optimal=0; 
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if peak=4 and mtdiso=2 and effr2>=0.4 then optimal=2; 
if peak=4 and mtdiso=2 and effr2<0.4 then optimal=0; 
if peak=4 and mtdiso=1 and effr1>=0.4 then optimal=1; 
if peak=4 and mtdiso=1 and effr1<0.4 then optimal=0; 
 
if peak=3 and effr3>=0.4 and mtdiso>=3 then optimal=3; 
if peak=3 and effr3<0.4 and mtdiso>=3 then optimal=0; 
if peak=3 and mtdiso=2 and effr2>=0.4 then optimal=2; 
if peak=3 and mtdiso=2 and effr2<0.4 then optimal=0; 
if peak=3 and mtdiso=1 and effr1>=0.4 then optimal=1; 
if peak=3 and mtdiso=1 and effr1<0.4 then optimal=0; 
 
if peak=2 and effr2>=0.4 and mtdiso>=2 then optimal=2; 
if peak=2 and effr2<0.4 and mtdiso>=2 then optimal=0; 
if peak=2 and mtdiso=1 and effr1>=0.4 then optimal=1; 
if peak=2 and mtdiso=1 and effr1<0.4 then optimal=0; 
 
if peak=1 and effr1>=0.4 and mtdiso>=1 then optimal=1; 
if peak=1 and effr1<0.4 and mtdiso>=1 then optimal=0; 
 
run; 
 
/** Number of times out of 1000 simulations that each dose level is 
chosen as the optimal dose for safety and efficacy **/ 
proc freq; 
tables optimal; 
run; 
 
 
SAS code for the extended TEQR design for obtaining the observed response rate 
at each dose level and the difference in observed response rates between 
adjacent dose levels from each simulation: 
 
data simi2 aa4; 
call streaminit(1); 
 
array a{10,100}; 
array aeff{10,100}; 
array sumi{1000,10}; 
array sumieff{1000,10}; 
array sumitot{1000,10}; 
array dltr{10}; 
array effr{10}; 
array dosel{1000}; 
array totalpop{1000}; 
array dr1{10}; 
array dreff{10}; 
array peopledosel{10}; 
array dltdosel{10}; 
 
maxdlt=0.34; 
target=0.2; 
trange=0.05; 
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maxmtdss=50; 
cohortsize=5; 
 
er=0.6; 
r=0; 
flagytox=0; 
flagyeff=0; 
flagyboth=0; 
 
do k=1 to 1000; 
 
/** true DLT and response rates **/ 
dr1[1]=0.01; 
dr1[2] =0.02199; 
dr1[3]=0.06165; 
dr1[4]=0.2; 
dr1[5]=0.55412; 
dr1[6]=0.88790; 
dr1[7]=0.98936; 
dr1[8]=0.99959; 
dr1[9]=0.99999; 
dr1[10]=1; 
 
dreff[1]=0.1; 
dreff[2]=0.35; 
dreff[3]=0.5; 
dreff[4]=0.3; 
dreff[5]=0.2; 
dreff[6]=0.05; 
dreff[7]=0.01; 
 
 
do i1=1 to 10; 
do j1=1 to maxmtdss; 
        a[i1,j1]=.; 
        aeff[i1,j1]=.;  
  sumi[k,1]=0; 
  sumieff[k,1]=0; 
  sumitot[k,1]=0; 
  dltr[i1]=.; 
  effr[i1]=.; 
  dltr[1]=0; 
  effr[1]=0; 
end; 
end; 
 
 
i=2; /** start at dose level 2 to allow de-escalation **/ 
sumi[k,2]=0; 
sumieff[k,2]=0; 
sumitot[k,2]=0; 
peoplec=0; 
 
do j=1 to cohortsize; 
  
276 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sumi[k,i]+a[i,j]; 
  sumitot[k,i]=sumitot[k,i]+1; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sumieff[k,i]+aeff[i,j];   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
end; 
 
/** dosing decisions of the TEQR design (escalate, stay at the same 
dose, de-escalate) performed until the maximum MTD sample size is 
reached or we need to de-escalate beyond dose level 1 **/ 
 do until ((sumsum=maxmtdss and dltrate<maxdlt) or i=0 /* or 
effrate>=er*/);  
 
 
    if 0<=dltr[i]<(target-trange) and dltr[i+1]<maxdlt then do; 
    i=i+1; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
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    end; 
  else if 0<=dltr[i]<(target-trange) and dltr[i+1]>=maxdlt then do; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
    end; 
 
 else if (target-trange)<=dltr[i]<=(target+trange) then do; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
    end; 
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 else if (target+trange)<dltr[i]<=1 then do; 
    i=i-1; 
 if i > 0 then do; 
 range=sum(sumitot[k,i],0); 
 do j=range+1 to range+cohortsize; 
  a[i,j]=rand('Bernoulli', dr1[i]); 
  sumi[k,i]=sum(sumi[k,i],a[i,j]); 
  sumitot[k,i]=sum(sumitot[k,i],1); 
  sumsum=sumitot[k,i]; 
 
  p1=dr1[i]; 
        p2=dreff[i]; 
  q1=p2+(r/p1)*sqrt(p1*(1-p1)*p2*(1-p2)); 
     q2=(p2-q1*p1)/(1-p1); 
        if a[i,j]=1 then aeff[i,j]=rand("binomial", q1,1); 
        else aeff[i,j]=rand("binomial",q2,1); 
  sumieff[k,i]=sum(sumieff[k,i],aeff[i,j]);   
 
  dltr[i]=sumi[k,i]/sumitot[k,i]; 
  dltrate=dltr[i]; 
  effr[i]=sumieff[k,i]/sumitot[k,i]; 
  effrate=effr[i]; 
 
  peoplec=peoplec+1; 
  peopledosel[i]=sum(peopledosel[i],0.001); 
  dltdosel[i]=sum(dltdosel[i],a[i,j]/1000); 
 end; 
    end; 
 end; 
 
end;  
 
if i ne 0 then dosel[k]=i; 
if i eq 0 then dosel[k]=20; 
 
totalpop[k]=peoplec; 
if k>=1 then output aa4; 
end; 
 
maxdose= max(of dosel1-dosel1000);  
medianpeop= median(of totalpop1-totalpop1000);  
run; 
 
 
data aa5; 
set aa4; 
keep effr1-effr10; 
run; 
 
/** This data set provides the observed response rate at each dose 
level from each simulation **/ 
data aa6; 
set aa5; 
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if effr1=effr2 then effr2=effr2+0.001; 
if effr1=effr3 then effr3=effr3+0.001; 
if effr1=effr4 then effr4=effr4+0.001; 
if effr1=effr5 then effr5=effr5+0.001; 
if effr1=effr6 then effr6=effr6+0.001; 
if effr2=effr3 then effr3=effr3+0.001; 
if effr2=effr4 then effr4=effr4+0.001; 
if effr2=effr5 then effr5=effr5+0.001; 
if effr2=effr6 then effr6=effr6+0.001; 
if effr3=effr4 then effr4=effr4+0.001; 
if effr3=effr5 then effr5=effr5+0.001; 
if effr3=effr6 then effr6=effr6+0.001; 
if effr4=effr5 then effr5=effr5+0.001; 
if effr4=effr6 then effr6=effr6+0.001; 
if effr5=effr6 then effr6=effr6+0.001; 
 
run; 
 
data aa7; 
set aa5; 
effra1=effr1-effr2; 
effra2=effr2-effr3; 
effra3=effr3-effr4; 
effra4=effr4-effr5; 
effra5=effr5-effr6; 
effra6=effr6-effr7; 
effra7=effr7-effr8; 
effra8=effr8-effr9; 
effra9=effr9-effr10; 
run; 
 
/** This data set provides the observed difference in response rates 
between adjacent dose levels from each simulation **/ 
data aa8; 
set aa7; 
 
if abs(effra1-effra2)<=0.001 then effra2=effra2+0.0001; 
if abs(effra1-effra3)<=0.001 then effra3=effra3+0.0001; 
if abs(effra1-effra4)<=0.001 then effra4=effra4+0.0001; 
if abs(effra1-effra5)<=0.001 then effra5=effra5+0.0001; 
if abs(effra1-effra6)<=0.001 then effra6=effra6+0.0001; 
if abs(effra2-effra3)<=0.001 then effra3=effra3+0.0001; 
if abs(effra2-effra4)<=0.001 then effra4=effra4+0.0001; 
if abs(effra2-effra5)<=0.001 then effra5=effra5+0.0001; 
if abs(effra2-effra6)<=0.001 then effra6=effra6+0.0001; 
if abs(effra3-effra4)<=0.001 then effra4=effra4+0.0001; 
if abs(effra3-effra5)<=0.001 then effra5=effra5+0.0001; 
if abs(effra3-effra6)<=0.001 then effra6=effra6+0.0001; 
if abs(effra4-effra5)<=0.001 then effra5=effra5+0.0001; 
if abs(effra4-effra6)<=0.001 then effra6=effra6+0.0001; 
if abs(effra5-effra6)<=0.001 then effra6=effra6+0.0001; 
 
keep effra1-effra9; 
run; 
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R code for the extended TEQR design for nearly isotonic regression applied to 
the observed response rates: 
MyData <- read.csv(file="C:\\Users\\HP\\Desktop\\teqriso1.csv", header=TRUE, 
sep=",") 
library(neariso) 
lambda=c(0) 
 
i <- 1 
while (i<1001){ 
z<- which(is.na(MyData[i,]))[1] 
y<- MyData[i,][!is.na(MyData[i,])] 
y<- y[-z] 
if(z > 2){ 
res0 <- neariso(y, lambda=lambda) 
ii <- which(res0$beta >=0.4)[1] 
MyData$effd[i]=ii 
} else { 
   MyData$effd[i]=1 
} 
 
i=i+1 
} 
table(MyData$effd) 
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